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 ABSTRACT 
Apical broad-spectrum neutral (0) amino acid transporter B0AT1 (encoded by the SLC6A19 
gene) is mainly expressed in small intestine and kidney, mediating the transport of all neutral 
amino acids in a Na+-dependent manner. Its ancillary proteins, carboxypeptidase angiotensin-
converting enzyme 2 (ACE2) and the homolog collectrin (TMEM27, transmembrane protein 
27), are critical for the surface expression and catalytic transport function in small intestine and 
kidney, respectively. Slc6a19 nullizygous mice have improved insulin sensitivity and show 
reduced weight gain on a HFD (high fat diet) compared to wild-type mice. Moreover, reduced 
insulin secretion could protect β-cells from endoplasmic reticulum (ER) stress and long-term 
failure in insulin secretion. Hence, pharmacological inhibition of B0AT1 using chemical 
compounds could lead to new drugs to treat type 2 diabetes (T2DM) and its related metabolic 
disorders. A CHO (Chinese Hamster Ovary) - based cell line was generated, stably expressing 
B0AT1 and collectrin with the aid of a Flp-In™ transfection system. Using this cell line, a high-
throughput screening (HTS) assay was developed, which uses a fluorescent dye to detect 
depolarisation of the cell membrane during amino acid uptake via B0AT1. A radio-labelled 
substrate uptake assay was used to determine the potency (IC50) and mechanism (competitive 
or non-competitive) of inhibition, as well as the specificity of B0AT1 inhibitors. Potential novel 
inhibitors were derived from three sources, first commercially available substrate analogues, 
second medium-scale virtual screening, and third high-throughput screening of chemical 
libraries. Selected inhibitors were further tested in in-vitro (Xenopus laevis oocytes), ex-vivo 
(mouse small intestine) and in-vivo (C57BL/6NCrl wild-type mice) systems. I characterised a 
series of novel inhibitors of the B0AT1 transporter in more detail. Benztropine (NSC63912) 
was identified as a competitive inhibitor showing an IC50 of 44±9µM; whereas 2-benzyl-1-(3-
phenylpropyl)piperidine (NSC22789) was identified as a non-competitive inhibitor with an 
IC50 of 90±21µM. These two compounds were selective with regard to related transporters 
(system L, ASCT2), and they blocked substrate (leucine) uptake in both Xenopus oocytes 
overexpressing B0AT1 and collectrin, and inverted mouse small intestine. Two more potent 
B0AT1 inhibitors with IC50 below 10µM were further identified from the HTS of a small 
molecule compound library. The tools established in this study can be widely used to identify 
new transport inhibitors. Using these tools we were able to identify compounds that can be 
used to study epithelial transporters or be developed further through medicinal chemistry. 
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Chapter 1: General Introduction 
1.1 The role of amino acids in the development of insulin resistance and type 2 diabetes; 
the benefits of protein restriction to improve metabolic health 
Type 2 diabetes mellitus (T2DM) was formerly known as non-insulin-dependent diabetes 
mellitus (NIDDM), a disorder in which there is a chronically elevated blood glucose 
concentration resulting from both insufficient insulin secretion and insulin resistance (IR) 
usually associated with obesity. It is the main type of diabetes mellitus since it accounts for 90-
95% of all diabetics, particularly in adultsDeshpande, Harris-Hayes [1]. Due to its acute and 
chronic complications such as cardiovascular disease and stroke, it results in increased 
morbidity and mortality and thus places a heavy burden on society. Obesity caused by over-
nutrition and/or lack of physical activity is a key risk factor in the development of IR, which 
consequently causes increased demand for insulin. The majority of individuals with IR can 
remain normoglyceamic in the early stage due to a compensatory increase in insulin secretion 
supported by an increase in β-cell mass and function. However, such compensation may fail 
due to a progressive decrease in β-cell mass and function, ultimately resulting in T2DM [2]. 
Elevated levels of neutral amino acids, especially branched-chain amino acids (BCAAs), have 
been reported to be linked to the development of IR or even T2DM [3]. It was reported that in 
a Chinese and Asian-Indian male population, IR was correlated with increased levels of alanine, 
proline, valine, leucine/isoleucine, phenylalanine, tyrosine, glutamate/glutamine and ornithine. 
These changes were not due to increased protein intake [4]. Similar in an American population, 
five branched-chain and aromatic amino acids had highly-significant associations with future 
diabetes, namely isoleucine, leucine, valine, tyrosine, and phenylalanine. Meanwhile, a 
combination of three amino acids (isoleucine, phenylalanine, tyrosine) were found to be good 
predictors of future diabetes, suggesting that amino acid profiles could help in diabetes risk 
assessment [5]. Therefore, significant efforts have been made to understand how these amino 
acids affect the metabolic balance in our bodies. 
The mammalian target of rapamycin complex 1 (mTORC1) signalling pathway is the most 
widely-studied and well-known amino acid sensing pathway, regulating protein translation 
through the phosphorylation and activation of mTORC1’s downstream target p70S6 kinase 
(p60S6K) and 4E-binding protein 1 (4E-BP1) [6-11]. This signalling pathway also regulates 
autophagy through the interaction between mTORC1 and the ulk1 (UNC51-like kinase 
1)/atg13 (autophagy 13)/FIP200 (focal adhesion kinase-interacting protein 200kDa) complex 
[12]. In general, when amino acids become abundant, mTORC1 is recruited to the lysosomal 
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surface where it is activated by Ras homologue enriched in brain (Rheb) to enhance protein 
biosynthesis, while under amino acid depletion, the inactive mTORC1 is dispersed throughout 
the cytoplasm, leading to the progressively increased association between mTORC1 and ulk1 
complex to induce protein degradation; thus, this amino acid sensing pathway is critical for 
maintaining cellular amino acid homeostasis [12, 13]. The general control non-derepressable 2 
(GCN2)/activating transcription factor 4 (ATF4) pathway is activated in addition to the 
suppression of mTORC1 signalling during amino acid restriction. Unlike the mTORC1-
dependent sensing of amino acids, the protein kinase GCN2 is stimulated by binding to 
uncharged tRNAs, which are accumulated during amino acid restriction. The upregulation of 
the GCN2/ATF4 pathway results in a reduction of global translation through phosphorylation 
of the eukaryotic initiation factor 2α (eIF2α) and an increase of the intracellular amino acid 
pool by promoting amino acid biosynthesis and/or transport [12]. In addition to the mTORC1- 
and GCN2- dependent signalling pathways, G protein-coupled receptors (GPCRs) and the 
Cxcl10 transcriptional/Dusp16 posttranscriptional responses were reported to be involved in 
sensing of amino acid excess and limitation, respectively [14]. However, their molecular 
mechanisms still remain to be elucidated [14]. Systemic amino acid homeostasis is also tightly 
modulated in a mTORC1-dependent manner. Elevated levels of circulating amino acids after 
food intake contribute to the release of insulin, which in turn up-regulates the transport of amino 
acids, particularly BCAAs, into muscles where they incorporate into proteins through the 
activation of mTORC1 and its downstream targets p70S6K and 4E-BP1 as mentioned above. 
Meanwhile, insulin itself is also capable of stimulating mTORC1 by binding to and activating 
insulin receptor substrate proteins to trigger a signalling cascade of PI3K (phosphoinositide 3-
kinase) /PKB (protein kinase B)/mTORC1. Muscle protein can be degraded to refill the amino 
acid pool during fasting [12]. The amino acid sensing pathways are summarized in figure 1.1. 
The understanding of amino acid sensing pathways under physiological conditions is essential 
to understand why BCAAs correlate with IR or T2DM, and different mechanisms have been 
suggested. Previous studies have provided evidence that insulin responses are attenuated due 
to BCAA-mediated mTORC1 activation (see review [15]). However, the causative role of 
BCAAs has been challenged by another work [15]. For example, middle-aged mice showed a 
dissociation between mTORC1 activation and change of insulin sensitivity after feeding with 
BCAAs for 3 months [16]. As a result, BCAAs may rather be considered biomarkers or 
predictors for IR or T2DM, than the cause of the disease [3]. Currently, a more widely accepted 
hypothesis invokes mitochondrial dysfunction in pancreatic β-cells and stress signalling, 
caused by the accumulation of toxic metabolites resulting from BCAA dysmetabolism 
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(branched chain α-keto acids and branched chain acyl-coenzyme A), as the mechanism 
underlying IR [17]. 
Caloric restriction protects against age-related diseases in a wide range of species, although to 
a variable extent. Restriction of protein showed the best protective effects compared to the 
restriction of carbohydrates and fat [14]. Restriction of the intake of proteins or of specific 
amino acids (e.g. tryptophan, methionine) proved to be beneficial to the extension of lifespan 
and healthspan in rodent models, as well as being associated with lower risks of cancer, obesity, 
insulin resistance, diabetes, cardiovascular disease and overall mortality in humans [18, 19]. 
Furthermore, low-protein diet proved to be beneficial for kidney function in diabetic 
nephropathy [20]. On the contrary, when providing mice with high-protein diets, even with 
restriction on total calorie intake, there was no beneficial effect on lifespan, which correlated 
with the activation of hepatic mTORC1 signalling by elevated circulating levels of BCAAs 
[21]. In contrast to long-term activation, short-term activation of mTORC1 protects against 
insulin resistance, because it up-regulates the secretion of satiety hormone leptin in brain, 
leading to a decrease in food intake [22]. However, the persistent hyperactivation of mTORC1 
can be harmful for health by inducing endoplasmic reticulum (ER) stress due to enhanced 
protein translation [15, 23-29]. 
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Figure 1.1: Amino acid sensing pathways. When amino acids become abundant, mTORC1 is 
activated by GTP-bound Rheb, which potentiates global translation and protein synthesis by the 
phosphorylation and activation of p60S6K and 4E-BP1, whereas the activated mTORC1 down-
regulates autophagy by suppressing the ulk1/atg13/FIP200 complex. Meanwhile, insulin released post 
the elevation of circulating amino acid levels also stimulates mTORC1 by a signaling cascade of 
PI3K/PKB/mTORC1. Under amino acids depletion, the inactivated mTORC1 associates the 
ulk1/atg13/FIP200 complex to induce autophagy-mediated protein degradation. In addition, the amino 
acid restriction leads to the accumulation of uncharged tRNAs, which stimulates the protein kinase 
GCN2 and subsequently results in ATF4-mediated suppression of global translation and protein 
synthesis [12, 13]. In addition, the amino acid abundance and depletion can also be sensed by GPCRs 
and Cxcl10 transcriptional/Dusp16 posttranscriptional responses, respectively, via unknown 
mechanisms [14]. 
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1.2 Intestinal protein absorption and renal transport 
Approximately 30% of our nutrition stems from proteins, which are critical sources of energy 
and building blocks for human beings. Upon dietary intake, proteins are digested and 
enzymatically hydrolysed into large peptides in stomach under the action of protease pepsin, 
then further degraded into smaller peptides in the presence of a variety of pancreatic proteases 
(e.g. trypsin, chymotrypsin, elastase and carboxypeptidases) entering into the small intestine. 
Finally, individual amino acids, di- and tri-peptides are generated by brush-border peptidases 
in the apical membranes of small intestine enterocytes [30]. The hydrolysed small peptides and 
amino acids are transported into the small intestinal epithelial cells by specific peptide 
transporters (PEPT1 [31] and amino acid transporters (figure 1.2), respectively, all of which 
are located in the apical membrane of intestinal enterocytes. The majority of absorbed small 
peptides are further digested into amino acids by cytoplasmic peptidases before the release by 
another set of transporters located in the basolateral membrane of intestinal enterocytes. These 
amino acids are subsequently collected by the hepatic portal vein (figure 1.2). 
To maintain systemic amino acid homeostasis, amino acids are reabsorbed by the kidney before 
they are wasted through urine, and such reabsorption is mediated by the epithelial cells of the 
proximal convoluted and straight tubules [32]. Notably, low-affinity amino acid transporters 
were identified in the proximal convoluted tubule; whereas high-affinity ones were found in 
the proximal straight tubule [33]. A wide variety of amino acid transporters are involved in the 
transcellular amino acid reabsorption by the proximal tubule cells, which are shown in figure 
1.2, whereas the di-and tri- peptides are transported by PEPT2 in kidney [34]. Eventually, the 
reabsorbed amino acids return to the circulatory system through the renal vein. 
Generally, similar transport systems are expressed in both intestinal enterocytes and kidney 
epithelial cells. There are four major transport systems on the apical side of the membrane in 
both small intestine and kidney. The term “system” indicates a type of transport activity 
identified in various cells, whereas the term “solute carrier (SLC)” indicates the molecular 
identification of a particular transporter. 
1. System X-AG: facilitating the transport of anionic amino acids (aspartate, glutamate) in a Na+- 
and H+- dependent manner, the transporter was identified as EAAT3 (SLC1A1) [35] in kidney 
and intestine; 
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2. System b0,+: facilitating the uptake of cationic amino acids (lysine, arginine) and cystine in 
exchange with neutral amino acids, the correlated transporter (SLC7A9) forms a heterodimer 
with the heavy subunit rBAT (SLC3A1) [36] in kidney and intestine; 
3. The IMINO/glycine System Comprised of PAT1 (SLC36A1) (intestine) and PAT2 
(SLC36A2) (kidney), which are proton symporters participating in the absorption of proline 
and glycine in kidney with lower affinities compared to SIT1 and XT2 [37]. The 2Na+, 1Cl- 
and proline cotransporter SIT1 (SLC6A20) [38] in kidney and intestine; The Na+- and Cl-- 
dependent glycine transporter XT2 [39], later called B0AT3 (SLC6A18) [40]. This transporter 
is only relevant in mouse, in humans the transporter is replaced by PAT2. 
4. System B0: facilitating neutral amino acid transport in a Na+-dependent manner. Three 
transporters were identified in this system, including B0AT1 (SLC6A19) expressed in kidney 
and small intestine, B0AT2 (SLC6A15) expressed in brain [41], and B0AT3 (SLC6A18) 
expressed in kidney [40]. B0AT1 is introduced in detail in later sections. 
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Figure 1.2: Amino acid transporters on apical and basolateral sides of intestine and kidney. 
*ASCT2 on the apical side and SNATs on the basolateral side are only detected in distal intestine. The 
net efflux of anionic amino acids across the basolateral membrane remains to be elucidated. AA, amino 
acid; Cn, cystine [12, 42-44]. 
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1.3 Amino acid transporter pharmacology 
Amino acids are essential for protein synthesis and serve as important energy sources for all 
living cells. Amino acids are absorbed or reabsorbed through various transporters in different 
organs, and these transporters belong to different SLC families, namely SLC1, SLC3, SLC6, 
SLC7, SLC16, SLC17, SLC25, SLC32, SLC36, SLC38 and SLC43 families [12]. Importantly, 
suppression of single/multiple specific transporter(s) could cause beneficial effects in humans 
under pathological conditions, thus, amino acid transporters are investigated as 
pharmacological targets in a variety of areas, such as cancer, nervous system disorders and 
metabolic disorders.  
Cancer: Amino acid transporters are highly expressed in tumour cells to support rapid 
replication, hence, being investigated as targets for treating various cancers. For example, 
system L amino acid transporter 1 (LAT1, SLC7A5) was shown to be highly expressed in 
human tumour cell lines [45]. Initially, substrate analogues were used as transporter inhibitors, 
for example, the nonmetabolizable amino acid analogues, 2-aminobicyclo-(2,2,1)-heptane-2-
carboxylic acid (BCH) and N-Methylaminoisobutyric acid (MeAIB), were used as inhibitors 
of system L and system A transporters, respectively [46]. However, due to poor selectivity of 
these inhibitors to the targets, they are unlikely to be developed as drug candidates. BCH, for 
instance, was found to inhibit transporters other than LAT1 [47, 48], so significant efforts have 
been put into synthetic chemistry and in vitro screening to identify more specific LAT1 
inhibitor, such as JPH203 (previously known as KYT0353) [49]. As a proof of principle, 2-
aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) showed inhibitory effects on cancer 
cell proliferation in a non-small cell lung cancer cell line [50], and silencing of LAT1 
suppressed cell invasion and migration in a cholangiocarcinoma cell line [51]. The novel LAT1 
specific inhibitor, JPH203, has demonstrated therapeutic potential in treating 
cholangiocarcinoma [52] and thymic carcinoma [53]. Occasionally, approved drugs can be 
repurposed as transport inhibitors. For instance, the anti-inflammatory drug Sulfasalazine 
(initially approved to treat arthritis) was identified as an effective antagonist of the 
cystine/glutamate antiporter SLC7A11 (also known as xCT) potentially useful for the treatment 
of small-cell lung cancer [54]. As another example, alanine/serine/cysteine transporter 2 
(ASCT2, SLC1A5) mediates glutamine uptake as a harmonizer in many cancer cells. 
Glutamine is essential for many cancer cell lines to support glutaminolysis, which is critical 
for cancer cell growth and protein translation [55]. It was reported that pharmacological 
inhibitors of ASCT2 or shRNA-mediated ASCT2 knockdown suppressed cell growth and 
proliferation of triple-negative basal-like breast cancer cells, but not for luminal breast cancer 
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cells [56]. A novel ASCT2 inhibitor, 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids was 
synthesized on the basis of previously reported ASCT2 inhibitors, which were glutamine or 
serine analogues, but with much higher potency, shedding light on cancer treatment when 
ASCT2 is a target [57]. However, inhibition of ASCT2 alone may not be sufficient to suppress 
cancer cell growth because it is compensated by an up-regulation of sodium-coupled neutral 
amino acid transporter 1 (SNAT1, SLC38A1), whereas combined inhibition of GCN2 and 
ASCT2 could overcome this compensation [58]. 
Nervous system disorders: The high-affinity, Na+-dependent excitatory amino acid transporters 
(EAATs) are widely-known as the main mediators of L-glutamate removal in mammalian 
central nervous system (CNS), and at least five distinct EAAT subtypes have been identified in 
humans as well as in rodents [59]. As a dominant excitatory neurotransmitter, L-glutamate 
participates in many key physiological events in the CNS, such as fast synaptic 
communications, regulation of synaptic plasticity, learning and memory. However, excessive 
levels of L-glutamate can trigger excitotoxicity and cause neuronal damage in both acute CNS 
injuries or chronic neurodegenerative diseases [60, 61]. Therefore, the removal of L-glutamate 
from the synaptic cleft into glial cells and neurons via the symport with 3Na+ and 1H+ in 
exchange for 1K+ by EAATs is critical to avoid excitotoxicity [62]. EAAT2 is responsible for 
up to 80-90% of the total extracellular glutamate reabsorption within the CNS, so its 
translational activators (ceftriaxone and LDN/OSU-0212320) or pharmacological activators 
(parawixin 1 and GT949/GT951) have been reported to be neuroprotective in animal models 
of ischemic stroke, brain trauma and neurodegenerations [63, 64]. Another sodium-coupled 
amino acid transporter, B0AT2 (SLC6A15), is widely expressed at the plasma membrane of 
neurons across the cerebral cortex, hippocampus, cerebellum, midbrain and olfactory bulb, and 
plays an important role in leucine and proline homeostasis in the brain [65]. Based on a 
genome-wide association study (GWAS), SLC6A15 was identified as a susceptibility gene for 
major depression disorder (MDD). Interestingly, SLC6A15 knock-out mice showed lower 
levels of anxiety and depression after chronic social stress. Thus, B0AT2 inhibitors could 
potentially be used as novel antidepressant drugs [65-67]. Glycine is an inhibitory 
neurotransmitter, whose receptors are predominantly found in inhibitory synapses in the spinal 
cord, brainstem and retina. Moreover, glycine can be excitatory when acting as a co-agonist at 
NMDA (N-methyl-D-aspartate) receptors, whereby their association at the glycine-B site is 
required for the activation of NMDA receptors by L-glutamate. On the one hand, inhibitors of 
glycine transporter 1 (GlyT1) can be used to increase glycine availability for NMDA receptors, 
leading to an up-regulation of NMDA receptor excitability, which is beneficial in treating 
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schizophrenia. On the other hand, inhibition of GlyT2 has therapeutical potential in pain 
treatment because it reduces the reuptake of glycine from glycinergic synapses in the spinal 
cord, resulting in the blocking of pain signal transmission to the thalamus [68]. A highly-
selective and potent GlyT1 (SLC6A9) inhibitor bitopertin was tested in Phase III clinical trials 
in patients with schizophrenia [69], whereas GlyT2 (SLC6A5) inhibitors are explored to reduce 
chronic pain [70]. 
Metabolic disorders: Amino acids are also contributing to metabolic syndromes in various 
ways, allowing their transporters to be potential targets in treating these diseases. For example, 
it was reported that the active form of vitamin A (all-trans retinoic acid) suppressed up-
regulation of ASCT2 in 3T3-L1 cells (an adipogenesis cell model), which was required for 
lipid accumulation as ascertained by inhibition of ASCT2 with l-γ-glutamyl-p-nitroanilide 
(GPNA), hence providing a potential target for obesity [71]. 
1.4 B0AT1 (SLC6A19) 
Apical broad-spectrum neutral (0) amino acid transporter B0AT1 (SLC6A19) belongs to the 
solute carrier family 6, which has 20 family members in four major branches [72]. They are (i) 
the GABA transporter branch composed of GABA transporters GAT1-4, the taurine transporter 
TauT and creatine transporter CT1; (ii) the monoamine transporter branch containing the 
dopamine transporter DAT, the noradrenaline transporter NET and serotonin transporter SERT; 
(iii) the amino acid transporter branch (I) consisting of the general amino acid transporter 
ATB0,+, glycine transporters GlyT1-2 and the proline transporter PROT; and (iv) the amino acid 
transporter branch (II) containing the neutral amino acid transporters B0AT1-3, NTT4, the 
proline transporter SIT1 and NTT5, a transporter of unknown function. 
B0AT1 is a Na+-dependent neutral amino acid transporter mainly expressed in small intestine 
and kidney and localized at the apical side of the brush-border membrane (BBM), showing 
increasing expression from the crypts towards the tip of the villi [73]. Its expression in small 
intestine increases from duodenum to ileum, whereas its expression in kidney is mainly in the 
proximal convoluted tubule (S1 and S2 segment) rather than proximal straight tubule (S3 
segment), as shown by immunohistochemical analysis [74]. Although B0AT1 was detected in 
pancreas at mRNA level [42], its expression in pancreatic β-cells remained uncertain, whereas 
its trafficking subunit collectrin was detected in β-cells [75, 76]. Lower, but significant 
expression of B0AT1 mRNA was also detected in skin [73], prostate [77], stomach and liver 
[78]. Expression of B0AT1 protein has not been verified in these tissues. Mouse B0AT1 has 634 
amino acids, with 12 transmembrane domains and a larger loop between helix 7 and 8 
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compared with other SLC6 family members [73]. The mouse Slc6a19 gene is localised on 
chromosome 13 in cytoband C1, in a region syntenic to human chromosome 5p15 [73]. Co-
expression of B0AT1 with the carboxypeptidase angiotensin-converting enzyme 2 (ACE2) in 
the intestine or its homolog collectrin (TMEM27, transmembrane protein 27) in the kidney is 
critical for the activity of the transporter mainly by affecting its trafficking to the apical 
membrane surface [79-81]. Apart from trafficking the transporter, collectrin is essential for the 
catalytic activity of B0AT1 and B0AT3, acting as an essential subunit of a heterodimeric 
secondary active transporter. Site-directed mutagenesis suggested that collectrin occupies a 
groove between TM5 and -7 of the transporter [40]. In mouse kidney collectrin expression 
develops late but eventually replaces ACE2. Low expression levels of B0AT1 and collectrin 
cause aminoaciduria during the first week of life, a situation that resolves during the second 
week of life due to increased B0AT1 and collectrin expression [82]. 
In addition, B0AT1 was reported to form a complex with another peptidase, namely APN 
(aminopeptidase N/CD13), whose major role was to increase transport activity by increasing 
the local substrate concentration through a proximal binding site. Compared to ACE2 and 
collectrin, its role in increasing the surface expression of B0AT1 was minimal [83]. The uptake 
of amino acid substrate leucine by B0AT1, when expressed in Xenopus laevis oocytes was 
characterised as Na+ -dependent, Cl- -independent, membrane potential-driven, refractory to 
osmolarity change, and pH-dependent [73]. Later studies proved that the transport activity was 
electrogenic, substrate was co-transported with Na+ in a 1:1 stoichiometry. Increased Na+ 
concentration decreases the Km of substrate without affecting its Vmax, and vice versa, 
increased concentration of substrate decrease the Km for Na+. Although there is no strict 
binding order, amino acid preferentially binds to the transporter before Na+ [84]. B0AT1 
transports substrates with similar Vmax values but quite different affinities [44]. It shows a 
preference for branched-chain amino acids (leucine, isoleucine, valine) and methionine (Km 
~1mM), over large polar neutral amino acids glutamine, alanine, phenylalanine, asparagine and 
cysteine (Km ~4mM), over smaller polar amino acids such as serine, glycine, threonine, proline 
and aromatic amino acids such as tyrosine, histidine, and tryptophan (Km ~11mM). Anionic 
amino acids (aspartate and glutamate) and cationic amino acids (lysine and arginine) are not 
transported by B0AT1. It is noteworthy that B0AT1 is the only transporter for large neutral 
amino acids in the small intestine, whereas smaller amino acids are also transported by PAT1 
[85]. 
Several regulators of B0AT1 have been reported in different studies. Serum- & glucocorticoid- 
inducible kinase (SGK) isoforms SGK1-3 [86] and protein kinase B (PKB) [87] were reported 
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as stimulators of B0AT1, by stabilizing the transporter at the plasma membrane to increase its 
surface abundance, further revealing the regulation of this transporter in intestinal and renal 
epithelial cells. Moreover, B0AT1 was also found being stimulated by JAK2 (Janus kinase-2), 
a protein critical for the proliferation and survival of a variety of cancer cells in the development 
of many myeloproliferative diseases, hence, the upregulation of B0AT1 was thought to provide 
an important source of amino acid nutrients to these JAK2 expressing cells [88]. 
1.5 ACE2 and collectrin 
As mentioned above, ACE2 and collectrin are auxiliary proteins of B0AT1 in intestine and 
kidney, respectively. In addition, these two proteins are co-expressing with B0AT3 (SLC6A18) 
at the cell surface [89]. The angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase 
that catalyses the conversion of angiotensin I to angiotensin 1-9, and more importantly, the 
conversion of angiotensin II to angiotensin 1-7, which is a critical regulator of cardiovascular 
function [90, 91]. In addition, ACE2 also contributes to glucose homeostasis in obese C57BL/6 
mice by regulating β-cell mass and function in response to hyperinsulinemia [92]. In another 
study, ACE2-deficient mice showed a β-cell defect with low insulin and collectrin levels. ACE-
2 knock-out mice also demonstrated a shift of energy consumption towards glucose utilization 
in an angiotensin II-dependent manner [93-95]. In confirmation of its role as an ancillary 
protein for B0AT1, immunofluorescent staining and immunoprecipitation experiment 
demonstrated that ACE2 knockout mice lack B0AT1 expression in the intestine [96], leading to 
reduced plasma concentration of neutral amino acids (10-25%) because of their malabsorption 
in the intestine [97]. By contrast, the expression and function of B0AT1 was barely affected in 
kidney [89]. The study of ACE2 deficient mice revealed its influence on gut microbiota 
composition, which might provide an explanation for diarrhea and intestinal inflammation seen 
in SLC6A19 mutated humans (Hartnup disorder patients) (see below) [98]. Even so, the ACE2 
knockout mice did not manifest any symptoms of Hartnup disorder, such as skin rash or niacin 
deficiency, even under a low-protein and low-niacin diet [94]. In fact, these ACE2 null mice 
showed a variety of symptoms unrelated to the lack of neutral amino acid transport in the 
intestine but related to its role as a negative regulator of the renin-angiotensin system, including 
accelerated diabetic renal injury, acute respiratory stress syndrome and impaired cardiac 
contractility [95]. Apart from B0AT1, ACE2 was also reported to be co-expressed with SIT1 
(SLC6A20) in proximal tubule kidney cells both at protein level observed by 
immunofluorescence staining and at transcript level detected by RT-PCR [99]. 
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Collectrin, also known as transmembrane protein 27 (TMEM27), is a type I transmembrane 
glycoprotein sharing 47.8% homology with C-terminal end of ACE2 [100] in its homologous 
domain. The N-terminal dipeptidylcarboxypeptidase catalytic domain of ACE2 is absent in 
collectrin, resulting in a larger size of ACE2 and a loss of enzymatic activity in collectrin [101]. 
Collectrin is most abundantly expressed in kidney, but is also observed in vascular endothelium 
[102] and pancreatic β-cells [103] in humans. Similar to ACE2, collectrin has a vascular 
protective effect, so the depletion of collectrin could cause hypertension, probably by 
uncoupling endothelial nitric oxide synthase [102]. In pancreas, it interacts with SNAPIN, a 
protein involved in the fusion of insulin-containing vesicles with the plasma membrane during 
exocytosis, resulting in reduced insulin secretion in collectrin-deficient mice [75]. Malakauskas 
et al. [104], by contrast, saw no change in pancreatic morphology (β-cell mass and proliferation) 
or function (acute-phase insulin response and glucose-stimulated insulin-release) in collectrin-
deficient mice compared to wild-type mice. In this study collectrin-deficient mice 
demonstrated increased peripheral insulin sensitivity and decreased adiposity at 6 months of 
age, indicating protective effects on age-induced insulin resistance and obesity. Similar 
observations were made in Slc6a19 knockout mice [105]. 
1.6 Hartnup disorder 
Mutations in different amino acid transporters cause various aminoacidurias, which are 
described in the Online Mendelian Inheritance in Man (OMIM) database. For example, 
mutations in either rBAT (SLC3A1) or b0,+AT lead to cystinuria (OMIM220100 and 
OMIM600918) [106]; mutations in PAT2 (SLC36A2) and IMINO (SLC6A20) [107] result in 
iminoglycinuria (OMIM242600). 
Inactivating mutations in SLC6A19 in humans are known to cause an autosomal recessive 
inherited disorder named Hartnup disorder (OMIM234500) [77, 78]. The frequency of its 
occurrence is about 1:30,000 in European populations [108]. It is characterised by a reduced 
uptake of branched-chain and other neutral amino acids in the intestine and by their loss 
through the urine. Thus, very high levels of neutral amino acids are found in urine, with the 
exception of proline [109]. Hartnup disorder was first described on two siblings in the Hartnup 
family of British ancestry in 1956 [110]. Its clinical symptoms, pellagra-like skin rash, 
cerebellar ataxia, and psychotic behaviour [111], are generally rare and only observed in 
younger patients. Individuals with Hartnup disorder tend to have lower body weight relative to 
their healthy siblings [112]. A large proportion of patients remain asymptomatic except for the 
hyperaminoaciduria [112, 113]. It has been argued that the skin rash is a consequence of 
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tryptophan depletion, as it is similar to that observed in niacin deficiency. Both tryptophan and 
niacin are major precursors of NAD(P)H biosynthesis. In agreement with this notion, the skin 
rash in Hartnup disorder responds to nicotinic acid supplementation [114], and also to 
supplementation of tryptophan-ethyl ester [115]. It appears likely that tryptophan 
malabsorption in Hartnup disorder can be compensated by peptide uptake and also by amino 
acid absorption in distal sections of the intestine [116]. In the two initial studies, nine mutations 
and two aberrant splicing in SLC6A19 were described [77, 78], in two subsequent studies, 
another ten mutations were identified [79, 96, 113]. Most mutations are rare occurring at a 
frequency of below 0.1% [111]. D173N was identified as the major mutation of SLC6A19 in 
the Australian population, with a frequency of 1 in 140 people (0.007) [77]. 
1.7 Slc6a19 knockout mice 
Our lab previously reported that Slc6a19 nullizygous mice had neutral aminoaciduria, a 
reduction in body size and body weight, and decreased insulin secretion in response to food 
ingestion after fasting [42]. More importantly, Slc6a19 nullizygous mice showed improved 
glycaemic control, indicating that inhibition of the transporter might lead to improved insulin 
sensitivity. Moreover, glucose transport in the intestine was also decreased by more than 50% 
possibly due to the formation of a complex between the apical glucose transporter SGLT1 
(sodium-dependent glucose transporter 1) and B0AT1. Reduced amino acid absorption in the 
intestine resulted in reduced activation of mTOR (mammalian target of rapamycin) as indicated 
by reduced ribosomal protein S6 phosphorylation and the activation of the GCN2 (general 
control non-derepressible 2) /ATF4 (activating transcription factor 4) stress response pathway 
resulting in eIF2α (eukaryotic initiation factor 2α) phosphorylation [42]. Further 
characterisation of Slc6a19 knockout mice revealed that the reduced uptake of neutral amino 
acids in the intestine causes an increased amino acid load in the lumen of the intestine, which 
triggered the release of the two incretins glucagon-like peptide 1 (GLP-1) and gastric inhibitory 
polypeptide (GIP) from the intestine. Delayed amino acid absorption in addition results in the 
release of the hormone fibroblast growth factor 21 (FGF21) by a starvation response in the 
liver. The combination of these hormones caused a series of beneficial phenotypes including 
efficient glucose removal particularly by heart, reduced adipose tissue mass, browning of white 
adipose tissue, stimulation of ketone body production, reduced hepatic glucose output and 
reduced liver triglycerides. These results provided new evidence for B0AT1 as a novel target to 
treat type 2 diabetes [105]. GLP-1 and GIP are two incretins that prepare the body for nutrient 
intake by enhancing insulin secretion and reducing appetite. GLP-1 has also been reported to 
increase glucose consumption in heart, thus, dual agonists of these two hormones are being 
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developed as drugs to treat T2DM [117]. FGF21 was reported to inhibit liver fatty acid 
synthesis and to stimulate white adipose tissue browning via the activation of GCN2 signalling. 
FGF21 expression can be stimulated by the restriction of methionine [118] or leucine [119]. 
Clinical trials using FGF21 mimetics showed significant improvements of the plasma lipid 
profile in obese patients, however, body weight and glucose homeostasis was not affected by 
the drug. Moreover, hypersensitivity reactions caused by subcutaneous injection are significant 
side-effects of the drug [120]. 
1.8 Hypothesis 
We hypothesized that the pharmacological inhibition of B0AT1 using small molecule chemical 
compounds could be able to replicate the metabolic phenotype of Slc6a19 knockout mice, thus 
providing new lead compounds to treat type 2 diabetes. 
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Chapter 2: Cell Line Generation and Method Validation 
2.1 Introduction 
In this chapter I shall introduce tools and methods that are used for drug and inhibitor screening 
that can be scaled up for the use in high-throughput screening (HTS) using B0AT1 as an 
example. 
Previously, B0AT1 and its interaction with ancillary proteins ACE2 and collectrin has been 
studied in Xenopus laevis oocytes [73]. This expression system is superior for the study of 
transporter kinetics and structure-activity relationships. However, for the efficient screening 
and characterisation of novel inhibitors, a system that is more suitable for rapid data generation 
had to be developed. Using cell lines as in vitro models for drug screening, particularly HTS, 
is widely accepted due to its standard tissue culture procedures, fast cell proliferation, well 
understood culture medium requirements, high transfection efficiency, as compared to primary 
cells and stem cells [121]. As mentioned above, amino acid transporters are highly expressed 
in many human cancer cell lines for the demand of tumour growth. In this case, an oncology 
microarray database called Oncomine is potentially useful for identifying cell models with high 
expression levels of the desired transporter. Oncomine is a web-based data-mining platform 
with standardized microarray datasets (currently 715 in total) derived from published data or 
authors’ correspondence by Compendia Bioscience. It comprises a total of 86,733 samples 
including gene expression data from over 500 cancer types and a wide range of human cancer 
cell lines [122]. Oncomine has been used widely for gene target or cell model selection [123, 
124], biomarker development [125, 126] and anticancer drug screening studies [127, 128]. 
Moreover, Oncomine was also used in studies related to amino acid transporters [58, 129, 130]. 
If the endogenous expression of a transporter is sufficient, the selected cell line can directly be 
used for inhibitor screening. However, more often the target protein needs to be expressed 
heterologously. Stable transfection [131] is used to integrate the gene of interest into the 
genome of suitable cells, avoiding the loss of transfected material. It is accomplished by 
introducing a marker gene as a selectable tool together with the gene of interest. The Flp-In™ 
stable transfection system is a Saccharomyces cerevisiae-derived DNA recombination system, 
allowing the integration of a gene of interest into the genome of mammalian cells at a particular 
location called the Flp Recombination Target (FRT) site [132]. The FRT site is first introduced 
into the genome of a mammalian cell line of choice using a Flp-In™ target site vector, 
pFRT/lacZeo, to generate a host cell line. Subsequently, an expression vector containing any 
gene of interest can be integrated into the genome via Flp recombinase-mediated DNA 
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recombination at the FRT site. Successfully transfected clones expressing the gene of interest 
can be selected using hygromycin resistance and Zeocin sensitivity (Flp-In™ System User 
Manual, Invitrogen). In detail, the Flp-In™ host cell line contains an SV40 early promoter, an 
ATG initiation codon, a single integrated FRT site acting as the binding and cleavage site for 
Flp recombinase, and a Zeocin resistance gene for selection. Then the pcDNA/FRT expression 
vector containing the gene of interest is co-transfected with pOG44 into the Flp-In™ host cell 
line. The pOG44 plasmid expresses Flp recombinase constitutively under the control of the 
human CMV promoter, catalysing the insertion of the pcDNA5/FRT construct into the genome 
at the FRT site. The insertion inactivates the lacZ-Zeocine fusion gene and at the same time 
introduces a hygromycin resistance gene in frame with the SV40 promoter and ATG initiation 
codon. As a result, the transfected cells become hygromycin resistant but Zeocine sensitive, 
which allows the selection of stable Flp-In expression cell lines by using hygromycin as an 
antibiotic. This Flp-In transfection system has been used routinely to generate highly 
reproducible stable transgenic cells for the expression of cytosolic or membrane proteins in 
various parental cell lines, including HEK293 (human embryonic kidney) cell line [133], CV-
1 (African Green monkey kidney) cells line [134], CHO-K1 (Chinese Hamster Ovary cells) 
[135], BHK (Baby hamster kidney cells) [136], NIH/3T3 (mouse embryonic fibroblast) [137] 
and Jurkat (human T-cell leukemia) [138]. 
The Chinese hamster ovary (CHO) cell line was one of the first hosts to be used in stable 
transfection, and has become one of the most popular cell line for recombinant protein 
production [139]. It was first isolated by T.T. Puck in 1957 [140], and requires proline in the 
culture medium because of a defect in proline synthesis [141]. Three CHO cell lines are 
commonly used: the CHO-K1 line, the CHO-DXB11 line and the CHO-DG44 line, among 
which CHO-K1 is the only cell line still having a functional DHFR (dihydofolate reductase) 
gene. DHFR-deficient cell lines can be used for introducing the gene of interest (GOI) by a 
DHFR selection system [142]. The genome of CHO-K1 was sequenced for the first time by Xu 
et al. in 2011, which accelerated the application of this cell line [143]. CHO cells have become 
a popular mammalian expression system, particularly for the overexpression of recombinant 
proteins due to their rapid growth and high protein production [142]. Due to their epithelial-
like property, CHO cells were also used to study membrane proteins, such as ion channels 
(KCNQ potassium channel and epithelial sodium channels) [144], α2β adrenergic receptor by 
transient transfection [145] or β2 adrenergic receptor by stable transfection [146] in structural 
studies. CHO cells are also useful for the expression of amino acid transporters, because their 
endogenous transporters have been studied in some detail [147]. System L-like transport 
 18 
(including LAT1 and LAT2) was reported to mediate the Na+-independent pregabalin (PGB) 
uptake in CHO cells [148]. Both of these transporters are functional in a heteromeric complex 
with the heavy subunit 4F2hc (SLC3A2) to act as exchangers and harmonizers of large neutral 
amino acids [12]. LAT1 substrate selectivity for neutral amino acids is more narrow compared 
to LAT2; and only LAT1, but not LAT2, interacts with D-amino acids [149]. A LAT1-like 
activity was detected in CHO cells also by Shikano et al. [150]. 
Apart from choosing an appropriate in-vitro cell model, selection of appropriate assays is 
critical for compound screening studies. Membrane potential based assays including 
Fluorescent (Fluorometric) Imaging Plate Reader (FLIPR) assays and Fluorescence Resonance 
Energy Transfer (FRET) assays are widely used to monitor the function of ion channels and 
electrogenic transporters [151]. FLIPR assays were designed to quantitively analyse changes 
in membrane potential, elicited by activation of ion permeable receptors, ion channels or 
transporters [152]. They have been used in a variety of drug discovery applications including 
HTS of chemical compound libraries at the initial stage [153, 154], and analysis of compound 
potency, selectivity and specificity at the follow-up stage [155, 156]. The major advantages of 
this system include real-time recording and rapid measurement of membrane potential changes 
in either a 96-well or 384-well format, which are essential for the HTS [157]. Bis-(1,3-
dibutylbarbituric acid)trimethine oxonol [DiBAC4(3)] is a traditional membrane potential 
sensitive dye also used in fluorescence resonance energy transfer (FRET) assays. Membrane 
depolarization causes it to partition into the membrane, which in turn increases its fluorescence. 
It is extruded out of the membrane following hyperpolarization, resulting in a decrease in 
fluorescence [157]. Because of its slow response, DiBAC4(3) is not well suited for fast 
screening applications [151]. Moreover, this dye is temperature sensitivity and works only at 
37°C. A faster responding and temperature-flexible dye has been developed as the FLIPR 
membrane potential assay kit by Molecular Devices (FMP) (figure 2.1.1). In addition, the 
fluorescent sensor is pre-combined with impermeable quenchers (either a blue quencher or a 
red quencher) in the kit to reduce the background fluorescence signal and to improve the signal-
to-noise ratio. This is necessary because the dye-loaded cells cannot be washed. Last but not 
the least, the FMP dye has higher temperature stability compared to the traditional dyes, e.g. 
dye loading and plate reading can occur at room temperature. In addition to FLIPR assays, 
FRET is also a popular technique used for the detection of membrane potential changes [158, 
159] and the characterization of amino acid transport [160, 161]. The principle of FRET is to 
have a donor dye (e.g. coumarin-linked phospholipid (CC2-DMPE) in the Pan Vera system) 
outside the cell coupled with an oxonol dye (e.g. DiSBAC2(3) in the Pan Vera system) acting 
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as a mobile voltage sensor and FRET acceptor [162]. Upon depolarization, the negatively-
charged hydrophobic oxonol dye partitions into the plasma membrane, whereas the FRET 
donor only binds to the exterior side of the cell membrane, consequently resulting in an 
increased emission ratio of donor’s blue fluorescence signal (@460nm) over acceptor’s red 
fluorescence signal (@570nm) (BMG Labtech). When using two FRET acceptors [DiSBAC1(5) 
and DiSBAC1(3)] in the Axiom system, it increases the sensitivity of the assay (Axiom 
Biotecnologies Inc.). Wolff et al. systematically compared ion channel screening assays using 
the above two FLIPR systems and two FRET systems. The study showed a good correlation 
among these 4 systems when determining IC50 values. The FLIPR dye from Molecular Devices 
showed the highest signal over background ratio and the FRET system from Pan Vera had the 
fastest response [151]. Although no obvious improvement in signal stability or Z’ parameter 
was seen when comparing to the traditional oxonol dye DiBAC4(3), the author still found a few 
benefits of using these novel dye systems in the large-scale HTS, such as reduced temperature 
sensitivity, faster responses and simplified assay procedures. The Z’ parameter, also known as 
Z’ assay sensitivity factor, is a measurement of statistical effect size that considers the average 
and standard deviation of both positive and negative controls, when Z’>0.8, it is ideal for HTS, 
although Z’>0.5 is also acceptable [163]. 
As outlined above, the electrogenicity of B0AT1 transport is due to the symport of sodium ion 
with amino acid substrate at the ratio of 1:1, hence, the detection of sodium ion crossing the 
membrane by ion-sensitive fluorescent dyes is another option to measure transport function. 
One of the most commonly used Na+-indicators is sodium-binding benzofuran isophthalate 
(SBFI), which was first designed and characterized in 1989 [164]. The applications of this 
indicator in the quantification of intracellular free sodium ion is flexible, allowing fluorescence 
ratiometric analysis, fluorescence lifetime imaging microscopy (FLIM) [165, 166], and it can 
be adapted to microplate readers as well [167]. However, SBFI requires UV excitation and is 
difficult to load. Attempts were made to find alternatives excitable in the visible range, 
including Sodium Green [168], CoroNa Red [169] and CoroNa Green [170]. Unfortunately, 
they are not ideal for various problems, such as inaccurate measurements of sodium ion due to 
the association with cell proteins [171], incapability to detect small [Na+]i changes [172], and 
fast leakage from cells after loading [173]. An improved efficient and sensitive sodium dye, 
namely Asante NaTRIUM Green (ANG), has been developed recently. It enables accurate 
measurements of intracellular Na+ dynamics in situ with a bright fluorescent signal during 
physiological responses [174]. When comparing with SBFI, it displays a range of desirable 
characteristics, including high sensitivity and loading efficiency, resistance to photobleaching, 
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as well as good fluorescent brightness and dynamic range (TEFLABs). Acetoxymethyl (AM) 
ester are used to improve loading efficiency by increasing the permeability of the sodium dye 
(figure 2.1.2). In addition, Pluronic F-127 is always used as a surfactant polyol to disperse the 
AM esters of fluorescent ion indicators [175]. Lower concentrations of Pluronic F-127 
dissolved in DMSO proved to yield a better loading and staining efficiency of an AM ester 
calcium dye [176]. Both the FLIPR assay and the sodium indicator assay were used in HTS 
because of their adaptability to multi-well plate readers. One lab has previously evaluated the 
ANG-2 sodium sensing dye (TEFLABs) in a 1536-well format assay by comparing with the 
FMP blue dye (Molecular Devices), identifying a large amount of unique hits from each assay. 
The author suggested to use both assays in an HTS strategy to increase the likelihood of 
recognition of true positives [177]. 
To reduce false positive rates, a secondary assay is usually required in the drug screening, 
especially after HTS. For example, a radio-labelled substrate uptake assay is a reliable direct 
measurement of the transport activity. 14C and 3H are beta-particle emitting radioisotopes 
generally used for labelling due to safety issues, however, 14C is employed more often because 
of its higher energy and higher efficiency in liquid scintillation counting (LSC), in which the 
beta particle transfers energy to the scintillator, which in turn emits light. The number of light 
flashes generated by a beta-particle is a direct measure of its energy and is detected by a 
scintillation counter. The assay has been used in numerous studies. A recent example from our 
lab is the analysis of amino acid fluxes in 143B osteosarcoma cells using 14C-labelled 
glutamine revealed the essential role of two system A amino acid transporters in glutaminolysis 
in cancer cell lines with depletion of ASCT2 [58]. 
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Figure 2.1.1: Principle of membrane potential (FLIPR) assay (Molecular Devices): the voltage-
sensitive dye allows the detection of membrane potential changes in the following way. During 
membrane hyperpolarization, fluorescent signal decreases in intensity as the negatively charged blue 
dye accumulates outside the membrane (middle). During membrane depolarization, the fluorophore 
penetrates into the membrane bilayer, increasing in intensity as the dye accumulates inside the 
membrane (right). Fluorescence is quenched by specific dyes outside the cell (orange half circles). 
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Figure 2.1.2: Principle of sodium dye assay. The acetoxymethyl ester (AM)-ester of Asante 
NaTRIUM Green 2 (ANG-2) is used to increase the permeability of the dye to the plasma membrane. 
Once the dye permeates into the cytosol, its acetoxymethyl group is cleaved by intracellular esterases 
to allow the interaction between the dye and Na+. Meanwhile, cleavage of the acetoxymethyl group 
dramatically increases the hydrophilicity of the dye to prevent its leaking out of the cell. The 
extracellular unloaded dye will be washed away, and the intracellular sodium-bound dye can be detected 
by a fluorescence detector with the excitation wavelength of 488nm and the emission wavelength of 
540nm. 
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2.2 Materials and Methods 
2.2.1 Cell lines and media 
A CHO (Chinese Hamster Ovary) Flp-InTM host cell line (CHO parental) and a CHO cell line 
stably expressing human B0AT1 (hB0AT1) and human collectrin (hcollectrin) using a Flp-In™ 
transfection system (Invitrogen) (CHO-BC) were provided by Sanofi-Aventis Pharmaceutical 
Company. CHO parental cells were cultured in Ham’s F-12 Nutrient Mix GlutaMAXTM 
medium (Gibco® GlutaMAXTM supplement L-alanyl-L-glutamine dipeptide was used as a 
replacement of L-glutamine due to higher stability and minimal levels of toxic ammonia) 
(Invitrogen, #31765035) supplemented with 10% (v/v) heat-inactivated fetal bovine serum 
(FBS) (Invitrogen, #10082147) and 100µg/mL Zeocin selection antibiotic (Invitrogen, #R250-
01), while CHO-BC cells were maintained in the same medium supplemented with 10% (v/v) 
FBS, and selection antibiotics Hygromycin B (0.33mg/mL, Invitrogen, #10687010) and 
Geneticin (G418 sulfate) (0.275mg/mL, Invitrogen, #10131035). The Ham’s F-12 
GlutaMAXTM medium could be replaced by Ham’s F-12 medium (Sigma, #N4888) 
supplemented with 1mM L-alanyl-L-glutamine dipeptide (Sigma, #A8185). CHO-BC cells 
were not used for radio-labelled substrate uptake assays after passage 10 or in membrane 
potential assays after passage 15 due to the gradual loss of transport activity. 
GP2d (human colon adenocarcinoma cell line), LLC-PK1 (pig kidney epithelial cell line) and 
MCF-7 (human breast adenocarcinoma cell line) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) / Ham’s Nutrient Mixture F12 (Sigma, #D8437) supplemented with 
10% (v/v) FBS, 1X non-essential amino acids (NEAAs, 1:100 dilution of the original stock 
solution) (Gibco, #11140) and 2mM L-glutamine. 143B TK- (human osteosarcoma cell line) 
cells were cultured in the same medium without the addition of NEAAs. HuH7 (human 
hepatoma cell line) cells were cultured in MEM GlutaMAX™ (Invitrogen, #41090036), 
supplemented with 10% (v/v) FBS, 1X NEAAs, as well as 5mM glucose (glucose final 
concentration was 10mM). HuH7 cells were seeded onto collagen (Sigma, #c4243) – coated 
dishes to enhance attachment. MDCK (Madin-Daby canine kidney cell line) and Li-7 (human 
hepatoma cell line) cells were maintained in DMEM / F-12 Ham medium (Sigma, #D8437) 
supplemented with 10% (v/v) FBS. Li-7 cells were purchased from the Riken BRC Cell Bank 
(RCB1941), other cell lines were from stocks available in the laboratory. 
All cells were maintained in 75cm2 flasks containing 20mL culture media in a 95% air, 5% 
CO2, 37°C humidified incubator. The medium was changed every 3-4 days. Cells were 
passaged and subcultured once reaching 80-90% confluence. After removing old culture 
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medium from the flask, cells were detached by addition of 5mL of 0.05% trypsin-EDTA 
solution (Invitrogen, #25300054) for 3-4min at 37°C. After trypsinization, the detached cells 
were resuspended in 15mL culture medium, and a total volume of 20mL cell suspension was 
transferred to a 50mL falcon tube for centrifugation. For cell counting, 100µL cell suspension 
at this stage was taken out and mixed with same volume of 0.4% (w/v) Trypan Blue solution 
(Invitrogen, #15250061). After thoroughly mixing the cell suspension with Trypan Blue 
solution, 20µL of the mixture was added under the cover-slip of a hemocytometer. Four fields 
were counted under 100x microscope magnification and the total cell number was calculated 
by the average count per field x 2 (dilution factor of cells in trypan blue mixture) x 104 x 20 
(total volume of cell suspension). The remaining cell suspension was spun down at 1500rpm 
for 5min and the supernatant was completely removed. The cell pellet was resuspended in 1mL 
culture medium, with about 2x105 cells added back to the 75cm2 flask for maintenance, while 
the rest of the cells were seeded out for experiments. For future use, cell pellets were 
resuspended in freezing medium (90% FBS and 10% DMSO) and gradually chilled to -80°C. 
After 24hr, cells were transferred to liquid nitrogen for long-term storage. 
2.2.2 Transient transfection using Lipofectamine 
Before transfection, the cells were seeded in 35mm dishes at a density of 0.5x106 cells/dish and 
maintained in full culture medium overnight so that cell density reached 70-90% confluence at 
the time of transfection. The transient transfection with constructs of hB0AT1, hcollectrin or 
hHNF1α were conducted in the presence of LipofectamineTM 2000 (Invitrogen, #11668019), 
LipofectamineTM LTX (Invitrogen, #15338100) or LipofectamineTM 3000 (Invitrogen, 
#L3000001) according to the manufacturer’s instructions. The plasmid constructs were 
generated previously in our lab [40]. On the day of transfection, the culture medium in each 
dish was replaced by fresh medium without antibiotics. The transfection reagent was prepared 
in microtubes as follows: 
Tube 1: 10µL LipofectamineTM 2000 + 240µL Opti-MEMTM medium (Invitrogen, #31985062), 
or 9µL LipofectamineTM LTX + 241µL Opti-MEMTM medium; 
Tube 2: 2.5µg plasmid DNA + Opti-MEMTM medium, total volume 250µL; 
For Lipofectamine 3000: 
Tube 1: 5µL LipofectamineTM 3000 + 120µL Opti-MEMTM medium; 
Tube 2: 2.5µg plasmid DNA + Opti-MEMTM medium + 5µL P3000TM Reagent (from the 
LipofectamineTM 3000 kit), total volume 125µL; 
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The mixtures were incubated at room temperature for 5min, followed by adding the content of 
tube 2 to tube 1. The transfection reagent (500µL, 250µL for LipofectamineTM 3000) was 
further incubated at room temperature for 20min, then added drop-by-drop to the 35mm dish 
with cells and 1.5mL medium (1.75mL for LipofectamineTM 3000). The transfection medium 
was replaced by full culture medium at 6hr post-transfection. The cells were incubated for 48hr 
before further testing or subculture. Maps of constructs used in transient transfection are shown 
in figure 2.2.1. The map of pcDNA3.1/hB0AT1 is shown in figure 2.2.2C, the expression 
plasmid of mouse HNF1α integrated in a pCMV6 vector was purchased from Origene 
(#MC202766). 
 
Figure 2.2.1: Maps of constructs. A) pIRES/hB0AT1/hcollectrin; B) pcDNA3.1/hcollectrin. 
 
2.2.3 Generation of pcDNA5/FRT/hB0AT1 construct 
The principle of Flp-mediated recombination and the procedures of generating 
pcDNA5/FRT/hB0AT1 construct is illustrated in figure 2.2.2, while the confirmation of each 
step by electrophoresis in the generation of the construct is shown in figure 2.2.3. The 
orientation of the insert (B0AT1) was confirmed by electrophoresis (figure 2.2.3E) and the 
insertion was confirmed by sequencing (data not shown) using the T7 priming site (bases 863-
882) and BGH reverse priming site (bases 1022-1039). 
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Figure 2.2.2: The principle of Flp-mediated recombination and the procedures of generating the 
pcDNA5/FRT/hB0AT1 construct. A) The Zeocin-resistant Flp-In™ host cell line has a FRT site 
inserted just downstream of its SV40 promoter and ATG initiation codon. Co-transfection with plasmids 
pOG44 and pcDNA5/FRT facilitates recombination of the gene of interest into the FRT site of the host 
cell line. The pcDNA5/FRT vector carries a hygromycin resistance gene with a FRT site embedded in 
the 5’ coding region but without a promoter and the ATG initiation codon. Meanwhile, the pOG44 
plasmid expresses the Flp recombinase, which catalyses a homologous recombination event between 
the FRT sites both in the genome of the host cell line and in the expression vector. The insertion of the 
expression vector into the genome at the FRT site results in the relocation of the hygromycin resistance 
gene behind the SV40 promoter and in frame with the ATG initiation codon and at the same time 
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relocates the lacZ-Zeocin fusion gene to a site without promoter. Therefore, the successfully transfected 
clones could be selected by hygromycin resistance. B) The flow diagram of the generation of 
pcDNA5/FRT/hB0AT1 construct. C) The ligation of the target vector (pcDNA5/FRT) and the insert 
(hB0AT1) to form the final construct. 
 
Figure 2.2.3 Generation of pcDNA5/FRT/hB0AT1 construct. A) The purity and integrity of 
propagated vectors was checked by electrophoresis. 1µg of plasmid DNA was loaded onto a 1% agarose 
gel. From left to right: supercoiled NEB DNA ladder (BioLabs, N0472s), pcDNA5/FRT vector 
(5070bp), pOG44 vector (5785bp). B) First restriction digestion of pcDNA5/FRT vector and 
pcDNA3.1/B0AT1 plasmid by HindIII. The digested products as well as undigested plasmid DNA were 
run on a 1% agarose gel. The left ladder is a 1kB DNA ladder (BioLabs, N3232), the right ladder is 
supercoiled NEB DNA ladder. C) Second restriction digestion by NotI. The NotI-digested products 
were run on a 1% agarose gel, with a small amount for size checking (Lane 1 for pcDNA5/FRT, Lane 
3 for pcDNA3.1/B0AT1) and a large amount for gel cutting. The digested products with correct sizes 
were cut out of the gel, purified and checked on a 1% agarose gel (Lane 2 for pcDNA5/FRT target 
vector, Lane 4 for B0AT1 insert). D) Rapid screening of E. coli transformants containing the ligated 
vector and insert on a 1% agarose gel. Expected sizes of the bands: pcDNA5/FRT target vector (5002bp), 
hB0AT1 insert (2007bp), pcDNA5/FRT/hB0AT1 construct (7009bp). Colony #1, 8, 11, 12, 14 were 
regarded as complete constructs, whereas colony #2, 3, 9, 16 contained the insert only and colony #4, 
5, 6, 7, 10, 13, 15, 17, 18 were vector only. E) Orientation check for the insert by restriction digestion 
using KpnI. The location of the insert (hB0AT1) in the pcDNA5/FRT/B0AT1 construct is between 969 
and 2873 bps. KpnI cuts at 917bp and 1495bp, so the expected sizes of bands are 6431bp and 578bp if 
the orientation is correct. 
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The pcDNA5/FRT expression vector and the pOG44 vector were provided with the Flp-In™ 
transfection system kit (Invitrogen, #K601001). Both vectors were first propagated in a recA1-
reduced, endA1-eliminated E.coli strain (NEB 5-alpha Competent E. coli) following NEB 
C2987H/C2987I high efficiency transformation protocol. To this end, 100ng plasmid DNA was 
mixed with a tube of thawed competent E.coli cells and incubated on ice for 30min. Then the 
mixture was heat-shocked at 42°C for 30sec, followed by an incubation on ice for another 5min. 
To improve recovery of E. coli after transformation, 950µL of SOC medium (Invitrogen, 
#15544034) was added into the cell-plasmid mixture and mixed thoroughly by shaking at 
250rpm and 37°C for 90min. Different volumes (2µL, 5µL, 15µL) of the mixture were spread 
onto pre-warmed selection LB agar plates and incubated at 37°C overnight. On the following 
day, single colonies on LB agar plates were picked and propagated by shaking in 5ml LB broth 
(25g/L) containing 100µg/mL ampicillin selective antibiotic at 37°C for 8hr. For plasmid 
isolation the starter culture was diluted 1/1000 into 100mL LB broth containing 100µg/mL 
ampicillin and propagated by shaking at 300rpm and 37°C overnight. 
For transfection, the plasmid DNA was purified to Endotoxin-free standard using a Nucleobond 
Xtra Midi EF kit (Macherey-Nagel, #740420.10) according to the manufacturer’s instructions. 
After overnight incubation, plasmid containing cells were first spun down by centrifugation in 
two 50mL falcon tubes at 3270 x g and 4°C for 20min. The supernatant was discarded and the 
pellet was resuspended completely in Resuspension Buffer. The cells were lysed by gently 
mixing Lysis Buffer into the suspension and incubating at room temperature for 5min. The cell 
lysate was then neutralized in Neutralization Buffer and incubated on ice for 5min before 
loading onto the pre-equilibrated NucleoBond Xtra column filter for clarification by gravity 
flow. After three washes of the column, the plasmid DNA was detached with Elution Buffer 
and the yield was determined by measuring A260 with a NanoDrop™ 1000 microvolume 
spectrophotometer (Invitrogen). The eluted plasmid DNA was precipitated with isopropanol 
and collected by centrifugation at 15,000 x g for 30min in a benchtop centrifuge. The 
precipitates were washed with 70% endotoxin-free ethanol and air-dried at room temperature 
for 10-15min to remove all ethanol. Finally, the DNA pellet was dissolved in endotoxin-free 
buffer or water to a final concentration of 0.5-1µg/µL. The final yield was determined with a 
NanoDrop™ 1000, and the purity and integrity of plasmid DNA was confirmed by 
electrophoresis using 1% agarose gel. 
The Endotoxin-free pcDNA3.1/hB0AT1 construct was generated in our lab previously. The 
hB0AT1 insert of this construct was cut out and subcloned into the pcDNA5/FRT expression 
vector from the Flp-In™ transfection system kit using the following strategy. Two restriction 
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digestions were applied on both pcDNA5/FRT vector and pcDNA3.1/hB0AT1 construct. The 
first digestion was conducted with HindIII (BioLabs, R0104s) in 50µL 1X NEB buffer2 
(BioLabs, R7002s) containing 6µg of pcDNA5/FRT vector or pcDNA3.1/hB0AT1 construct 
and 40 units of HindIII. The mixture was incubated at 37°C for 4hr and the digested products 
were checked on a 1% agarose gel to ensure complete digestion. Then the digested products 
were heat-inactivated at 65°C for 20min and purified using Wizard SV gel and a PCR clean-
up system (Promega, A9281). The second digestion was done with NotI (BioLabs, R0189s). 
The digestion reaction was assembled in a total volume of 50µL 1X NEB Buffer3.1 (BioLabs, 
B7203s), containing the products from the first digestion, and 40 units of NotI. The mixture 
was incubated at 37°C for 4hr and the digested products were heat-inactivated at 65°C for 
20min. After digestion was completed, Antarctic Phosphatase (BioLabs, M0289s) was used on 
the target vector (pcDNA5/FRT) to remove 5’ phosphoryl groups and prevent its self-ligation. 
The alkaline phosphatase reaction was conducted by adding 5µL of 10X Antarctic Phosphatase 
Reaction Buffer and 1.5µL (7.5 units) of Antarctic Phosphatase (BioLabs, M0289s) into the 
second digestion reaction and incubating at 37°C for 1hr, followed by heat-inactivation at 65°C 
for 5min. Then the target vector and the insert were run on a 1% agarose gel, with a small 
amount (about 500ng) used to determine the size and the remaining digestion products used for 
gel purification. The cut gel was melted by heating at 65°C for 10-20min in chaotropic buffer. 
The plasmid fragment was purified using a Wizard SV gel and PCR clean-up system (Promega 
A9281) and checked on a 1% agarose gel. Ligation of the target vector (pcDNA5/FRT) and the 
insert (hB0AT1) was performed using a Quick Ligation Kit (BioLabs, M2200s). To this end, 
50ng of the vector was combined with a 3-fold molar excess of insert, together with 1X Quick 
Ligation Reaction Buffer and 2µL of Quick T4 DNA Ligase to make a total volume of 20µL. 
After mixing and collecting the reagents at the bottom of a microcentrifuge tube, the ligation 
reaction was incubated at room temperature for 30min. The high-efficiency transformation of 
E.coli was conducted immediately after the completion of ligation using NEB protocol 
C2987H/C2987I as described above. On the next day, single colonies were selected and spread 
on agar plates. Plasmid-containing colonies were selected by a rapid screening process as 
follows. The smears of the colonies were first collected in microcentrifuge tubes and 
resuspended in 40µL of 10mM EDTA (pH8.0). The suspension was then incubated at room 
temperature for 5min in the presence of 50µL of 2X cracking buffer (1mL of 2X cracking buffer 
contained 0.2g sucrose, 50µL of 10% SDS, 40µL of 5M NaOH), followed by incubation on ice 
for 5min in the presence of marker mix (1.5µL of 4M KCl, 1µL of 0.4% Bromophenol blue, 
and 10µL of 10mM EDTA). The samples were spun down in a benchtop centrifuge at top speed 
(13,200rpm) for 3min and 25-50µL of supernatant was loaded on a 1% agarose gel. The 
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selected colonies were propagated in LB broth (25g/L) containing 100 µg/ml ampicillin by 
shaking at 300rpm and 37°C overnight and the plasmids purified using a PureLink Quick 
Plasmid DNA miniprep kit (Invitrogen, K2100-10) according to the manual. Finally, the 
orientation of the insert was tested by cutting the construct with KpnI (BioLabs, R0142s). The 
restriction digestion was done in 50µL 1X NEB Buffer I containing 1µg of the plasmid DNA 
and 2µL of KpnI (20 units) at 37°C for 1.5hr. The final digestion products were run on a 1% 
agarose gel.  
Five pre-selected colonies were sequenced to confirm the insertion of B0AT1. The purified 
plasmid DNA was used as a template in the cycle sequencing reaction containing 2µL Big Dye 
Terminator (BDT), 3µL of 5x sequencing buffer, 3.2pmol T7 primer (5’-
TAATACGACTCACTATAGGG-3’) or BGH reverse primer (5’-
TAGAAGGCACAGTCGAGG-3’), 300ng template, ddH2O to a final volume of 20µL. The 
sequencing reaction was performed under the following conditions: 
1. Incubate at 94°C for 5 min---Initialization 
2. Incubate at 96°C for 10 sec---Denaturation 
3. Incubate at 50°C for 10 sec---Annealing 
4. Incubate at 60°C for 4 min---Extention/Elongation 
Repeat step 2-4 for 30 cycles 
5. Incubate at 60°C for 4 min ---Final Elongation 
6. Hold at 22°C 
For purification, the 20µL cycle sequencing reaction was mixed with 2µL of 3M NaAcetate 
(pH4.6 or pH5.2), 50µL of Ethanol (100%), and incubated at room temperature for 15min. The 
products were then pelleted by centrifugation at maximum speed (16,000 x g) for 20min in a 
benchtop centrifuge. The pellets were washed twice with 70% Ethanol, 250µL/time. After 
removing the ethanol, the pellets were air-dried and stored in a -20°C freezer until being 
delivered to Biomolecular Resource Facility (BRF) in the Australian National University for 
sequencing. 
2.2.4 Generation of CHO cell line stably expressing hB0AT1 and hcollectrin 
The CHO Flp-InTM host cell line with a single integrated FRT (Flp Recombination Target) site 
was purchased from Invitrogen (R758-07). The host cell line was maintained in Ham’s F-12 
medium (Sigma, #N4888) supplemented with 1mM Ala-Gln peptide (Sigma, #A8185), 10% 
(v/v) FBS and 100µg/ml Zeocin. The sensitivity of the host cell line to Hygromycin B 
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(Invitrogen, #10687010) was measured by IncuCyte Live Cell Analysis (Essen BioScience, 
Inc.) to determine the concentration of the antibiotic used for selecting successfully transfected 
colonies. To this end, the host cells were seeded at a density of 2000 cells/well in 200µL 
suspension in a 96-well plate. The cells were allowed to settle down in full culture medium for 
6hr before exposing them to different concentrations of Hygromycin B (0, 50, 100, 200, 400, 
600, 800µg/ml), 12 wells/concentration. The confluence of each well was scanned by IncuCyte 
every 3hr, and the medium was refreshed every 2-3 days to ensure sustained pressure from the 
antibiotics in the medium. The growth curve, depicted as percentage of confluence over time, 
was generated at the end of the incubation and the concentration for selection was determined 
as the minimal concentration (400µg/ml) that prevented growth within the timeframe required 
for the control cells to reach confluence. The Flp-In host cells were then transfected with 
pcDNA5/FRT/hB0AT1 construct using LipofectamineTM 2000 in the way described above. The 
pOG44 plasmid was co-transfected with the expression construct at a ratio of 9:1 (w/w), i.e. a 
total of 22.5µg pOG44 and 2.5µg pcDNA5/FRT/hB0AT1 was transfected together. 6hr post 
transfection, the transfection medium was replaced with culture medium without any 
antibiotics, and 48hr after transfection, the cells were split and seeded onto 10cm plates at a 
density of 8.8x105 cells per plate (10% confluence) containing medium with the preselected 
concentration (400µg/ml) of Hygromycin B. The medium with Hygromycin B was changed 
once every 2-3days until clones of hygromycin-resistant cells were identified. Then the 
hygromycin-resistant foci were picked from the 10cm plates and transferred to 24-well plates. 
The foci were first located and marked under a microscope. After removing the culture medium, 
the foci were enclosed by cloning cylinders (Sigma, c1059), detached by addition of 100µl of 
0.05% trypsin-EDTA inside the cylinders for couple of minutes, and then transferred into 
sterilized microcentrifuge tubes containing 200µl culture medium. The cells were pelleted by 
centrifugation at 500 x g for 5min in a benchtop centrifuge, and transferred into 24-well plates 
with full culture medium containing Hygromycin B for propagation. When confluent in 24-
well plates, the cells were transferred to 25cm2 or 75 cm2 flasks for further propagation. Once 
growing to a larger cell number, B0AT1 expression was checked at protein and mRNA level 
before performing the co-transfection with collectrin. 
After successful transfection with B0AT1, CHO cells were tested for their sensitivity to 
Geneticin (G418 sulfate, Invitrogen, #10131035) by IncuCyte technology to determine the 
concentration (800µg/ml) to be used for selection of collectrin-transfected cells. Collectrin was 
subcloned into pcDNA3.1 which carries a Geneticin resistance gene. The pcDNA5/B0AT1 
transfected cells were seeded into 35mm dishes and maintained overnight in full medium 
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containing 400µg/ml Hygromycin B. The transfection with 2.5µg pcDNA3.1/hcollectrin 
construct was performed in the presence of LipofectamineTM 2000 in the way described above. 
Transfection medium was replaced with full medium containing 400µg/ml Hygromycin B 6hrs 
after transfection, and 8.8x105 cells were seeded into 10cm plates with culture medium 
containing the preselected concentration (800µg/ml) of G418 48hrs post transfection. The 
medium was refreshed once every 2-3days until clones formed. Hygromycin-and G418- 
resistant foci were further propagated for testing expression of B0AT1 and collectrin by western 
blot as well as the function of the transporter by radioactive uptake assays. 
To select cells with the highest transport activity of B0AT1 in co-transfected CHO cells, cells 
were subcloned by limiting dilution and propagated from single clones as outlined in the 
following. After trypsinization, cells were pelleted by centrifugation at 500 x g for 5min, and 
the total number was counted by hemocytometer. The cells were first diluted to 1x106cells/mL 
in the suspension, and were further diluted with full culture medium to 0.5 cell/200µL. Then 
200µL cell suspension was distributed into each well of a 96-well plate to maximize the 
likelihood of single clones in the wells. When seeing a single colony growing in the well, the 
cells were transferred to 6-well plates, then to 25cm2 and 75 cm2 flasks for further propagation 
until the cell number was high enough for testing. 
2.2.5 Radioactive Uptake Assay 
Hank’s buffer with or without sodium was prepared beforehand using the following recipe: 
Hank’s buffer + Na+ (*pH 7.5) containing: 
Compound Final concentration (mM) Powder concentration (g/L) 
NaCl 136.6 8 
KCl 5.4 0.4 
KH2PO4 0.44 0.06 
MgCl2.6H2O 0.5 0.1 
MgSO4.7H2O 0.4 0.1 
HEPES 10 2.38 
Na2HPO4.2H2O 2.7 0.48 
#CaCl2 1 100mM stock solution prepared 
#D-glucose 5 1M stock solution prepared 
Hank’s buffer - Na+ (*pH 7.5) containing: 
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Compound Final concentration (mM) Powder concentration (g/L) 
N-Methyl-D-
Glucamine (NMDG) 
137 26.7 
KCl 5.4 0.4 
KH2PO4 0.44 0.06 
MgCl2.6H2O 0.5 0.1 
MgSO4.7H2O 0.4 0.1 
K2HPO4 2.7 0.47 
HEPES 5 1.23 
#CaCl2 1 100mM stock solution 
prepared 
#D-glucose 5 1M stock solution prepared 
*The pH value was adjusted to 7.5 by 5M NaOH for Hank’s + Na+ buffer, and by 5M HCl for 
Hank’s - Na+ buffer. After adjusting the pH, the buffer was autoclaved for storage. 
#Before using the buffer for experiments, 1mM CaCl2 and 5mM D-glucose was added. 
For uptake experiments the cells were seeded at a density of 1-2x105 cells/dish in 35mm dishes 
and grown in culture medium for 2-3days until reaching 80-90% confluence. To initiate the 
assay, the medium was removed and the cells were pre-washed with 2mL Hank’s +/- Na+ buffer 
for 3 times. The cells were then incubated with 1mL Hank’s +/- Na+ buffer containing radio-
labelled substrates (L-[U-14C]leucine (11.1 GBq/mmol), L-[U-14C]isoleucine (11.1 GBq/mmol) 
or L-[U-14C]glutamine (10 GBq/mmol) at a final concentration of 100 µM in a 37°C water bath 
for 6min. For pharmacological tests, substrate analogues and related chemical compounds were 
added to the transport buffer before the experiment at the concentration indicated in figures or 
tables. All radioisotopes were all purchased from Perkin Elmer. After the incubation, the buffer 
was immediately removed and the transport was terminated by 3 washes with 2mL ice-cold 
Hank’s + Na+ buffer. The cells were then harvested with 500µL of 0.1M HCl and scraped off 
the dishes using a scraper. An aliquot of 400µL cell lysate was added into a vial and mixed 
with 2.5-3mL scintillation fluid for counting of radioactivity in a scintillation counter, while 
the rest of the lysate was used for Bradford assay to measure the protein amount. 
2.2.6 Membrane Potential Assay 
Membrane Potential Assay was performed with the FLIPR® kit ordered from Molecular 
Devices (R8042 BLUE DYE). Before the assay, the voltage-sensitive blue dye in each vial was 
dissolved in 10mL of 1X assay buffer provided in the kit to make the dye-loading buffer. 
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Aliquots of the loading buffer could be stored at -20ᵒC for up to 5 days. The cells were first 
seeded in black-wall 96-well plates (Corning, #3603) at a density of 60,000 cells/well and 
grown overnight. On the following day, the culture medium was removed and the cells were 
washed three times with 200µL/well of Hank’s + Na+ buffer before the addition of 100µl 
Hank’s + Na+ buffer containing test compounds and 100µl dye-loading buffer into each well. 
The cells were then incubated at room temperature for 30min and the fluorescence signal was 
detected by a TECAN INFINITE M1000 PRO Plate Reader. The fluorescence signal was read 
every 10sec for each cycle, with three cycles occurring before the addition of substrate and 10 
cycles after the addition. The substrates were dissolved in Hank’s +Na+ buffer as stock 
solutions and 50µL was injected either manually or automatically to yield the final 
concentration as indicated in the figures. 50µL Hank’s +Na+ buffer without substrates was 
injected as a negative control. After injection, the plate was shaken in the machine for mixing. 
The signal was detected from the bottom of the plate, with an excitation wavelength of 530nm 
and an emission wavelength of 565nm (bandwidth 10nm). The program was set up in iControl 
as follows: 
ü Choose kinetic---kinetic cycle---kinetic condition: Execute at cycle 4; Number of 
cycles: 13; kinetic interval: 10sec 
ü Choose Actions---Injection. Injector A/B, volume 50µl, speed 100µl/sec, tick ‘refill 
speed equals to injection speed’. Refill mode: standard 
ü Shaking after injection 
ü Choose Measurements---Fluorescence Intensity (well-wise): 
• Wavelength/Excitation: 530nm; bandwidth: 10nm 
• Wavelength/Emission: 565nm; bandwidth: 10nm 
• Mode: BOTTOM 
• Gain: Manual 70 
• Flashes: Mode 1 [400Hz]: 50 
• Settle time: 10ms 
2.2.7 Sodium Dye Assay 
Sodium dye assay was performed with the Na+-sensitive fluorescent dye Asante NaTRIUM 
Green-2 (ANG-2) AM (Abcam, ab142802), and the protocol of the assay was downloaded 
from TEFLabs [178]. The stock solution of the dye was prepared by adding 460µL of 
anhydrous dimethylsulfoxide (DMSO) to 500µg of the powder to yield a final concentration of 
1mM. The stock solution was divided into aliquots of 50µL and stored at -20°C for future use. 
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For the experiment, an aliquot of the stock was brought to room temperature, and then diluted 
to twice the original volume with 20% (w/v) Pluronic F-127 in DMSO (Invitrogen, P3000MP) 
to generate a working solution. The cells were seeded in a black-wall 96-well plate (Corning, 
#3603) at a density of 60,000 cells/well and grown in full culture medium overnight. For the 
sodium titration experiment, conditions were used as provided by TEFLabs [179] as follows. 
After removing the medium, the cells in each well were pre-loaded with 200µL fresh culture 
medium without antibiotics, supplemented with 2µM ANG-2 and 0.0075% (w/v) Pluoronic F-
127 in the 37°C incubator for 60min. After removing the dye-loading solution, cells were 
washed three times with Hank’s -Na+ buffer and incubated in the same buffer during the assay. 
After recording the baseline readings by a TECAN INFINITE M1000 PRO Plate Reader, 
Monensin or Gramicidin A were added from a 1mM stock solution to generate a final 
concentration of 5µM and 2.5µM, respectively. This manipulation depletes cells of Na+. When 
the fluorescent signal became stable, the extracellular Na+ concentration was raised by the 
addition of NaCl to various levels (5, 15, 45, 145mM), with 145mM KCl added in the end. The 
assay was varied to optimise it for compound screening using CHO-BC cells as follows. After 
overnight growth in 96-well plates, the culture medium was removed and the cells were washed 
with Hank’s buffer for three times before the addition of 200µL Hank’s buffer containing 0.2-
1% ANG-2/Pluronic F-127 working solution into each well. The cells were then incubated in 
dye loading buffer at room temperature or in the 37°C incubator for 10-30min. After the 
incubation, the cells were washed twice with Hank’s buffer to remove the extracellular 
unloaded dye. Then 200µL Hanks’s buffer was applied to each well, and the fluorescent signal 
was read by a TECAN INFINITE M1000 PRO Plate Reader before and after the manual 
addition of Na+ and amino acid substrates. The optimized condition is highlighted in table 2.3.2 
and was used in the subsequent experiments. The signal was detected from the bottom of the 
plate, with an excitation wavelength 488nm and an emission wavelength 540nm (bandwidth 
10nm). 
2.2.8 Whole Membrane Preparation of proteins from adherent cell culture 
Cells cultured in a 60mm dish were washed 3 times with ice-cold 5mL pre-lysis PBS buffer 
(137mM NaCl; 2.7mM KCl; 5mM Na2HPO4; 0.9mM CaCl2; 0.5mM MgCl2; pH7.4). The cells 
were then scrapped off the bottom of the culture dish with 1mL pre-lysis PBS buffer and 
transferred into a microcentrifuge tube. After centrifugation at 500 X g (2300rpm) in a 
benchtop centrifuge for 5min, the supernatant was discarded and the cell pellet was 
resuspended with 1mL hypotonic buffer (10mM HEPES pH8.0; 15mM KCl; 2mM MgCl2; 
0.1mM EDTA) and incubated on ice for 5min. The cells were homogenised by 30-35 strokes 
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using a 1mL syringe and needle (25 Gauge x 5/8”), followed by centrifugation at 600 X g 
(2500rpm) for 10min to remove the cell nuclei. Aliquots (800-900µL) of the supernatant from 
each sample were transferred to an ultra-centrifuge tube and spun down at 150,000 X g 
(65,000rpm) and 6°C for 60min to isolate the membranes. The pellet was resuspended in 50µl 
of 5mM L-glycine and vortexed vigorously until completely dissolved. Total protein amount 
was quantified via Bradford assay using a 1:10 dilution of the sample, and equal amounts of 
protein were loaded for SDS-PAGE. 
2.2.9 Surface Biotinylation 
The cells of a 60mm dish were washed 3 times with ice-cold pre-lysis PBS buffer (137mM 
NaCl; 2.7mM KCl; 5mM Na2HPO4; 0.9mM CaCl2; 0.5mM MgCl2; pH 8). The cells were then 
biotinylated by incubating with 2ml pre-lysis PBS buffer supplemented with 0.5mg/mL Sulfo-
NHS-LC-Biotin (Invitrogen, #B6353) at room temperature on a slow shaker for 30 min. After 
incubation, the cells were washed 3 times with ice-cold pre-lysis PBS containing 100mM 
glycine to quench the unbound reagent, and were then collected in 1mL lysis buffer (150mM 
NaCl; 20mM Tris-HCl, pH7.6; 1% Triton X-100) by scraping and transferring into a 
microcentrifuge tube. The cell lysate was incubated on ice for 1.5hr with occasional inversions, 
followed by a centrifugation at 11000rpm for 10min in a benchtop centrifuge. The supernatant 
was transferred to another microcentrifuge tube. The protein amount was determined by 
Bradford assay using a 1:10 dilution of the sample, and the same volume of protein sample 
(approximately 75µg) was added to 50µL streptavidin beads (high capacity streptavidin 
agarose Resin, Invitrogen, #20357). The sample-beads mixture was incubated at 4°C on a 
rotator overnight. On the following day, the mixture was washed with 1mL lysis buffer for 5 
times, and then resuspended in 4x sample buffer for SDS-PAGE. 
2.2.10 Bradford assay 
Different concentrations (50, 75, 100, 200, 300, 400, 500µg/mL) of bovine serum albumin 
(BSA, Sigma, #A4612) were used to generate a standard curve. An assembly of 30µL protein 
sample or BSA standard and 270µL of Bradford assay reagent was added into each well of a 
96-well plate. After 5 minutes, the absorbance was measured at 595nm with a TECAN 
INFINITE M1000 PRO Plate Reader and the protein amount was calculated based on the 
standard curve. 
2.2.11 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blot Analysis 
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The protein samples were mixed with (4x) NuPAGE LDS sample buffer (Invitrogen, #NP0008) 
and (10x) NuPAGE Reducing Agent (Invitrogen, #NP0004) to give a 1x final concentration. 
Cell homogenate or whole membrane preparation samples were incubated at 70°C for 10min 
and surface biotinylation samples were heated to 95°C for 5min, before separating by 4-12% 
SDS-PAGE (Invitrogen, #NP0321). SeeBlueTM Plus2 pre-stained protein standard (Invitrogen, 
#LC5925) was used to estimate molecular weights. The electrophoresis took about 45min at 
150-180 volts. 
The separated proteins on the gel were transferred onto a 0.45µm nitrocellulose membrane (GE 
Healthcare, #10600003) at 100 volts for 120min using a wet transfer system (Bio-Rad) with 
transfer buffer (25mM Tris Base, 192mM glycine, 20% methanol). After transfer, the 
membrane was soaked in 5% (w/v) skimmed milk dissolved in 1x PBST (137mM NaCl, 
2.7mM KCl, 5mM Na2HPO4, PH7.4, 0.1% Tween 20) at room temperature for 1hr on an orbital 
shaker to block non-specific binding sites, and then stored at 4°C overnight. On the following 
morning, the membrane was washed three times with 1xPBST buffer and incubated with a 
primary antibody solution at room temperature for 2hr, followed by an incubation with the 
secondary antibody solution at room temperature for 1hr. Both primary and secondary 
antibodies were diluted in a PBST buffer containing 2% membrane blocking agent (GE 
Healthcare, #RPV2125V). Three washing steps with 1xPBST buffer were applied after the 
incubation with each antibody. To visualize the bands of interest, the blot was evenly covered 
by western HRP substrate (Millipore HRP substrates Luminata Forte) and luminescence was 
imaged using a Fusion SL Gel Chemiluminescence Documentation System 2012(Vilber 
Lourmat/Peqlab). 
Table 2.2.1: Antibodies used in western blot 
Primary Antibody Source Dilution 
HRP-conjugated 
secondary antibody 
Band 
Size 
Anti-mouse B0AT1 
Customized, Pineda 
Antibody Service 
1/2000-
1/3000 
donkey anti-rabbit IgG 
64kDa 
Anti-mouse collectrin 
R&D Systems, 
AF4965 
1/3000-
1/5000 
donkey anti-sheep IgG 
43kDa 
Anti-human β-actin Abcam, ab8227 
1/2000-
1/3000 
donkey anti-rabbit IgG 
47kDa 
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Anti-human ACE2 Abcam, ab15348 
1/500-
1/2000 
donkey anti-rabbit IgG 
97kDa 
2.2.12 RT-PCR 
Total RNA Isolation NucleoSpin RNA II Kit (Machery-Nagel) was used to extract RNA for 
RT-PCR according to the manufacturer’s protocol. In brief, the cells were maintained in full 
culture medium in 60mm dishes until 80-90% confluent. After removing the culture medium, 
the cells were lysed by thoroughly mixing with 700µL Buffer RA1 and 7µL β-mercaptoethanol. 
The lysate was then pushed through a NucleoSpin Filter into a collection tube by centrifugation 
at 11,000 x g for 1min in a benchtop centrifuge. After adding an equal amount of 70% Ethanol 
to the sample, the RNA was bound to a NucleoSpin RNA II column. Then 350µl Membrane 
Desalting Buffer was added to desalt the silica membrane, and the flow-through was discarded 
after centrifugation at 11,000 X g for 1min. DNA was digested by a mixture of 10µL 
reconstituted rDNase and 90µl Reaction Buffer directly added onto the centre of the silica 
membrane of the RNA column, followed by an incubation for 20 min at room temperature. The 
membrane was then washed with buffer RA2 once and buffer RA3 twice, and dried completely. 
Finally, RNA was eluted in 60ul RNase-free water and RNA concentration was measured by 
NanoDrop™ 1000 microvolume spectrophotometry. 
The SuperScriptTM II Reverse Transcriptase (RT) (Invitrogen, #18064014) was used for cDNA 
synthesis. An amount of 2µg total RNA from each extraction was used as the template for 
reverse-transcription in a 20µL reaction. The RNA template was first mixed with 1µL random 
primers (Invitrogen, #48190011), 1µL of 10mM dNTPs (a mixture of dATP, dCTP, dGTP and 
dTTP from a dNTP set, Invitrogen, #10297018) as well as DNase-free RNase-free H2O to 
generate a total volume of 12µL. The mixture was heated to 65°C for 5min and then quickly 
chilled on ice. After adding 4µL of 5x First-strand buffer, 2µL of 100mM DTT provided with 
the RT kit, together with 1µL of RNaseOUTTM Recombinant Ribonuclease Inhibitor 
(Invitrogen, #10777019), the mixture was incubated at 25°C for 2min. Finally, 1µL (200 units) 
of the SuperScriptTM II Reverse Transcriptase was added into the reaction, then the mixture 
was incubated at 25°C for 10min, followed by an incubation at 42°C for 50min. The reaction 
was terminated by heating at 70°C for 15min. 
The PCR reaction was set up to a final volume of 50µL by assembling 5µL of 10x PCR buffer 
(containing MgCl2), 1.5 Unit Taq DNA polymerase provided in a DNA polymerase kit 
(Invitrogen), 1µL of 10mM dNTPs, 0.5µL Forward Primer (10µM stock), 0.5µL Reverse 
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Primer (10µM stock), 1µL cDNA template and ddH2O to complete the volume in a PCR tube. 
Sequence of primers for human B0AT1 and human collectrin (Proligo) are listed in the appendix. 
Actin (Gibco) and Clathrin (Sigma) were used as housekeeping genes. 
The PCR program was set as follows: 
1. Incubate at 94°C for 3 min---Initialization 
2. Incubate at 94°C for 30 sec---Denaturation 
3. Incubate at 55°C for 1 min---Annealing 
4. Incubate at 72°C for 1 min---Extention/Elongation 
Repeat step 2-4 for 30 cycles 
5. Incubate at 72°C for 1 min---Final Elongation 
6. Hold at 20°C 
2.2.13 TAE-Agarose gel electrophoresis 
For agarose gel electrophoresis, 1.5% (w/v) Agarose (Melford) was dissolved either in 1x TAE 
buffer (40mM Tris-acetate, 1mM EDTA, pH 8) or in SYBRTM Safe DNA Gel Stain in 1x TAE 
(Invitrogen, #S33111) by heating in the microwave oven for approximately 2min. The melted 
agarose solution was poured onto the casting tray and allowed to set. RT-PCR products were 
mixed with 6x sample loading buffer (50% (v/v) glycerol, 0.1M EDTA (pH 8), 1% (w/v) SDS, 
1mg/mL bromophenol blue, 1mg/mL xylene cyanol) at a ratio of 5:1, and loaded alongside a 
100bp DNA ladder (New England Biolabs). Agarose gels were run horizontally in 1x TAE 
buffer at 100 volts for 40-50 minutes. After running, if not prepared in SYBRTM Safe DNA Gel 
Stain, the gel was stained in Ethidium Bromide (0.5µg/mL in 1X TAE buffer) for 15-30min 
and DNA was detected under UV light. 
2.2.14 Statistical Analysis 
Results are expressed as means ± standard deviations. Data were analysed by one-way analysis 
of variance, ANOVA, followed by Bonferroni correction for pair-wise comparisons in larger 
samples, or by two-tailed paired T-test using GraphPad Prism 6.0. Significance was assigned 
at p< 0.05. In figure legends, n indicates the number of replicates in each experiment, whereas 
e indicates the number of independent repeats of the experiments. 
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2.3 Results 
The following sections describe several strategies and attempts to generate a cell line that 
expresses B0AT1 plus one of its ancillary protein either heterologously or endogenously, as a 
tool to identify new inhibitors for the transporter and to develop high-throughput screening 
assays. 
2.3.1 CHO-cells expressing B0AT1 and collectrin 
Sanofi Aventis provided us with six clones of CHO cells stably expressing B0AT1 and collectrin 
using the Flp-In™ transfection system, as well as their parental cells for functional testing and 
characterisation. The best performing clone (Clone #1), will be called CHO-BC 
(B0AT1+collectrin) from now on. Clone #1 was chosen based on the following reasons: 1) 
B0AT1 and collectrin were abundantly and simultaneously detected at the surface of the 
membrane of CHO-BC cells, but not of CHO parental cells (figure 2.3.1A), using whole 
membrane preparation and surface biotinylation. Notably, in the surface biotinylation sample 
of CHO-BC cells, an additional B0AT1 immunoreactive band just above the 98kDa protein 
marker was observed. It may represent an SDS resistant B0AT1 dimer, or more likely an SDS 
resistant heterodimer formed between B0AT1 (64kDa) and collectrin (43kDa). 2) B0AT1 was 
detectable in all 6 clones of CHO Flp-In B0AT1 + collectrin cells, however, collectrin was only 
detectable in membrane preparations of CHO-BC, clone #2 and #4 (figure 2.3.1A, B). Above 
all, CHO-BC was the best clone with regard to the protein level of B0AT1 and collectrin at the 
cell surface (figure 2.3.1 B/C). 3) The uptake of radio-labelled substrate by transporter-
expressing cells is the most robust way to measure transport activity, and the BCAA isoleucine 
is a preferred substrate of the B0AT1 transporter. Hence, I measured the uptake of 100µM 14C-
labelled isoleucine by CHO-BC, CHO parental, clone #2 and #4 cells over a 6-minute time 
frame (figure 2.3.1D). In the parental cells, uptake of isoleucine was entirely Na+-independent, 
thus, any functional expression of B0AT1 should induce Na+-dependent isoleucine uptake. 
CHO-BC cells had the highest sodium-dependent isoleucine uptake, which was incidentally a 
similar level to the sodium-independent isoleucine uptake by the endogenous transporters 
(most likely by the hamster isoform of LAT2 in CHO cells). Clone #2 also had some sodium-
dependent isoleucine uptake, but its level was much lower as compared to CHO-BC cells, 
whereas there was nil net uptake in CHO parental cells and clone #4. The abundance of B0AT1 
expression at the membrane was positively correlated to the transport activity, i.e. less sodium-
dependent isoleucine uptake was seen in clones (#2 and #4) with less B0AT1 in whole 
membrane proteins. 4) As a symporter of amino acid and one sodium ion, the transport of 
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amino acid substrate by B0AT1 is electrogenic and will cause membrane depolarization due the 
simultaneous intake of Na+, which could be recorded by the fluorescence-based membrane 
potential assay. Figure 2.3.1E showed a large depolarization peak in CHO-BC cells induced by 
the addition of 1.5mM isoleucine to the buffer, while depolarization was neither observed in 
CHO parental cells, suggesting that the endogenous transport activity was electroneutral, nor 
in CHO-BC cells without isoleucine added, consistent with the co-transport of AA substrate 
and one sodium ion. This was further confirmed by a similar response to 1.5mM leucine, 
another preferred substrate of B0AT1 (figure 2.3.1F). It is noteworthy that a small peak was 
induced by leucine, but not by isoleucine, in CHO parental cells, suggesting that isoleucine 
might be a more selective substrate for B0AT1 in CHO cells. The functional assays also 
indicated that CHO-BC was the preferred cell line for the study of B0AT1. 
However, one major problem of CHO-BC cells was the gradual decrease of B0AT1 activity 
after passaging. Radioactive substrate uptake assays demonstrated a steady drop of Na+-
dependent isoleucine uptake after passage 3, whereas the endogenous Na+-independent 
isoleucine uptake was unaffected by passaging (figure 2.3.2). Hence, we only used CHO-BC 
cells of passage numbers < 10 in the uptake assay. One possibility for the decline of B0AT1 
transport activity over time is the osmotic load that the transporter imposes on the cells. The 
cotransport of sodium may increase internal osmotic pressure and subsequently down-regulate 
sodium transport via B0AT1 (Na+ feedback inhibition), as previously shown by the epithelial 
Na+ channel ENaC [180]. Moreover, the osmotic imbalance has been shown to cause cell 
viability change, which could be improved by the inclusion of extracellular osmotic regulator 
such as sucrose, which is mostly membrane impermeable [181]. To test this hypothesis, we 
added sucrose to the media and measured B0AT1 activity and cell growth. However, addition 
of sucrose resulted in the deterioration rather than improvement of the transport activity or cell 
growth (figure 2.3.3A&B). 
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Figure 2.3.1: Characterisation of B0AT1 expressing CHO cell lines. A) Whole membrane 
preparation and surface biotinylation were used to isolate membrane proteins from CHO-BC (aka clone 
#1) and CHO parental cells for immunoblotting to detect B0AT1 and collectrin protein expression. Both 
proteins were only detectable in CHO-BC cells, but not in CHO parental cells. β-actin was used as a 
loading control. Protein markers are indicated beside the blots (n=1, e=5). B) Whole membrane protein 
samples were prepared for another 5 clones of CHO Flp-In B0AT1+collectrin cells to test the protein 
expression of B0AT1 and collectrin by immunoblotting. B0AT1 was detectable in all five clones, 
whereas collectrin was only detected in clone #2, #4 and weakly in #6 (n=1, e=1). C) Clone #2 and #4 
were compared with CHO-BC by immunoblotting using whole membrane protein samples. B0AT1 
expression level was lower in these two clones. CHO parental cells were used as a negative control 
(n=1, e=1). D) 14C-labelled isoleucine uptake assay on CHO-BC, CHO parental, and clone #2 and #4 
cells. The cells were exposed to 100µM [14C]isoleucine in Hank’s buffer with and without Na+ buffer 
 44 
for 6min. Subsequently, the radioactivity of cell lysates was measured. The result is shown as nmol 
isoleucine uptake ± std (n=3, e=5). The Na+ (net) uptake level (red columns) was calculated by 
subtraction of -Na+ uptake activity (green columns) from the total uptake activity (blue columns). E) 
Membrane potential assay on CHO-BC (n=3, e=10) and CHO parental (n=3, e=5) cells. The fluorescent 
signal was induced by the addition of 1.5mM isoleucine into the buffer, as indicated by the arrow in the 
figure. F) Membrane potential assay on CHO-BC (n=3, e=35) and CHO parental (n=3, e=5) cells. The 
fluorescent signal was induced by the addition of 1.5mM leucine into the buffer, as indicated by an 
arrow in the figure. The result is shown as average percentage of baseline readings (before the addition 
of substrate) ± std. (n indicates number of replicates in each experiment, e indicates number of 
independent experiments.) 
 
 
Figure 2.3.2: Passaging CHO-BC cells caused a gradual decrease in heterologous expression. The 
uptake of 100µM [14C]isoleucine was measured over a period of 6 min using CHO-BC cells at different 
passages (2 to 10). The sodium-dependent isoleucine uptake level (red dots) decreased steadily after 
passage 3, while endogenously expressed sodium-independent isoleucine uptake activity (green dots) 
was not influenced by passaging (n=3, e=10). 
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Figure 2.3.3: Effect of osmolarity on B0AT1 expression. Sucrose slowed down the growth of CHO-
BC cells and affected B0AT1 activity. A) CHO-BC cells were seeded in a 96-well plate and incubated 
in medium containing different concentrations of sucrose for 72hr. Cell density in each well was 
monitored every 2hr by IncuCyte technology and the growth curve was generated by the averaged 
confluence of 12 wells under each condition (n=12, e=1). B) CHO-BC cells were incubated in medium 
containing sucrose for 72hr before measuring the uptake of 100µM [14C]isoleucine over 6min (n=3, 
e=1). **, p<0.01; n.s. not significant; as compared to control (0mM sucrose). 
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2.3.2 Characterization of B0AT1 using CHO-BC cells 
The first series of experiments showed that CHO-BC had the highest B0AT1-like transport 
activity. In the next series of experiments, I wanted to verify that the transporter expressed in 
CHO-BC cells has indeed the properties of B0AT1 as published before [73, 84, 182]. Firstly, 
the transport of AA substrates was sodium dependent. The sodium dependence was evidenced 
by the disappearance of depolarization peaks in the absence of either sodium ions or AA 
substrate leucine or both in the membrane potential assay (figure 2.3.4A). Secondly, the 
selectivity of amino acid substrates was also determined by membrane potential assay (figure 
2.3.4B). Methionine seemed to be the preferred substrate of B0AT1, followed by BCAAs 
leucine and isoleucine. Cysteine, phenylalanine, alanine, valine and glutamine induced similar 
depolarisation, but less than the top three substrates. As expected, anionic (aspartate and 
glutamate) and cationic (lysine and arginine) amino acids were not transported by B0AT1. 
Thirdly, a competition experiment was conducted by measuring the uptake of 100µM 
[14C]isoleucine in the presence of a 100-fold excess (10mM) of unlabelled amino acids 
including arginine, phenylalanine, serine and glycine in CHO parental (figure 2.3.4C) and 
CHO-BC cells (figure 2.3.4D). The sodium-dependent isoleucine uptake in CHO-BC cells was 
abolished by B0AT1 substrates phenylalanine and serine, and slightly decreased by the less-
preferred substrate glycine. However, arginine, which was not transported by B0AT1, did not 
influence the uptake of isoleucine by the transporter (figure 2.3.4D). A similar inhibitory 
pattern was shown by sodium-independent isoleucine uptake in both CHO parental (figure 
2.3.4C) and CHO-BC cells (figure 2.3.4D), indicating a similar substrate preference of the 
endogenous transporter to B0AT1. Finally, the Km values of two preferred substrates, leucine 
and isoleucine, were determined by both membrane potential (FLIPR) assay and radioactive 
uptake assay. Based on FLIPR assay (figure 2.3.4E&F), the Km values of leucine and 
isoleucine were determined as 0.5 ± 0.1mM and 0.8 ± 0.1mM, respectively, whereas by uptake 
assay (figure 2.3.4G&H), the Km values of leucine and isoleucine were 1.05 ± 0.05mM and 
1.4 ± 0.1mM, respectively. These characteristics of B0AT1 observed in CHO-BC cells were 
consistent with the published features, confirming that CHO-BC was a good cell model to study 
B0AT1. 
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Figure 2.3.4: Characterization of B0AT1 using CHO-BC cells. A) Sodium dependence tested by 
membrane potential assay on CHO-BC cells. The blue dye was dissolved in ddH2O instead of the assay 
buffer provided in the kit to exclude Na+ in the solution. Half of the cells were washed with Hank’s -
Na+ buffer and pre-loaded with 100µL of blue dye in ddH2O plus 100µL of 2x Hank’s -Na+ buffer, 
whereas another half of the cells were washed with Hank’s +Na+ buffer and pre-loaded with 100µL of 
blue dye in ddH2O plus 100µL of 2x Hank’s +Na+ buffer. After the baseline readings, the -Na+- treated 
wells were injected with 50µL leucine dissolved in Hank’s -Na+ buffer to a final concentration of 1.5mM 
or with Hank’s -Na+ buffer only. The +Na+- treated wells were injected with 50µL leucine dissolved in 
Hank’s +Na+ buffer to a final concentration of 1.5mM or with Hank’s +Na+ buffer only (n=3, e=5). B) 
Amino acid selectivity of B0AT1 measured by membrane potential assay in CHO-BC cells. After the 
baseline readings, 50µL Hank’s +Na+ solution containing each indicated amino acid was manually 
injected into each well at a final concentration of 5mM. Substrate-induced changes of fluorescence were 
normalized to the fluorescent increase level induced by methionine (n=3, e=5). C) and D) 
[14C]isoleucine uptake assay with competitors in CHO parental cells (C) and CHO-BC cells (D). After 
washing, CHO cells were exposed to Hanks’ buffer containing 100µM [14C]isoleucine as well as 10mM 
Arg, Phe, Ser or Gly for 6min. The data was normalized to the uptake level of control cells, which were 
only treated with isoleucine (n=3, e=5). E) and F) Km values of isoleucine (E) (n=3, e=5) and leucine 
(F) (n=3, e=1) determined by membrane potential assay. The depolarization signals were induced by 
various concentrations of the substrates, and the data points in the figure indicate the peak value of the 
increase of the signal at each substrate concentration. G) and H) Km values of isoleucine (G) and leucine 
(H) determined by radioactive substrate uptake assay (n=3, e=1). The cells were treated with various 
concentrations of the substrates in the presence of sodium, and the data points in the figure indicate the 
average uptake level at each substrate concentration. 
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2.3.3 Cell lines that express B0AT1 endogenously 
As outlined above, CHO-BC cells were a suitable model to study the pharmacology of B0AT1. 
However, the significant decline of transport activity after several passages suggested that 
heterologous expression was stressful for the cells resulting in active down-regulation. As a 
result, I investigated whether cell lines existed that express collectrin/ace2 and B0AT1 
endogenously. 
After searching through Oncomine, three human cancer cell lines were selected as potential 
candidates based on their endogenous expression of SLC6A19 (B0AT1) or TMEM27 
(collectrin) (table 2.3.1). All data shown in the table were log2-transformed, median-centred 
per array, and the standard deviation was normalized to one per array [183]. Because kidney is 
one of the major organs expressing B0AT1, two renal cell lines were also investigated, namely 
LLC-PK1 (pig kidney epithelial) and MDCK (Madin-Daby canine kidney). 
Table 2.3.1: Expression of B0AT1 (SLC6A19) and collectrin (TMEM27) in selected cell line 
candidates. 
Cell line Cell Type 
log2-transformed, median-centred Intensity 
SLC6A19 TMEM27 
Li-7 Hepatocellular carcinoma 4.60976 4.56135 
HUH7 Hepatocellular carcinoma 2.84029 2.19699 
GP2D Colon Adenocarcinoma 3.84229 1.40495 
Using RT-PCR (figure 2.3.5A), we detected B0AT1 expression in HUH7, GP2d and LLC-PK1 
cells, whereas the expression of collectrin was only seen in HUH7 and GP2d cells. Meanwhile, 
one band between 800bp and 1000bp was observed in LLC-PK1 cells, which was larger than 
the expected band for collectrin (700bp). This could be because the primers were designed for 
human collectrin, and may not be suitable for detecting collectrin expression in non-human 
cells. There are only 88.74% of the human TMEM27 (collectrin) sequence matching the 
sequence of its orthologue in dog, whereas the percentage of human sequence matching the pig 
sequence is even lower (81.98%) (Ensembl Genome Database). Next, I determined the 
expression of B0AT1 and its auxiliary proteins collectrin and ACE2 by immunoblotting (figure 
2.3.5B). Both B0AT1 and collectrin were detected among the membrane proteins of our positive 
control, CHO-BC cells. None of these three proteins were found in the membrane of LLC-PK1 
cells, which might be due to the lack of protein expression in the cell membrane or the species 
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reactivity of the antibodies. B0AT1 and collectrin were not detected in the plasma membrane 
of HUH7 cells, either. However, robust ACE2 expression was found in this cell line. GP2d 
seemed to be the best candidate among the three cell lines, due to the abundance of B0AT1 and 
ACE2 proteins as well as small amounts of collectrin at the surface of the membrane, which 
theoretically should give sufficient transport activity for measurement. Five cell line candidates 
along with CHO-BC cells were then tested in a functional assay using [14C]isoleucine uptake 
(figure 2.3.5C). Surprisingly, only CHO-BC cells had obvious Na+-dependent isoleucine 
uptake (at a rate of about 18nmol per mg of protein in 6min). Neither GP2d nor any other tested 
cell line (HUH7, LLC-PK1, MDCK and Li-7) had significant Na+-dependent uptake of 
isoleucine. Therefore, we tried to increase the transport activity by enhancing the expression in 
these cell lines using transient transfection. 
Firstly, because there was abundant ACE2 expression in the membrane of HUH7 cells (figure 
2.3.5B), we tried to co-express B0AT1 in this cell line. Since SLC6A19 was detected at mRNA 
level in HUH7 cells (figure 2.3.5A), I tried to co-transfect mouse HNF1α to enhance expression 
of endogenous B0AT1.  HNF1α was reported by our group as activating transcription factor of 
the Slc6a19 gene in villus enterocytes [184]. Moreover, HNF1α was also reported controlling 
the collectrin gene in kidney, which is the main organ expressing HNF1α [185]. Upon 
transfection with B0AT1 only, its protein expression was significantly increased at the surface 
of the membrane. At the same time, ACE2 surface expression was also increased, compared to 
non-transfected WT cells, which was detected by immunoblotting (figure 2.3.6A). Transfection 
with HNF1α alone, however, did not promote any production of B0AT1 protein in the 
membrane, and its co-transfection with B0AT1 did not improve the surface expression of 
B0AT1 or ACE2 (figure 2.3.6A), indicating that HNF1α was unable to induce B0AT1 or ACE2 
expression. Since B0AT1 appeared at the cell surface after transfection, I tested whether this 
transfection also improved transport activity by measuring [14C]isoleucine uptake in B0AT1-
transfected HUH7 cells. Despite the detection of protein in the membrane, Na+-dependent 
isoleucine uptake was not significantly increased in transfected cells compared to WT cells 
(figure 2.3.6B). Since neither of B0AT1, collectrin or ACE2 was seen in the membrane 
preparation of LLC-PK1 (figure 2.3.5B), but gene expression of B0AT1 was detected in this 
cell line by RT-PCR (figure 2.3.5A), attempts were made to express functional human B0AT1 
by transfection with either B0AT1 alone or together with collectrin in separate vectors. However, 
neither of the transfections increased Na+-dependent isoleucine uptake, while the endogenous 
Na+-independent and -dependent uptake level remained unchanged (figure 2.3.6C). Expression 
of B0AT1 and collectrin in MDCK cells has been reported previously [80]. Transfecting B0AT1 
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and collectrin simultaneously either through two separate vectors (pcDNA3.1/B0AT1 and 
pcDNA3.1/collectrin) or combined in one vector (pIRES/B0AT1/collectrin) did not obviously 
improve transport activity of B0AT1 in this cell line (figure 2.3.6D). Although LipofectamineTM 
3000 was shown to have higher transfection efficiency than LipofectamineTM 2000 in other cell 
lines such as HEK293 [186], it failed to improve transport activity after transfection (figure 
2.3.6E). Finally, a hepatocellular carcinoma cell line, Li-7, was tried. According to Oncomine, 
both B0AT1 and collectrin are naturally expressed in this cell line (table 2.3.1), however, little 
Na+-dependent isoleucine uptake was observed (figure 2.3.5C). After introducing B0AT1 and 
collectrin via two vectors solely or simultaneously, there was only a small increase in Na+-
dependent isoleucine uptake activity (figure 2.3.6F). Since none of the above attempts 
succeeded in providing a good cell model for this study, we began to generate our own B0AT1 
and collectrin stably-transfected cell line. 
  
 52 
 
Figure 2.3.5: Expression of B0AT1 and its auxiliary proteins in various cell lines. A) Gene 
expression of B0AT1 and collectrin in HUH7, GP2d and LLC-PK1 cells was detected by RT-PCR, 
expected band sizes for B0AT1 and collectrin are 378bp and 700bp, respectively. Actin and Clathrin 
were used as house-keeping genes (n=1, e=1). B) Protein expression of B0AT1, collectrin and ACE2 in 
whole membrane preparations of CHO-BC, LLC-PK1 and HUH7 cells as well as at the cell surface 
(surface biotinylation) of GP2d cells. β-actin was used as a loading control (n=1, e=1). C) Uptake of 
[14C]isoleucine into various candidate cell lines  and CHO-BC cells. Cells were exposed to 100µM 
[14C]isoleucine in Hank’s +Na+ or -Na+ buffer for 6min. The net Na+-dependent uptake activity (red 
columns) was calculated by subtracting uptake activity in the absence of Na+ (green columns) from the 
total uptake. Data is shown as average ± std (n=3, e=1). 
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Figure 2.3.6: Transiently-transfected cell lines. A) HUH7 cells were transfected with either 
pcDNA3.1/hB0AT1 or pCMV6/mHNF1α, or co-transfected with both, using LipofectamineTM LTX. 
48hr post transfection, the cells were harvested for whole membrane preparation (left panel) or surface 
biotinylation (right panel) to detect the expression of B0AT1 and ACE2 by immunoblotting. β-actin was 
used as a loading control (n=1, e=1). B) Uptake of [14C]isoleucine by WT and pcDNA3.1/hB0AT1-
transfected HUH7 cells. Cells were exposed to 100µM radiolabelled isoleucine in Hank’s +Na+ or -Na+ 
buffer for 6min. The Na+ (net) uptake activity (red columns) was calculated by subtracting the uptake 
activity in the absence of Na+ (green columns) from the total uptake activity. Data is shown as average 
± std (n=3, e=1). C) LLC-PK1 was either transfected with pcDNA3.1/hB0AT1, or co-transfected with 
pcDNA3.1/hB0AT1 and pcDNA3.1/hcollectrin (1.25µg of each plasmid DNA, 2.5µg in total), using 
LipofectamineTM LTX, before measuring the uptake of [14C]isoleucine (n=3, e=1). D) Isoleucine 
transport activity in MDCK cells transfected with pcDNA3.1/hB0AT1+pcDNA3.1/hcollectrin (labelled 
as pcDNA in the figure), or with pIRES/hB0AT1/hcollectrin (labelled as pIRES), using LipofectamineTM 
LTX (n=3, e=1). (E) Uptake of [14C]isoleucine in MDCK cells transfected with 
pcDNA3.1/hB0AT1+pcDNA3.1/hcollectrin using LipofectamineTM 3000 (n=3, e=1). F) Li-7 cells were 
transfected with pcDNA3.1/hB0AT1, or pcDNA3.1/hcollectrin, or both, using LipofectamineTM 3000, 
48h before measuring the uptake of [14C]isoleucine in the presence and absence of sodium ions (n=3, 
e=1). 
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2.3.4 Generation of hB0AT1+hcollectrin stably transfected CHO cells using Flp-InTM 
transfection system 
The CHO-BC cell line showed that hB0AT1 and collectrin can be expressed heterologously, 
but the use of the cell line was restricted due to contractual agreements with Sanofi-Aventis. 
As a result, we decided to recreate the cell line, which should also aid in the understanding of 
heterologous expression of this transporter complex. 
The Flp-InTM transfection system (Invitrogen) was used to generate our own stably-transfected 
cell line. The CHO Flp-In host cell line with a single integrated Flp Recombination Target 
(FRT) site was purchased from Invitrogen. The cloning strategy was to first integrate 
pcDNA5/FRT/hB0AT1 via a Flp recombinase-mediated DNA recombination at the FRT site, 
then to cotransfect with hcollectrin. The two vectors, pcDNA5 and pcDNA3.1, held different 
antibiotic resistance genes, making cells resistant to Hygromycin B and Geneticin, respectively, 
once the transfection was successful. Therefore, an appropriate concentration of the antibiotics 
would be capable of killing untransfected cells without interfering with transfected ones. This 
concentration should be the minimum concentration killing all wild-type (WT) cells within 15 
days. Firstly, the sensitivity of CHO host cell line to Hygromycin B was measured by IncuCyte 
technology. The growth curves of cells under different concentrations of Hygromycin B is 
shown as percentage of confluence at certain time points (figure 2.3.7A), and 400 µg/mL was 
determined as the concentration for subsequent selection of Hygromycin-resistant cells. The 
host cells were then transfected with pcDNA5/FRT/hB0AT1 construct (#1 and #8) and plasmid 
pOG44 using LipofectamineTM 2000. Six colonies (4 from construct #1 and 2 from construct 
#8) were eventually propagated and tested for the expression of hB0AT1. By RT-PCR, hB0AT1 
expression was clearly seen in all six clones as well as the positive control, CHO-BC cells, as 
illustrated by a band with the size of 378bp (figure 2.3.7B). However, B0AT1 was not detected 
at protein level in cell homogenates (figure 2.3.7C), suggesting lack of translation or 
degradation of B0AT1 in the absence of collectrin. Subsequently, one clone from construct #1 
and one clone from construct #8 were used for collectrin transfection. Construct #1 and #8 
were the two constructs selected after orientation check (figure 2.2.3E). Again, the sensitivity 
of B0AT1-transfected cells to G418 (Geneticin) was measured with IncuCyte technology 
(figure 2.3.7D), and 800µg/mL was determined as the concentration for G418 selection. The 
procedures of hcollectrin transfection was the same as that of hB0AT1, and ten G418-resistant 
colonies were isolated for further testing. This time, B0AT1 protein was detected in membrane 
preparations of seven colonies although not at the same level as in CHO-BC cells (figure 
2.3.7E). Notably, there was another strong band with higher molecular weight (around 100kDa) 
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detected in whole membrane samples of CHO-BC cells, which was only weakly expressed in 
the new clones (figure 2.3.7E). Colony #5 did not grow well and was discarded. Surprisingly, 
except for CHO-BC, I could not detect collectrin protein expression in any of the transfected 
colonies (figure 2.3.7E). To further investigate expression of B0AT1, uptake of [14C]isoleucine 
was measured in the new transfected cells. Net sodium dependent isoleucine uptake was lower 
in the new co-transfected colonies (3-21nmol/mg protein*6min) compared to CHO-BC cells 
(35±4nmol/mg protein*6min) (figure 2.3.7F, red bars). One possible explanation was the lack 
of collectrin protein expression at the membrane, suggesting that B0AT1 protein was only 
partially trafficked to the plasma membrane, hence, having less transport activity than CHO-
BC cells. Colony #6, #7 and #8 had relatively high levels of Na+-dependent isoleucine uptake, 
and were picked for a repeat transfection with pcDNA3.1/hcollectrin. The re-transfected cells 
were passaged and propagated in medium containing Hygromycin B and G418 until functional 
tests were performed. There was an 43-45% increase in the Na+-dependent isoleucine uptake 
in double-collectrin-transfected colonies #6 and #7 compared to single-collectrin transfected 
cells, and this increase was more than 2.6 folds in clone #8 (figure 2.3.8A), indicating that the 
repeated collectrin transfection did improve the transport activity. Similar to CHO-BC cells, a 
reduction in B0AT1 activity after passaging was also seen in colony #6, #7 and #8, e.g. compare 
sodium-dependent isoleucine uptake in figure 2.3.7F (passage 2) and in figure 2.3.8A (passage 
4). However, the improved Na+-dependent isoleucine uptake (maximum 16nmol/mg*6min in 
colony #6) was still less than the activity observed in CHO-BC cells (30-40 nmol/mg*6min in 
figure 2.3.7F). Another potential reason for the lower transport activity could be due to the 
dilution of transfected cells by untransfected ones. To solve this problem, I isolated individual 
clones of double-collectrin-transfected cells by limiting dilution into a 96-well plate. B0AT1 
function was measured on these cloned cell lines by both membrane potential assay (figure 
2.3.8B) and radioactive substrate uptake assay (figure 2.3.8C&D). Clone #8 H6 and clone #8 
G3 were eventually selected as the best performing cell lines reaching 86% and 81%, 
respectively, of the depolarization peak induced by 1.5mM leucine in CHO-BC cells (figure 
2.3.8B, highlighted by red rectangles). Na+-dependent leucine uptake activity in subclones H6 
and G3 reached 57% and 52%, respectively, of that observed in CHO-BC cells (figure 2.3.8D, 
highlighted by red rectangles). The endogenous Na+-independent leucine uptake was similar to 
the level observed in CHO-BC cells (figure 2.3.8C, highlighted by red rectangles). The 
collectrin transfection was then repeated once again on these two selected clones. The Na+-
dependent leucine uptake activity reached 67% and 62% in clone #8 G3 and clone #8 H6, 
respectively, of that observed in CHO-BC cells. Notably, the Na+-independent leucine uptake 
level increased in these two clones compared to CHO-BC (figure 2.3.8E). The triple-collectrin-
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transfection brought B0AT1 protein to the membrane although collectrin was still invisible in 
a total membrane preparation (figure 2.3.8F). However, large amounts of collectrin transcripts 
were observed in double- or triple- collectrin transfected clone #8 H6 cells, whereas collectrin 
mRNA was hardly detectable in triple-collectrin transfected clone #8 G3 cells, and even weaker 
in CHO-BC cells (figure 2.3.8G). The low mRNA level and high protein level of collectrin in 
CHO-BC cells and the opposite situation in triple-collectrin-transfected cells suggested that the 
translation efficiency of collectrin was likely to be higher in CHO-BC cells than in the newly 
generated cell lines. B0AT1 mRNA was expressed evenly in all of the tested cells (figure 
2.3.8G), again proving that B0AT1 was successfully introduced into the genomic DNA. The 
loss of transgenes was also reported in MDCK cells overexpressing B0AT1 and collectrin over 
several passages [187]. To see whether transient transfection could rescue B0AT1 activity in 
later passages, triple-collectrin transfected clone #8 H6 cells after passage 7 were transiently 
re-transfected with pcDNA3.1/hcollectrin and tested or harvested just 48hr after transfection 
without passaging. The fresh transient transfection increased B0AT1 activity to a similar level 
as in CHO-BC cells, according to the depolarization signal in the membrane potential assay 
(figure 2.3.9A) and the Na+-dependent substrate transport activity in [14C]leucine uptake assay 
(figure 2.3.9B). Protein expression of B0AT1 and collectrin was clearly detected at the surface 
of the membrane (figure 2.3.9C&D), indicating that collectrin expression might be unstable or 
the protein is rapidly degraded. This may underlie the loss of B0AT1 transport activity in stably 
transfected cells. It has been reported that lower incubation temperature can improve translation 
efficacy in CHO cells [188, 189]. Hence, we seeded the CHO-BC cells and triple-collectrin-
transfected CHO-H6 cells in 96-well plates or 35mm dishes containing culture medium and 
incubated them at 37°C or 33°C in 5% CO2 incubators for two days before testing or harvesting. 
In support of this notion, low-temperature-incubation increased the leucine-induced 
depolarization peak in the membrane potential assay in both cell lines (figure 2.3.9E). However, 
it did not alter sodium-dependent [14C]leucine uptake, which was slightly elevated in CHO-BC 
cells but decreased in CHO-H6 cells at lower temperature (figure 2.3.9F). The low-temperature 
incubation did not up-regulate the membrane expression of B0AT1 and collectrin in both cell 
lines (figure 2.3.9G&H). 
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Figure 2.3.7: Generation of B0AT1 and collectrin stably transfected CHO cells. A) Growth curves 
of CHO Flp-In host cells exposed to Hygromycin B. Cells were initially seeded in a 96-well plate at a 
density of 2000 cells/well. After attaching to the bottom of the plate, cells were challenged with different 
concentrations of Hygromycin B (0, 50, 100, 200, 400, 600, 800µg/mL, 12 wells/concentration). The 
growth curves were measured in an IncuCyte by monitoring the confluence of cells in each well every 
3hr for up to 120hr. Arrows indicate time of medium change. The average of confluence in 12 wells ± 
std is shown as a growth curve. B) Gene expression level of B0AT1 in pcDNA5/FRT/B0AT1 transfected 
CHO cells. After transfection, six colonies of cells were split into 6cm dishes and maintained in 
selection medium. After reaching 80-90% confluence, RNA was extracted. CHO-BC cells were used as 
a positive control. Clathrin was used as a house-keeping gene. B0AT1 mRNA was detected as a band of 
378bp. C) Protein expression level of B0AT1 in pcDNA/FRT/B0AT1 transfected cells. Cells were 
homogenized with Ripa buffer (Sigma, #R0278), and approximately 90µg of protein was loaded for 
each sample. Left to right: transfected colony #1-6, CHO-BC, SeeBlue plus2 pre-stained protein marker 
(Invitrogen, LC5925). β-actin was used as a loading control. D) Growth curves of B0AT1-transfected 
CHO cells exposed to G418. The cells were challenged with 0-1000µg/mL G418 for up to 160hr. E) 
Protein expression of B0AT1 and collectrin after co-transfection. Membrane proteins were extracted 
from the cell lysate and about 10µg of protein was loaded for each sample. F) Uptake of 150µM 
[14C]isoleucine by B0AT1 and collectrin co-transfected cells was measured after 6min incubation. 
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Figure 2.3.8 Optimisation of B0AT1 and collectrin expression in stably transfected CHO cells. A) 
CHO B0AT1+collectrin-transfected cell colony #6, #7 and #8 were re-transfected with 
pcDNA3.1/hcollectrin in the presence of LipofectamineTM 2000. No antibiotics were added when 
Lipofectamine was present in the medium. 6hr after transfection, the transfection medium was replaced 
by CHO cell culture medium supplemented with 400µg/mL Hygromycin B and 800µg/mL G418. 48hr 
after transfection, the cells were split and transferred into a 25cm2 flask for propagation until confluent 
enough to be seeded out for radiolabelled isoleucine uptake assay. The result is shown as mean of 
triplicates ± std in one experiment. B)-D) The double-collectrin-transfected CHO cells were seeded out 
in a 96-well plate by limiting dilution to propagate single clones. A total of 30 clones were eventually 
tested by membrane potential assay (B) as well as radioactive substrate uptake assay (C&D) in the 
presence and absence of Na+. The results were normalized to the assay activity in CHO-BC cells to 
compare the data from three independent experiments. Clone #8 H6 and clone #8 G3 were eventually 
selected as the best performing cell lines, which are highlighted by red rectangles. E) Clone #8 G3 and 
H6 were transfected with pcDNA3.1/hcollectrin for the third time, and transport activity was measured 
by [14C]leucine uptake assay. F) and G) B0AT1 and collectrin expression at protein level in whole 
membrane preparation samples (F) and at mRNA level (G) in the double- and triple- collectrin 
transfected cells compared to CHO-BC cells. 
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Figure 2.3.9: Characterisation of B0AT1 and collectrin stably transfected single clones. Functional 
expression of B0AT1 was evaluated by the following methods: A) membrane potential assay, B) 
[14C]leucine uptake assay, and C) membrane protein expression using surface biotinylation samples. 
For all assays, cells were directly used after fresh transient transfection with pcDNA3.1/hcollectrin 
(H6/T) and compared to the cells at passage 7 without transient transfection (H6) and with CHO-BC 
cells. D) Intensity of bands in figure (C) normalized to the loading control β-actin. E) Membrane 
potential assay, F) [14C]leucine uptake assay, and G) membrane protein expression measured on cells 
incubated at different temperatures for two days. H) Intensity of bands in figure (G) normalized to the 
loading control β-actin. 
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2.3.5 Validation of a sodium dye assay 
The sodium dependence of the B0AT1 transporter suggested that it might be possible to 
measure the uptake of AA substrate by a fluorescent sodium indicator, such as Asante 
NaTRIUM Green 2 (ANG-2). ANG-2 is loaded into the cells as an acetoxymethyl-ester. To 
calibrate the assay, I performed a sodium titration experiment (figure 2.3.10A&B). Two 
ionophores, Monensin (figure 2.3.10A) and Gramicidin (figure 2.3.10B), were used to 
equilibrate intra- and extracellular Na+-concentration. The addition of these two ionophores to 
cells incubated in Na+-free buffer generated small peaks but the signal returned to baseline 
immediately, indicating the depletion of intracellular sodium. Then the extracellular sodium 
concentration was increased to various levels, leading to the equilibration of intracellular and 
extracellular sodium ion concentration, resulting in corresponding increases in sodium 
indicator fluorescence. At the end of the experiment, 145mM KCl was added into the buffer. 
The sudden increase in extracellular potassium ion concentration caused an immediate outward 
flow of sodium ions in exchange for potassium ions, hence, decreasing the ANG-2 fluorescence 
sharply. This titration experiment showed a good response of the ANG-2 dye to changes of the 
Na+-concentration in CHO-BC cells. The next step was to optimize the assay conditions in 
CHO-BC cells for the study of B0AT1. According to the protocols (TEFLabs’s protocol for 
ANG-2, Invitrogen’s protocol for Pluronic F-127), several conditions could be optimized, 
including the concentration of working solution (no more than 1%, composition see table 2.3.2), 
the dye-loading buffer (serum-free medium or buffer), loading time (10-60min), and loading 
temperature (room temperature or 37°C). To minimize the background signal, we also tried 
using Hank’s buffer devoid of sodium ions in the dye-loading phase and post-loading phase. 
After several baseline readings, 50µL of 30mM leucine in Hank’s +Na+ solution was added 
into 200µL post-loading buffer in each well to stimulate the signal by co-transporting Na+ into 
the cells. In case of Hank’s -Na+ buffer as the post-loading buffer, the final concentration of 
sodium was 28mM (50µL of Hank’s +Na+ buffer containing 140mM Na+ was added into 200µL 
Hank’s -Na+ buffer). Conditions tried during optimization are listed in table 2.3.2. In figure 
2.3.10C, no signal indicating sodium influx was detected after the addition of amino acid 
substrate leucine under condition 1-3, suggesting no difference between Hank’s buffer and 
DMEM as the dye-loading buffer, and between different dye-loading temperatures. However, 
cells looked healthier (less detached cells on the plate) when pre-loading for 10min (condition 
3) compared to 30min (condition 2), while the fluorescence readings were not influenced by 
shortening the incubation time. Next, sodium depletion was tried during dye-loading (condition 
4) as well as post-loading stages (condition 5), and only the latter one generated an obvious 
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leucine-induced signal. Further optimization was tried by varying the percentage of working 
solution. The dye and Pluronic F-127 were dissolved in dimethylsulfoxide (DMSO) in working 
solutions which are toxic to cells above 1% [190], hence, lower concentrations of working 
solution were tested. The leucine-stimulated signal was similar in cells pre-loaded with 0.5% 
working solution (condition 6) to cells pre-loaded with 0.2% working solution (condition 7). 
Since condition 6 (highlighted in table 2.3.2) had higher readings than condition 7, most likely 
due to the larger amount of dye loaded into the cells, it was selected as the preferred condition 
in the following validation. Surprisingly, when using different concentrations of leucine as the 
stimulus, lower concentrations (1, 3, 6mM) induced a higher fluorescent signal than the higher 
concentration (9mM), and even the addition of sodium ions (to the final concentration of 28mM) 
alone in the absence of leucine generated a large signal (figure 2.3.10D). Such sodium-induced 
signal was also seen in CHO parental cells (figure 2.3.10E). One explanation for the lack of 
B0AT1-induced increases of cytosolic Na+ may involve the immediate extrusion of 
cotransported Na+ by the Na-K-ATPase. This would result in leucine-induced signals being 
weaker than expected. To reduce this compensation, we used Ouabain, a specific Na-K-ATPase 
inhibitor [191], or removed extracellular potassium [191], to render the Na-K-ATPase inactive 
and avoid the extrusion of Na+ by the pump. The use of 1mM Ouabain in the dye loading stage 
did not increase the sodium-induced signal, furthermore, Ouabain diminished the leucine-
induced signal (figure 2.3.10F), suggesting an inhibitory effect on B0AT1. The depletion of 
potassium in the extracellular buffer also made no difference to the buffer containing K+ (figure 
2.3.10G). The washing step after dye-loading caused cells to detach from the plate. Instead of 
washing, it was reported that the extracellular ANG-2 dye after loading could be quenched by 
PillarBox Red Food Dye (Personal communication: Irina Vetter from the University of 
Queensland at Gage Conference 2017). This is the same principle as used in the FLIPR dye kit, 
in which fluorescent sensor is pre-combined with impermeable quenchers (either a blue 
quencher or a red quencher) to reduce the background fluorescence signal and to improve the 
signal-to-noise ratio without washing the cells after dye loading. Hence, we tried to use 1:50 
diluted PillarBox Red for quenching. Figure 2.3.10H showed a small and lasting increase of 
the fluorescent signal before and after the addition of Hank’s +Na+ buffer with leucine 
compared to a lesser signal without leucine. Different from the curves in figure 2.3.10D, where 
the unloaded dye was removed, continued presence of the dye in the presence of PillarBox Red 
caused shifted upward drift of the fluorescent signal during baseline reading (100sec), and 
abolished the initial jump of fluorescence after the addition of leucine plus Na+. Overall, the 
sodium assay could not be optimised to the point where it would be able to become an 
alternative assay to measure B0AT1 activity. 
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Table 2.3.2: conditions tried during optimization of ANG-2 (AM) on CHO-BC cells. 
Condition No. 1 2 3 4 5 6 7 
Dye-loading buffer Hank’s 
+Na+ 
DMEM DMEM Hank’s -
Na+ 
Hank’s -
Na+ 
Hank’s -
Na+ 
Hank’s 
-Na+ 
% of working 
solution* in loading 
buffer 
1% 1% 1% 1% 1% 0.5% 0.2% 
Dye-loading 
temperature 
RT 37°C 37°C RT RT RT RT 
Dye-loading time 30min 30min 10min 10min 10min 10min 10min 
Post-loading buffer Hank’s 
+Na+ 
Hank’s 
+Na+ 
Hank’s 
+Na+ 
Hank’s 
+Na+ 
Hank’s -
Na+ 
Hank’s -
Na+ 
Hank’s 
-Na+ 
Na+ Final conc. (mM) 140 140 140 140 28 28 28 
*working solution contains 0.5mM ANG-2 Dye and 10% (w/v) Pluronic F-127 dissolved in DMSO. 
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Figure 2.3.10: Validation of sodium dye assay in CHO-BC cells. The excitation wavelength was 
488nm, and the emission wavelength was 540nm. A) & B) Calibration by sodium titration with different 
ionophores. After reaching a stable baseline signal, 5µM monensin (figure A) or 2.5µM Gramicidin A 
(figure B) was used to deplete cells of Na+, followed by the addition of NaCl to various levels (5, 15, 
45, 145mM), with 145mM KCl added in the end (n=3, e=1). C) Optimization of assay conditions in 
CHO-BC cells. Different dye loading buffer, temperature, time, concentration of dye, and post-loading 
buffer were tried as listed in table 2.3.2. After baseline readings, 6mM leucine in Hank’s +Na+ buffer 
was added to stimulate the fluorescent signal, as indicated by the arrow in the figure. Data points show 
the relative fluorescence in percentage of the first baseline reading (n=1, e=1). D) The ANG-2 
fluorescent signal induced by different concentrations of leucine in the presence of Na+. The CHO-BC 
cells were pre-loaded with Hank’s -Na+ buffer supplemented with 0.5% working solution at room 
temperature for 10min. The cells were washed twice with Hank’s -Na+ buffer and incubated in the same 
buffer after removing the dye solution. Hank’s +Na+ buffer containing different concentrations of 
leucine was added after recording the baseline, Hank’s -Na+ buffer was used as a negative control. Final 
concentrations of leucine are indicated in the figure (n=3, e=1). E) The CHO parental cells were pre-
loaded with Hank’s -Na+ buffer with 0.5% working solution at RT for 10min, then washed twice with 
Hank’s -Na+ buffer and incubated in the same buffer after removing the dye solution. Hank’s +Na+ 
buffer with or without leucine was added after recording the baseline, final concentration of leucine was 
6mM (n=3, e=1). F) The CHO-BC cells were pre-loaded with Hank’s -Na+ buffer and 0.5% working 
solution as well as 1mM Ouabain (from 100mM stock solution) at RT for 10min. After removing the 
pre-loading solution, the cells were incubated in Hank’s -Na+ buffer. After baseline readings, Hank’s 
+Na+ buffer with or without leucine was added (n=3, e=1). G) The CHO-BC cells were treated as in 
figure D, except that potassium was removed in the Hank’s buffer used in this experiment (n=3, e=1). 
H) The CHO-BC cells were pre-loaded with Hank’s -Na+ buffer and 0.5% working solution at RT for 
30min. After pre-loading, the excess unloaded dye was quenched by adding 1:50 PillarBox Red Food 
Dye into each well and incubating at RT for 15min. After incubation, the baseline readings were 
recorded without washing the cells, followed by the addition of Hank’s +Na+ buffer with or without 
leucine (n=3, e=1). 
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2.4 Discussion 
For the high-throughput screening (HTS) and the secondary screening of B0AT1 inhibitors, we 
first needed a cell line expressing functional B0AT1 at the surface of the membrane. Our 
collaborator, Sanofi Aventis Pharmaceutical Company, had generated single clones of a CHO 
stable cell line by co-expressing hB0AT1 and hcollectrin with the aid of the Flp-In™ 
transfection system. Its applications for the expression of cytosolic or membrane proteins were 
reported in various host cell lines [133-138]. CHO-K1 was chosen as a host cell line in this 
study because its endogenous uptake of isoleucine was purely Na+-independent (figure 2.3.1D) 
and electroneutral (figure 2.3.1E), allowing us to introduce the Na+-dependent electrogenic 
transport of amino acids by B0AT1 without any interference from the endogenous transporters. 
Based on the competition uptake experiment (figure 2.3.4C), the endogenous transport of 
isoleucine in CHO-K1 cells was most likely occurring via the hamster isoform of system L 
amino acid transporters [148]. The basic characteristics of B0AT1 (sodium-dependent, 
electrogenic and substrate preference) was confirmed in CHO-BC cells. These characteristics 
of B0AT1 were identical to those reported previously using electrophysiological recordings on 
Xenopus oocytes [84, 96]. The Km values of leucine and isoleucine determined by both 
membrane potential assay (figure 2.3.4E&F) and radioactive substrate uptake assay (figure 
2.3.4G&H) were also consistent with the published data [73, 84, 182]. Although the Km values 
for these two substrates were very close, isoleucine seemed to be a more specific substrate for 
B0AT1, indicated by the lack of a background signal in CHO parental cells in the FLIPR assay 
(figure 2.3.1E). Leucine, on the other hand, generated a small depolarization peak in parental 
cells (figure 2.3.1F), suggesting that leucine can be transported by other electrogenic 
transporters endogenously expressed in CHO cells, e.g. system A [192]. Hence, isoleucine was 
selected as the substrate used in the uptake assay for the secondary screening. One major 
problem of CHO-BC cells was the loss of activity of the heterologously expressed proteins 
after several cell culture passages (figure 2.3.2). The passaging, however, did not influence the 
endogenous sodium-independent transport activity. Torrente et al. reported a similar reduction 
of transgene expression at passage 10 when overexpressing B0AT1 and collectrin in MDCK 
cells, arguing that high extracellular amino acid concentration in cell culture medium down-
regulated the constitutive expression of the transporter [187]. In another study, the limitation 
of essential amino acids (EAAs) such as methionine and cysteine was reported to reactivate the 
transgene expression in mammalian cells by down-regulation of histone deacetylase 4 (HDAC4) 
[193]. However, I have not tried restriction of EAAs in culture medium as a strategy to solve 
this problem. When using stably transfected CHO cells, Bjork et al. noticed a loss of 
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homogeneity in expression of the α2A-adrenergic receptor after passage 13 and an attenuation 
of function after passage 20 [194]. The author noted the dissociation of receptor expression 
from antibiotic resistance, possibly caused by an inappropriate amount of antibiotics used in 
the maintenance of transfected clones, however, the specific mechanisms remained unclarified. 
Osmotic loading was proposed to increase after inducing the expression of GLT-1, a sodium-
dependent glutamate transporter, in CHO cells, indicated by the increased cell size [195]. 
However, addition of extracellular sucrose to CHO-BC cells did not improve the transport 
activity or cell growth (figure 2.3.3A&B). Hence, we only used CHO-BC cells with less than 
10 passages for functional tests. 
ACE2 and collectrin are auxiliary proteins of B0AT1 expression in intestine and kidney, 
respectively [79]. They are important not only for the trafficking of B0AT1 to cell surface, but 
also for the catalytic function of the transporter. However, the peptidase domain of ACE2 was 
proved to be irrelevant to the surface expression and catalytic function of B0AT1 [40]. 
Furthermore, collectrin was smaller in size compared to ACE2 due to the lack of its catalytic 
domain. Hence, we chose to co-express collectrin with B0AT1 to generate the cell model for 
the study of this transporter. The co-expression of collectrin was proved to be essential to the 
surface expression of B0AT1, based on our observation that B0AT1 was absent in whole 
membrane proteins of pcDNA5/FRT/B0AT1-transfected cells (figure 2.3.7C). This was in 
agreement with previous studies [79-81, 96]. As expected, the co-expression of collectrin was 
critical for the function of the transporter, as indicated by (i) higher sodium-dependent substrate 
uptake in CHO-BC cells; (ii) higher protein levels of B0AT1 and collectrin; (iii) further increase 
of transport activity and protein expression of B0AT1 and collectrin after transient transfection 
with collectrin. Notably, repeated collectrin transfection increased transcript levels but did not 
result in higher protein expression, suggesting limitations of the translation of collectrin or its 
degradation (figure 2.3.8E). Post-transcriptional modifications and protein degradation were 
reported as reasons for discrepancies between mRNA and protein levels [196]. In our 
experiments, B0AT1+collectrin transiently transfected CHO cells (0.6mg/mL G418 in culture 
medium) were more resistant to selection antibiotic G418 compared to CHO-BC cells 
(0.275mg/mL G418 in culture medium), thus, the high concentration of antibiotic in the culture 
medium could be toxic to protein synthesis. It is noteworthy that a higher-molecular-weight 
(HMW) band of about 98kDa was consistently detected in the blots of B0AT1 when analyzing 
membrane proteins of CHO-BC cells (figure 2.3.1A, 2.3.7E). This may represent a SDS 
resistant heterodimer formed between B0AT1 (64kDa) and collectrin (43kDa). However, such 
a HMW band was not detectable in the collectrin blot, thus, it might also represent a homodimer 
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of B0AT1, although the molecular weight seemed to be lower than expected. Interestingly, this 
HMW band was undetectable in transiently transfected cells (figure 2.3.6A), or much less 
obvious in other B0AT1+collectrin-transfected CHO clones (figure 2.3.1C, 2.3.7E) with lower 
transport activity. Its presence possibly correlates with transport activity measured by 
functional tests. Therefore, formation of higher-order complexes may play an important role in 
the function of the transporter. Heteromeric design is commonly observed in amino acid 
transporters. The most well-studied examples are the heavy subunits 4F2hc and rBAT, which 
associate by a disulfide bridge with the light subunits of system L/y+L amino acid transporters 
(LAT1, LAT2, y+LAT1 and y+LAT2) and system b0,+ amino acid transporters, respectively 
[197-199]. The functions of these two heavy chains are slightly different. Both 4F2hc and rBAT 
are necessary for trafficking the light chain to the surface of the plasma membrane, but 4F2hc 
alone is expressed on the cell surface even without the coexpression of a light chain, whereas 
rBAT does not reach the plasma membrane alone [200]. Moreover, 4F2hc only plays a role in 
the trafficking of the light chain to the membrane [201], but rBAT itself takes part in the 
transport activity [198]. Due to the heteromeric design, mutations in either rBAT or b0,+AT will 
cause lack of reabsorption of cystine and cationic amino acids in the kidney and thus lead to 
cystinuria [106]. Similarly, a profound aminoaciduria was also seen in collectrin-deficient mice, 
accompanied by decreased B0AT1 protein expression at the renal cortical plasma membrane 
[81]. Unlike 4F2hc, collectrin was only measurable when co-expressing with B0AT1 at the 
membrane of our cell lines. It was absent in membrane fractions of LLC-PK1 and HUH7 cells 
when B0AT1 was not expressed (figure 2.3.5B). Furthermore, collectrin was shown to be 
essential for transport activity in a previous study of our lab [40]. Thus, the interaction of 
collectrin and B0AT1 was more similar to that of rBAT and b0,+AT. Homodi- and 
multimerization is frequently observed in ion channels and transporters. Two examples are the 
potassium ion transporter TrkH in bacteria [202] and the SCN1B sodium channel in 
mammalian cells for the enhancement of cell-cell adhesion [203]. Dimerization of TrkH and 
SCN1B proteins occur via the transmembrane domain and extracellular domain, respectively. 
It is noteworthy that the neurotransmitter and sodium symporters in the SLC6 family often 
require oligomerization rather than heteromerization for endoplasmic reticulum (ER) exit to 
the plasma membrane [204]. The SDS-resistance is seen as an indicator of the hydrophobicity 
and stability of a protein complex at the plasma membrane [205]. Occasionally, protein-protein 
interactions, both in the form of a homodimer or heterodimer, can even be determined by mass 
spectrometry [206]. 
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To generate a cell model without IP restrictions for future studies of B0AT1, we tried both 
transient and stable transfections in different cell lines. The former method involves temporal 
expression of the gene of interest without its integration into the genome of the host. The 
introduced DNA will be degraded after several cell divisions. The latter method involves 
insertion of the foreign DNA into the host genome, and consequently sustained expression of 
the transgene is observed [131]. Although stable transfection is widely used in pharmacological 
studies and gene therapies, the integration event has much lower efficiency than transient 
transfection [207] and requires isolation of single clones. It becomes even more complex when 
multiple genes are required to be expressed. As a result, I searched the Oncomine microarray 
database for cell lines that naturally express either SLC6A19 or collectrin or both, and found 
several candidates including HUH7, GP2d and Li-7. Surprisingly, no sodium-dependent 
isoleucine uptake was seen in GP2d cells (figure 2.3.5C) even though B0AT1 and ACE2 were 
detected at the protein level on the cell surface (figure 2.3.5B). Similarly, transient expression 
of B0AT1 in HUH7 cells in which endogenous ACE2 was detectable (figure 2.3.6A), failed to 
show sodium-dependent isoleucine uptake (figure 2.3.6B). This could be due to the failure of 
heterodimerization between B0AT1 and ACE2, leading to the instability of B0AT1 at the cell 
surface. It was previously reported that Janus-activated kinase-2 (JAK2) [88] and protein 
kinase B (PKB/Akt) [87] could enhance the surface expression of B0AT1 in the presence of 
ACE2 or collectrin and thus promote the transport of neutral amino acids. Therefore, addition 
of agonists of these pathways may be used to increase activity of B0AT1 during functional 
assays. 
Because transient expression of B0AT1 and collectrin was unsuccessful, stable transfection was 
applied. The host cell line purchased from Invitrogen has only one FRT site, so the two genes 
of interest, B0AT1 and collectrin, had to be separately introduced into the genome [58, 186, 
188, 189, 208-211]. Stable simultaneous overexpression of multiple genes creates a number of 
problems, such as uneven expression and difficulties to select double transfected genes. Various 
methods have been reported for the integration stage as well as the selection stage. For example, 
a plasmid based multigene expression system called MultiLabel was reported to allow the 
assembly of independent expression vectors by a Cre/LoxP reaction into a single plasmid with 
multiple expression cassettes, yielding highly efficient co-transfection of multiple genes [212]. 
A Flp recombinase mediated cassette exchange (RMCE) technique was reported for the co-
expression of protein complex subunits in two independent exchange loci in CHO Lec3.2.8.1 
cells. The binary master cell line showed stable expression levels of a toll-like receptor and its 
chaperone after transfection. The author pointed out the possibility of generating multi RMCE 
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expression system on the basis of this protocol [213]. To improve the efficiency of cell selection 
after transfection, fluorescence activated cell sorting (FACS) technology was applied, and the 
successfully transfected cells could be sorted by different fluorescence-tagged plasmids, e.g. 
GFP-tagged (green) [210] or mCherry-tagged (red) [211]. It was also reported that a two-
colored fluorescence marking system was used when introducing two proteins into HEK293-
T cells. After antibiotic selection, the double-labelled transfected cells were further sorted by 
flow cytometry to ensure the success of co-expression [214]. 
Combination of two HTS assays can reduce the number of false-positive and false-negative 
hits. For instance, combination of the FLIPR membrane potential assay and the ANG-2 sodium 
indicator assay showed that both assays yield a large amount of unique hits in the HTS [177]. 
Unfortunately, the sodium indicator assay did not seem to provide a satisfactory transport-
dependent signal on our cell model. Inhibition of Na+-K+-ATPase by Ouabain (figure 2.3.10G) 
or by depletion of extracellular K+ (figure 2.3.10G) failed to reduce the background signal, 
indicating the existence of other factors mediating sodium influx in this cell line. Very few 
studies reported using ANG-2 as a sodium indicator mainly to probe neuronal circuits [174, 
215]. Although there is a concentration difference between extracellular (120-150mM) and 
intracellular (5-15mM) sodium ion concentration, the difference is not as high as that of Ca2+. 
As a result, it is more challenging to monitor sodium ions crossing plasma membrane, and there 
are less commercially available dyes as compared to Ca2+ indicators. In addition to the ANG-
2 sodium dye used in this study, two more dyes, namely SBFI (sodium-binding benzofuran 
isophthalate) and CoroNaTM Green, were tested and compared in prostate cancer cell lines. In 
this study, SBFI showed the slowest cell permeability even with the help of the dispersion agent 
Pluronic F127, whereas CoroNa exhibited the lowest sensitivity [172]. In a review paper, the 
authors pointed out that the relatively lower assay sensitivity and poorer signal-to-background 
ratio of the above three sodium indicators as compared to membrane potential assay dyes are 
the main disadvantages of them to be used in HTS [216]. 
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Chapter 3: High-throughput Screening and Optimization of Inhibitors 
3.1 Introduction 
We used computational screening (also called virtual screening) as an initial tool to discover 
compounds that would inhibit B0AT1. It makes use of virtual chemical compound libraries. 
The Zinc library, for instance, is a database containing 727,842 commercially available 
compounds for structure-based virtual screening [217]. Apart from the Zinc library, several 
smaller chemogenomic libraries from different providers are also commonly used in virtual 
screening. For example, the Sigma library of pharmacologically active compounds is 
comprised of 1280 commercially available compounds particularly targeting G protein-coupled 
receptors (GPCRs); the Prestwick Chemical Library only covers approved drugs with safety 
and bioavailability data; and the library provided by National Centre for Advancing 
Translational Sciences is particularly used for anticancer agent screening [218]. Homology 
modelling and docking are two key components for virtual screening when the structure of the 
real target is not available. A homology model refers to the molecular model of a target protein 
generated from the 3D structure of a homologous protein, whereas docking is the method to 
predict the orientation and binding sites of molecules when interacting with the target protein. 
Although much more economical compared to experimental HTS, the disadvantages of virtual 
screening are significantly greater hit rates including many false-positive and false-negative 
predictions. Major problems of virtual screening include the complexity of receptor structures 
and dynamic changes in receptor shapes when binding to their ligands, and difficulties in the 
calculation of ligand-receptor binding energies [219]. In different studies, the hit rates of virtual 
screening could be 100- to 1000- fold higher than experimental screenings [220, 221], however, 
the hits from experimental and computational approaches often show little overlap [220], 
indicating that they could be used complementarily. 
The availability of the high-resolution structure of the leucine transporter from Aquifex aeolicus 
(LeuTAa) has provided us with a suitable homology model for the virtual screening. LeuT is 
composed of 12 transmembrane helices, with helices 1-5 and 6-10 showing two-fold inverse 
symmetry. This 5+5 inverted repeat fold is called LeuT fold, which is also seen in B0AT1 as 
well as neurotransmitter transporters [222]. The structure of LeuT revealed one substrate 
binding pocket and two sodium ion binding sites, with sodium site 1 being in coordination with 
the carboxyl-group of the substrate leucine [223]. The reliability of the model is illustrated by 
its use to analyse transporter mutations found in the SLC6A19 in inherited disorders [109]. 
B0AT1 (SLC6A19) is functionally closer to LeuT than the related neurotransmitter transporters 
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in the SLC6 family for two reasons. Firstly, leucine is a shared substrate of both LeuT and 
B0AT1. Secondly, both LeuT and B0AT1 are Na+-dependent but Cl--independent. One 
significant discrepancy is the presence of two Na+-binding sites in LeuT, whereas only one 
functional binding site is observed in B0AT1 [224]. Another notable difference is that 
tryptophan is a competitive inhibitor of LeuT [225] but a substrate, although weak, of B0AT1 
[84]. More recently, the dopamine transporter from Drosophila melanogaster (dDAT) has been 
crystallized and could be regarded as a more accurate homology model of B0AT1 due to its 
higher sequence identity (33%) with B0AT1 than LeuT (18%) [226]. A high-resolution structure 
of the B0AT1 transporter has not been determined. 
Apart from the computational screening, experimental high-throughput screening (HTS) is 
another way to identify ligands for particular targets. HTS is a method used in drug discovery, 
which involves a large quantity of chemical, biochemical or pharmacological tests conducted 
in a relatively short period of time to identify molecular structures that selectively bind to and 
modulate the activity of a biological target. More complex screening methods can stimulate 
and measure a desired phenotype in a cell or organism population. Cell-based screening is one 
of the most frequently used approaches to identify compounds modulating a specific biological 
target, especially after the development of microfluidic devices using the perfusion flow mode, 
the droplet mode and the microarray mode [227]. HTS of small molecule compound libraries 
using cell lines overexpressing the transporters of interest has been widely used to identify lead 
compounds for the treatment of certain diseases [228, 229]. There are mainly four types of HTS 
assays for compound screening, namely ligand-binding assays, flux-based assays, 
fluorescence-based assays and automated electrophysiological assays [216]. Ligand-binding 
assays are used to measure the affinity of a labelled ligand to the target binding site without 
measuring functional changes of the receptor such as inhibition or activation. One example is 
the scintillation proximity assay (SPA), in which the receptor is immobilized on a bead and the 
ligand is labelled with a radioactive isotope [230]. It is often used in HTS because it can readily 
be adapted to multiwell formats [231]. Flux assays are radioactive assays that can measure 
transport function. An inhibitor reduces the accumulation of labelled substrate inside the cell 
or vesicle [232]. Flux assays can be conducted in a multi-well format with high sensitivity and 
high quality of data, but the safety considerations of radioactive disposal have restrained its 
application in HTS [233, 234]. Fluorescence-based assays are the most frequently used assays 
for HTS making use of voltage sensitive dyes (e.g. DiBAC4(3) dye and FLIPR membrane 
potential assay kit) or ion-specific fluorescent probes (e.g. Fluo-4 calcium sensitive dye and 
ANG-2 sodium indicator), both of which have a wide range of applications in HTS for 
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transporter/ion channel inhibitors [235, 236]. Automated electrophysiological assays provide a 
high information content but are more costly and provide medium throughput [216]. 
Although HTS is a relatively time- and cost- effective way to identify potential drug candidates, 
it has limitations at the same time. Fluorescence-based assays can be interfered by fluorescence 
from the test compounds. Orange or red fluorophores can be used in some cases as the 
interfering light emissions from test compounds are more likely to occur at shorter wavelengths 
[237]. Moreover, non-specific inhibition caused by the aggregation of test compounds could 
lead to false-positive hits, which is a problem affecting 1.7-1.9% of total compounds in libraries 
[237-239]. Increasing the hit threshold might be able to reduce the false-positive rate, but at 
the same time increases the false-negative rate. Hence, the optimization of hit threshold 
compound concentration is a critical task during pilot screening [240]. 
After HTS, dose-response curves are generated for each identified lead compound. Then 
selected compounds are further tested with regard to their action on the target by secondary 
assays such as a second messenger assays or tissue-specific bioassays. This is used to identify 
lead compounds with a potency of 100nM-5µM, followed by the optimization of these leading 
compounds [241]. Subsequently, in vitro and in vivo assays are frequently employed to 
accumulate information on absorption, distribution, metabolism and excretion (ADME), as 
well as physicochemical and pharmacokinetic (PK) values. For channels and transporters, 
Xenopus laevis oocytes, which are immature egg cells from the South African clawed frog, are 
commonly used as a tool for secondary screening. The advantages of oocytes include easy 
handling and low background. They are used for the overexpression of membrane proteins by 
cRNA injections of various molecular targets [242]. For example, automated oocyte 
electrophysiological assays have been developed for drug screening of ion channels [243]. In 
addition, Xenopus oocytes are used in combination with radiotracer uptake assay to study 
transporters, channels and receptors [244]. Tissue-based assays are also used for secondary 
screening. For instance, mouse small intestine was used to measure glucose transport [245]. At 
a later stage, leading compounds are often tested in disease-specific animal models [246] to 
collect important in-vivo data such as efficacy and toxicity before clinical trials in humans. In-
vivo studies are critical to identify compounds with high sensitivity and specificity to the target 
[247, 248]. 
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3.2 Material and Methods 
3.2.1 Computational screening 
The large-scale virtual screening of B0AT1 inhibitors was done by Nishank Shah in his 
honour’s project. Since a high-resolution structure of B0AT1 was not available, high-resolution 
structures of two related proteins were used, namely LeuT and dDAT (the dopamine transporter 
from Drosophila melanogaster), to generate homology models of B0AT1. The virtual screening 
started with 14,434 compounds of the ZINC database (Version 12 [217]), which were selected 
by the following criteria: (1) the compounds are listed in the National Cancer Institute (NCI) 
diversity set; (2) compounds known to bind to or inhibit other SLC6 family members and their 
structural analogues; (3) the published B0AT1 inhibitor nimesulide [249], and its analogues. 
All docking runs were conducted using AutoDock 4.2 compiled on the AVOCA IBM Blue 
Gene/Q supercomputer cluster [250] maintained by the Victorian Life Sciences Computation 
Initiative (VLSCI), and eventually 40 highest scoring compounds from various clusters were 
ordered from the Developmental Therapeutics Program of the NCI for further experimental 
tests. The second round of computational screening was based on a set of 158 structural 
analogues of two best B0AT1 inhibitors (NSC63912 and 186059) from the above compounds 
in in vitro experiments, resulting in another 38 compound candidates requested from NCI [251]. 
3.2.2 RT-PCR to analyse expression of various transporters in cell lines 
Sequence of primers are listed in the appendix. 
The set-up of PCR reactions and PCR programs was the same as for hB0AT1 and hcollectrin 
in Chapter 1. For visualisation, the PCR products were mixed (5:1) with 6x sample loading 
buffer (Invitrogen) and analysed on 1% (w/v) agarose gels containing SYBRTM Safe DNA Gel 
Stain. 1x TAE (Invitrogen, #S33111) was used as a running buffer. PCR products were detected 
under UV light. The expected band sizes of the analysed transporters were 407bp for hLAT1 
(PROLIGO), 432bp for hLAT2 (PROLIGO), 481bp for 4F2hc (Sigma), 394bp for hATB0,+, 
(PROLIGO) and 351bp for hASCT2 (PROLIGO). 
3.2.3 Animals 
The animal studies were performed in accordance with the National Health and Medical 
Research Council’s (NHMRC) Australian Code for the Care and Use of Animals for Scientific 
Purposes and the ACT Animal Welfare Act 1992, and were approved by the Animal 
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Experimentation ethics committee of the Australian National University (A2014/20 for the use 
of X. laevis and A2013/39 for the use of mice, updated version A2016/41). 
Male and female C57BL/6J mice (Animal services, the Australian National University) were 
sacrificed for intestinal substrate uptake assay at an age of 4-6 months, and C57BL/6NCrl 
female mice were used in the pharmacological study at an age of 6-8 months. Mice were held 
in individually ventilated cages (<5 mice per cage) under specified pathogen-free conditions 
with a 12hr light/12hr dark cycle and were checked daily for general health. Cervical 
dislocation or euthanasia with CO2 flow were used to sacrifice animals before taking out organs 
or at the end of the experiment.  
X.laevis were housed in tanks (<20 animals per tank) with tank water filtered in a closed system. 
Frogs were anesthetized by submersion in water containing MS-222 until loss of reflexes. The 
surgical procedures and preparation and injections of oocytes has been described previously 
[252] and was conducted by Angelika Broer and Stephen Fairweather. 
3.2.4 Radio-labelled substrate uptake assay on injected oocytes 
After being maintained in OR2+ buffer (82.6mM NaCl; 2.55mM KCl; 1.27mM Na2HPO4; 
2.1mM MgCl2; 5mM HEPES) overnight, healthy oocytes were selected for injection. Into each 
oocyte, 10ng hB0AT1 cRNA construct and/or 2ng hcollectrin cRNA construct was injected. 
The uptake assays were performed 4-5 days after the cRNA injection. Before the assay, the 
non-injected and injected oocytes were observed under microscope and 10-12 healthy ones 
were transferred into tubes for each treatment. The oocytes were pre-washed three times with 
4mL ND96 buffer (96.2mM NaCl; 2mM KCl; 2.1mM MgCl2; 5mM HEPES) (room 
temperature), then incubated in buffers containing 14C-labelled substrate (leucine or isoleucine) 
for 15 min, in the presence of 300µM inhibitors as indicated in the figures. At the end of the 
treatment, the radioactive buffer was removed immediately and the oocytes were washed four 
times with 4mL ice-cold ND96 buffer. Each oocyte was transferred into one scintillation vial 
containing 200µL of 10% SDS. The lysis of oocytes was completed in 2-3hr. After that, 2.5-
3mL of scintillation fluid was added into each vial and the radioactivity was measured by a 
scintillation counter. The activity of non-injected oocytes was subtracted before data analysis. 
3.2.5 Radio-labelled substrate uptake assay on inverted sections of mouse small intestine 
Before the assay, the following buffers were freshly prepared. 
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Buffer 1: 0.9% (w/v) NaCl + 1mM glutamine + Protease Inhibitor Cocktail Tablet (1 tablet per 
50mL, Roche, #11873580001) in ddH2O, pre-cooled on ice; 
Buffer 2: 90% Hank’s -Na+ buffer + 10% Hank’s +Na+ buffer + 1mM glutamine + Protease 
Inhibitor Cocktail Tablet, one 50mL tube pre-cooled on ice, one 50mL tube pre-warmed in 
37°C water bath; 
Buffer 3: Hank’s -Na+ buffer + 1mM glutamine + Protease Inhibitor Cocktail Tablet, pre-
warmed in 37°C water bath; 
Buffer 4: 90% Hank’s -Na+ buffer + 10% Hank’s +Na+ buffer + Protease Inhibitor Cocktail 
Tablet, two tubes pre-warmed in 37°C water bath; 
Buffer 5: Hank’s -Na+ buffer + Protease Inhibitor Cocktail Tablet, two tubes pre-warmed in 
37°C water bath; 
For the uptake assay C57BL/6J mice at an age of 4-6 months were sacrificed and the complete 
small intestine was taken out immediately afterwards. The small intestine was immersed in ice-
cold buffer 1 and the intestinal lumen was rinsed with the same buffer using a syringe with a 
blunt-end needle. Then the small intestine was fitted to the outside of a metal rod before being 
inverted from one end to another to expose villi and microvilli. It was then pulled off the rod 
and immediately transferred to a glass plate containing ice-cold buffer 2 and cut into 1cm pieces. 
The small pieces were slid onto plastic enzyme spatulas and immersed in pre-warmed buffer 2 
or buffer 3 for measuring sodium-dependent or -independent uptake, respectively. The pieces 
in buffer 2 were successively washed in two tubes of buffer 4 (to remove glutamine), while 
pieces in buffer 3 were washed in buffer 5. After washing, the intestinal pieces were pre-
incubated in tubes containing 2mL treatment buffer (buffer 4 for Na+-dependent uptake and 
buffer 5 for Na+-independent uptake, together with 300µM of the indicated inhibitors) at 37°C 
for 15min, then transferred to uptake buffer (Hank’s +Na+ buffer for Na+-dependent uptake and 
Hank’s -Na+ buffer for Na+-independent uptake, supplemented with 150µM [14C]leucine and 
300µM inhibitor) at 37°C for 30sec. Then each intestinal piece was briefly immersed in three 
tubes of ice-cold stopping buffer (Hank’s +Na+ buffer, 4mL/tube) to terminate the uptake. 
Every intestinal piece was transferred to one scintillation tube containing 400µL 10% SDS. 
After 2-3hr when the lysis was completed, the radioactivity was quantified by scintillation 
counting in the presence of scintillation fluid (2.5-3mL/tube). 
3.2.6 Mouse feeding and 24hr urine/faecal sample collection for pharmacological studies 
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For the pharmacological in vivo study, fourteen C57BL/6NCrl female mice at an age of 6-8 
months were ordered from the Australian Phenomics Facility (APF) and held in separate cages 
(one mouse per cage) in the animal holding room (Room 3.049, Building 134, the Australian 
National University). The administration of drugs and intraperitoneal glucose tolerance test 
(IPGTT) were all conducted in the laminar flow hood. Littermates were randomly assigned to 
treatment group and control group, so that the age and genetic background between two groups 
were matched. According to a previous study on food and water intake in 28 mouse strains, the 
daily food intake for C57BL/6 strain is approximately 4-5 grams per mouse [253]. Benztropine 
was reported to be used at a maximal dosage of 250mg/kg diet on mice in a study of energy 
expenditure [254]. Accordingly, 1.25mg benztropine in 5g of chow was given to each mouse 
every day. To administer the drug, benztropine mesylate powder (≥98% (HPLC)) was 
purchased from Sigma (#SML0847) and dissolved in ddH2O at a concentration of 1.25mg per 
250µL water. Since each mouse in the treatment group was provided with 5g chow, the pellets 
were soaked in 250µL water containing 1.25mg benztropine. The fortified pellets were given 
for 14 days. Each mouse in the control group was provided with same amount of chow soaked 
in 250µL water. The prepared chow pellets were stored at 4°C and pre-warmed to 37°C before 
providing them to mice. The consumption of chow pellet was recorded to calculate the daily 
drug dose. 
For each mouse, 24hr urine and faecal samples were collected before and after the 
administration of benztropine (d0 for baseline, d7 and d14 after drug administration on day 1). 
The mice were trained inhabiting metabolic cages for at least three days (2-3hr per day) before 
the first sample collection to minimize their stress in the new environment. Sample collection 
started at 5pm and ended at 5pm the following day, with sufficient drinking water provided. 
After overnight starvation (no more than 16hr) in metabolic cages, the mice were offered 5g 
chow pellet containing 1.25mg benztropine for 2hr in their original cages in the morning, 
before returning the mice to metabolic cages for further sample collection. The remainder of 
the chow pellet was weighed and the consumed amount of drug was calculated as the dose for 
24hr. The urine and faecal samples were collected in separate containers standing in dry ice. 
After collection, the aliquots of urine and faecal samples were stored at -80°C until GC-MS 
analysis. 
3.2.7 Intraperitoneal glucose tolerance test (IPGTT) 
Intraperitoneal glucose tolerance test (IPGTT) was performed on mice before and after the 
treatment with benztropine. The body weight of each mouse was recorded before the test. D-
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glucose test solution was prepared by dissolving 2g of D-glucose in 0.9% (w/v) NaCl in water. 
After overnight starvation (~16hr), the fasting blood glucose concentration was measured by 
an ACCU-CHEK Performa glucometer (Roche). Blood from the tail vein was used and a drop 
of blood was applied to the glucometer strip after getting rid of the first drop. Then each mouse 
was injected intraperitoneally with pre-prepared glucose solution (2g glucose per kg body 
weight), and the blood glucose concentration was measured at 15, 30, 60, 90, 120min after the 
injection. 
3.2.8 Sample preparation for GC/MS analysis 
Metabolites in urine and faecal samples were analysed by GC/MS. After thawing, the samples 
were spun down at 13,000rpm and 4°C for 5min. The osmolarity of the supernatant of urine 
samples was measured and adjusted to 500 mOsm/kg by ddH2O. Urea in the sample was 
hydrolysed by urease into carbon dioxide and ammonia (Sigma, #U1500-20kU, 1.28mg [50 
units] dissolved in 8µL ddH2O for 20µL urine sample). The hydrolysis was performed by 
incubation at 37°C for 60min with mixing at 15-minute intervals. The samples were cooled on 
ice immediately after urease treatment and centrifuged at full speed (16,000 x g) for 1min in a 
benchtop centrifuge. Then 90 µL of supernatant was mixed with 720µL methanol, 180µL H2O 
and 10µL of internal standard Ribitol (2mg/mL in methanol) in a new microcentrifuge tube. 
After incubation on ice for 20min, the mixture was centrifuged at 13,000rpm and 4°C for 15min, 
and 60µL of the supernatant was transferred to a glass vial and dried in a vacuum centrifuge 
overnight. The rest of the supernatant was stored at -80°C. Two vials containing amino acid 
standard solution and two vials containing quality controls (QCs, a mixture of aliquots from 
each sample) were also dried in the vacuum centrifuge. 
Faecal samples were lyophilized for 2 days until completely dry. Then the faecal samples were 
ground into powder with ball bearings using a Tissue Lyser II (Qiagen). Approximately 20mg 
of each faecal sample was added into a new microcentrifuge tube, and extracted with 
methanol/H2O (8:2) in the presence of 20µL of internal standard Ribitol in methanol (2mg/mL). 
The volume of methanol/H2O was adjusted to 1mL per 20mg faecal sample. Then the mixture 
was continuously vortexed for 10min, followed by centrifugation at 13,000rpm and 4°C for 
5min. The supernatant was transferred to a new tube and centrifuged again to completely 
remove any debris. Finally, 30µL supernatant was transferred to a glass vial and dried in a 
speed vac overnight together with vials containing AA standards and QCs (a mixture of aliquots 
from each sample). The rest of the supernatant was stored at -80°C. 
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After drying, the samples were ready for derivatisation and analysis by gas chromatography-
mass spectrometry (GC-MS). 
3.2.9 Statistical Analysis 
Data are shown as mean ± S.D, and the Na+ -dependent net uptake was the difference between 
the uptake level in -Na+ buffer and the total uptake level in +Na+ buffer. The fluorescent signals 
measured in the FLIPR assay were normalized to baseline readings (before the addition of 
substrates set at 100%). IC50 curves were generated by non-linear regression log[inhibitor] vs. 
response, and IC50 values were calculated using the equation ! = !#$% &1 − [%][%]+,-./0. Eadie-
Hofstee transformation of transport data was used to determine the mode of inhibition. T-test 
was used to compare two groups, whereas One-way ANOVA was used to compare multiple 
groups. 
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3.3 Results 
3.3.1 Inhibition of B0AT1 by substrate analogues 
Firstly, 24 analogues of amino acid substrates were purchased from Sigma and their inhibitory 
effects on B0AT1 transport was tested using CHO-BC cells. Compound No. 1-17 were 
analogues of L-cysteine, No. 18-20 were analogues of L-methionine, and No. 21-24 were 
analogues of L-serine. These compounds were first screened using the membrane potential 
assay at an inhibitor concentration of 300µM and a substrate concentration of 1.5mM (figure 
3.3.1A). Generally, analogues of L-cysteine showed stronger inhibition of B0AT1 activity 
compared to L-methionine and L-serine analogues. Four compounds caused an apparent 
membrane hyperpolarization rather than depolarization in the presence of 1.5mM leucine (the 
fluorescence signals became lower than baseline after the addition of leucine) and could not be 
analysed. Apart from the compounds with poor inhibition at 300µM (height of the bar was 
close to or above the red line in figure 3.3.1A), the rest of the analogues were further tested in 
dose-response experiments. IC50 values were determined by both membrane potential assay 
and radioactive substrate uptake assay, and the four best inhibitors with the lowest IC50 values 
are listed in Table 3.3.1 and highlighted in figure 3.3.1A by purple frames. The dose-response 
curves of S-Benzyl-L-Cysteine are shown in figure 3.3.1C as an example, inhibiting leucine 
uptake with an IC50 of 14±2µM according to the FLIPR assay, but a much higher IC50 of 
398±29µM was determined using a [14C]isoleucine uptake assay (Table 3.3.1, figure 3.3.1C). 
S-Benzyl-L-Cysteine was a more potent inhibitor of endogenous Na+-independent amino acid 
transport with an IC50 of 33±3µM (figure 3.3.1C). Next, the possibility of these analogues to 
be B0AT1 substrates was measured using the membrane potential assay in the absence of a 
physiological substrate (figure 3.3.1B). Three of the four selected compounds in table 3.3.1 
appeared to be substrates of B0AT1, inducing even higher depolarization peaks than the same 
concentration (300µM) of leucine, except S-(4-Tolyl)-L-Cysteine. 
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Table 3.3.1: IC50 values of AA substrate analogues as B0AT1 inhibitors. 
No. Compound Structure IC50(FLIPR) IC50(Uptake) 
1 L-Cysteine S-sulfate 
 
  
2 S-Carboxymethyl-L-
cysteine 
 
  
3 L-Cysteine(Z)-OH 
 
  
4 S-Benzyl-L-Cysteine 
 
14±2µM 398±29µM 
5 S-(4-Tolyl)-L-
Cysteine 
 
23±14µM 205±46µM 
6 (+)-S-Trityl-L-
cysteine 
 
  
7 S-Acetamidomethyl-
L-cysteine HCl  
  
8 S-tert-Butylmercapto-
L-cysteine 
 
  
9 S-Phenyl-L-cysteine 
 
49±23µM  
10 S-Allyl-L-cysteine 
 
  
11 S-Benzyl-L-cysteine 
sulphone 
 
  
12 H-Cys(4-
methoxytrityl)-OH 
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No. Compound Structure IC50(FLIPR) IC50(Uptake) 
13 H-Cys(carbamoyl)-
OH 
 
  
14 H-Cys(Fm)-OH 
 
  
15 H-Cys(Dpm)-OH 
 
  
16 H-Cys(Bzl)-OH 
 
  
17 S-Cys(aminoethyl)-
OH HCl  
  
18 L-methionine 
sulfoximine 
 
  
19 L-methionine sulfone 
 
  
20 L-methionine 
sulfoxide  
  
21 O-Benzyl-L-serine 
 
14±5µM 810±176µM 
22 O-Phospho-L-serine 
 
  
23 O-Acetyl-L-serine 
HCl 
 
  
24 O-tert-Butyl-L-serine 
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Figure 3.3.1: Screening of amino acid analogues. A) Inhibition of B0AT1 transport by substrate 
analogues. CHO-BC cells were pre-loaded with blue dye in Hank’s +Na+ buffer containing 300µM 
substrate analogues at RT for 30min. After baseline reading, 50µL of leucine solution was automatically 
injected into each well to a final concentration of 1.5mM to induce a depolarization peak (red line 
indicated positive control), while 50µL of Hank‘s +Na+ buffer was injected as a negative control (green 
line). The bar graph shows the peak hyperpolarization or depolarization as percent of baseline as 
average ± std (n=3, e=1). *, p<0.05; **, p<0.01; ***, p<0.001, as compared to +leucine control. 
Inhibitors chosen for radioactive uptake experiments are shown in purple boxes. B) Response of CHO-
BC cells to inhibitors in the absence of amino acid substrate. CHO-BC cells were pre-loaded with the 
blue dye in Hank‘s +Na+ buffer at RT for 30min. After baseline reading, 50µL of substrate analogues 
was manually injected into each well to a final concentration of 300µM, with leucine (300µM for L1 
and 1.5mM for L2) serving as positive controls (two red lines), while 50µL of Hank‘s +Na+ buffer was 
injected as a negative control (green line) (n=3, e=1). C) IC50 values of S-Benzyl-L-Cysteine determined 
by membrane potential assay (MPA, squares) and [14C]isoleucine uptake assay (circles). The 
[14C]isoleucine uptake assay was performed in the presence and absence of Na+ to determine the effect 
on B0AT1 (filled circles) and on the CHO-BC cell endogenous transporters (open circles). Various 
concentrations of S-Benzyl-L-Cysteine (1, 3, 10, 30, 100, 300 and 1000µM) were either incubated with 
blue dye for 30min in the MPA, or with the 150 µM [14C]isoleucine for 6min in the uptake assay. The 
results were normalized to positive controls, which was 1.5mM leucine stimulation in the MPA and 
uptake of 150 µM [14C]isoleucine in the absence of S-Benzyl-L-Cysteine (n=3, e=5). 
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3.3.2 Screening of NCI compounds 
A total number of forty compounds were selected from virtual screening and requested from 
NCI. The membrane potential assay was used as the initial screening tool for these compounds 
and 11 of them showed significant inhibition of B0AT1 transport function at a concentration of 
300µM (figure 3.3.2A). Three of the 11 compounds caused an apparent membrane 
hyperpolarization instead of depolarization after the addition of 1.5mM leucine. Compound No. 
5 and 19 were excluded from figure 3.3.2A because of their high toxicity to the cells, indicated 
by the detachment of cells at the end of the incubation. After further testing compound 
NSC63912 (No. 11) and NSC186059 (No. 25) (highlighted with orange boxes in figure 3.3.2A) 
were identified as the strongest inhibitors in this batch based on their IC50 values (figure 
3.3.2B&D). The IC50 values of NSC63912 (benztropine) were 44±9µM and 71±8µM by FLIPR 
assay and uptake assay, respectively (figure 3.3.2B). The IC50 values of NSC186059 were 
61±25µM and 92±22µM by FLIPR assay and uptake assay, respectively (figure 3.3.2D). In the 
membrane potential assay (figure 3.3.2F), 300µM NSC63912 (benztropine) resulted in a 
depolarization peak similar to that observed after addition of 300µM leucine, whereas same 
concentration of NSC186059 did not alter the membrane potential. A second round of 
computational screening was based on a similarity search starting with NSC63912 and 
NSC186059 (figure 3.3.2C&E), resulting in another 38 compound candidates which were 
requested from NCI. 
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Figure 3.3.2: Screening of NCI compounds Batch 1. A) Inhibitory effects of 40 NCI compounds on 
B0AT1 transport measured by membrane potential assay. *, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001, as compared to +leucine control (n=3, e=1). B) and D) IC50 values of NSC63912 (compound 
11) (n=3, e=5) and NSC186059 (compound 25) (n=3, e=1) determined by membrane potential assay 
(FLIPR, filled squares) or by [14C]isoleucine uptake assay (circles). The [14C]isoleucine uptake assay 
was performed in the presence and absence of Na+ to determine the effect on B0AT1 (filled circles) and 
on the CHO-BC cell endogenous transporters (open circles). C) and E) Chemical structures of 
NSC63912 and NSC186059. F) Test whether inhibitors are B0AT1 substrates by membrane potential 
assay. After baseline reading, 50µL of compounds was manually injected into each well to the final 
concentration of 300µM, with 300µM leucine as a positive controls (red line), while 50µL of Hank’s 
+Na+ buffer was injected as a negative control (green line) (n=3, e=1). 
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3.3.3 Screening of NCI compounds Batch 2 
Among the 38 compounds of the second batch, 21 caused significant inhibition of B0AT1 
transport function at a concentration of 300µM (figure 3.3.3A). The positive rate of this batch 
(55%) was 2-fold higher than that in the first batch (27.5%). Among these 21 compounds, two 
caused membrane hyperpolarization after the addition of 1.5mM leucine (No. 68 and No. 76). 
No compound was excluded due to toxicity as judged by cell adherence. Further functional 
tests confirmed that compound NSC22789 (No. 44) and NSC39706 (No. 51) (highlighted with 
orange boxes in figure 3.3.3A) were the most potent B0AT1 inhibitors in this batch. The IC50 
values of NSC22789 were 90±21µM and 78±16µM by FLIPR assay and uptake assay, 
respectively (figure 3.3.3B). The IC50 values of NSC39706 were 13±3µM and 70±21µM by 
FLIPR assay and uptake assay, respectively (figure 3.3.3D). The [14C]isoleucine uptake assay 
was performed in the presence and absence of Na+ to determine the effect on B0AT1 (filled 
circles) and on the CHO-BC cell endogenous transporters (open circles). In the membrane 
potential assay (figure 3.3.3F), 300µM NSC39706 caused a depolarization peak similar to that 
observed after addition of 300µM leucine, whereas the same concentration of NSC22789 raised 
the membrane potential to a lesser extent. The chemical structures of these two B0AT1 
inhibitors are shown in figure 3.3.3C&E. 
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Figure 3.3.3: Screening on NCI compounds Batch 2. A) Inhibitory effects of 38 NCI compounds on 
B0AT1 transport measured by membrane potential assay. *, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001, as compared to +leucine control (n=3, e=1). B) and D) IC50 values of NSC22789 (compound 
44) (n=3, e=5) and NSC39706 (compound 51) (n=3, e=1) determined by membrane potential assay 
(FLIPR, filled squares) and uptake of [14C]isoleucine (filled circles). Inhibition of the endogenous 
transporter is shown for comparison (open circles). C) and E) Chemical structures of NSC22789 and 
NSC39706. F) NSC22789 and NSC39706 were tested as putative substrates (300µM) of B0AT1 using 
the membrane potential assay. Leucine (300µM) was used as a positive control and Hank’s buffer as a 
negative control. NSC39706 elicited a similar depolarization signal as leucine, while NSC22789 was 
weaker (n=3, e=1). 
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3.3.4 Other transporter Inhibitors 
Nimesulide was previously reported as a B0AT1 inhibitor [249], hence, we tested this 
compound in our cell model. Surprisingly, nimesulide only inhibited B0AT1 after a 4hr-
preincubation, with an IC50 of 178±40µM (figure 3.3.4A). Loratadine is a published inhibitor 
of B0AT2 [255] and its structure is closely related to benztropine. However, it did not inhibit 
the transport of leucine via B0AT1 at 300µM (figure 3.3.4B). Another compound ALX1393, 
reported as an inhibitor of the glycine transporter 2 (GlyT2) [256], inhibited the endogenous 
Na+-independent isoleucine uptake rather than Na+-dependent uptake in CHO-BC cells (figure 
3.3.4C). Thus, none of these inhibitors was superior to the inhibitors selected from 
computational screening. 
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Figure 3.3.4: Testing known inhibitors of B0AT1 and related transporters. The [14C]isoleucine 
uptake assay was performed in the presence and absence of Na+ to determine the effect on B0AT1 (filled 
circles or red bars) and on the CHO-BC cell endogenous transporters (open circles and green bars). A) 
Dose-response curve (left) of nimesulide measured by radioactive substrate uptake assay after 4hr pre-
incubation with the indicated concentration of the compound (n=3, e=1) and chemical structure of 
nimesulide (right). B) The inhibition of B0AT1 by 300µM loratadine (Sigma, L9664) was tested by 
measuring the uptake of 100µM [14C]leucine over 6min in the presence of the inhibitor without pre-
incubation (n=3, e=1) (left). Chemical structure of loratadine is shown on the right. C) The inhibition 
of B0AT1 by 10µM compound ALX1393 (Sigma, A5475) was tested by measuring the uptake of 
150µM [14C]isoleucine over 6min, in the presence of the inhibitor without pre-incubation (n=3, e=1). 
Chemical structure of ALX1393 is shown on the right. 
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3.3.5 Mechanism of inhibition 
To characterise the selected B0AT1 inhibitors further, I investigated the mechanism of 
inhibition. Under physiological condition, the substrate and sodium ion bind to their binding 
sites on the transporter before being transported into the cells. In the presence of a competitive 
inhibitor, however, one or both binding sites will be occupied by the inhibitor, preventing 
binding of the substrate to the transporter. Because the inhibitor binds reversibly to the 
transporter, the inhibitor can be displaced by adding more substrate. Hence, regardless of the 
concentration of a competitive inhibitor, a sufficiently high substrate concentration will always 
displace the inhibitor from the active binding site, allowing the transport to reach its Vmax 
albeit at a higher substrate concentration, i.e. an increased Km is observed in the presence of a 
competitive inhibitor. In the Eadie-Hofstee transformation of transporter kinetics, the Vmax is 
the intercept of the regression line with the y-axis, while the slope is the - Km. For competitive 
inhibitors, different slopes are observed, while all regression lines converge on the ordinate. 
This pattern is shown by the substrate analogue S-Benzyl-L-cysteine and NCI inhibitors 
NSC63912 (benztropine) and NSC39706 (figure 3.3.5A, B, E). The membrane potential assay 
showed that these three compounds were substrates of B0AT1, with similar or even higher 
preference compared to leucine (figure 3.3.1B, 3.3.2F, 3.3.3F), indicating their binding at the 
substrate binding site. 
On the contrary, a non-competitive inhibitor binds to a site distinct from the substrate binding 
site of the transporter. It can form a complex with the transporter or the transporter-substrate 
complex to inhibit the transport activity. The inhibitor does not prevent binding of the substrate 
to the transporter, therefore, the increase of the substrate concentration cannot displace the 
inhibitor from the transporter. As a result, a constant Km and decreased Vmax is observed in the 
presence of increased non-competitive inhibitor. This pattern is shown by NCI compounds 
NSC186059 (figure 3.3.5C) and NSC22789 (figure 3.3.5D). The membrane potential assay 
showed no inhibitor-induced depolarization in NSC186059-treated cells (figure 3.3.2F), and 
only a small depolarization peak in NSC22789-treated cells (figure 3.3.3F). This is consistent 
with both compounds inhibiting B0AT1 in a non-competitive manner. 
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Figure 3.3.5: Mechanism of inhibition. Eadie-Hofstee transformation of the data was used to analyze 
the mode of inhibition. CHO-BC cells were exposed to Hank’s buffer containing different 
concentrations of inhibitors as indicated in the figures as well as different concentrations of amino acid 
substrate (0.1, 0.5, 1, 5, 10mM [14C]leucine) for 6min before harvesting and counting of radioactivity. 
A) S-Benzyl-L-cysteine was determined to be a competitive inhibitor based on a constant Vmax but 
altered Km with changing compound concentration. B) NSC63912 (benztropine) was also determined 
to be a competitive inhibitor. C) NSC186059 was determined to be a non-competitive inhibitor indicated 
by a constant Km but altered Vmax with changing compound concentration. D) NSC22789 was 
determined to be a non-competitive inhibitor, as well. E) NSC39706 was determined to be a competitive 
inhibitor. 
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3.3.6 B0AT1 inhibitors tested in other systems 
After the in vitro characterisation in CHO-BC cells, the selected inhibitors of B0AT1 were 
further tested in other systems. Xenopus oocytes are widely used for the characterisation of 
transporters including hB0AT1 and hcollectrin [40, 73]. As shown in figure 3.3.6A, expressing 
hB0AT1 was not sufficient to facilitate sodium-dependent uptake of isoleucine. Expression of 
hcollectrin alone in oocytes induced a small transport activity, while co-expressing hB0AT1 as 
well as hcollectrin induced an obvious intake of isoleucine in the presence of Na+. After the 
validation of this expression system, the inhibitory effects on B0AT1 by selected inhibitors were 
tested by incubating oocytes expressing hB0AT1 and hcollectrin in the presence of 300µM 
inhibitors and 100µM [14C]isoleucine for 15min. Almost no inhibition of Na+-dependent 
isoleucine uptake was observed in the presence of NSC63912 (benztropine) and NSC186059, 
whereas a slight reduction of isoleucine uptake was caused by the substrate analogue, S-(4-
Tolyl)-L-cysteine (figure 3.3.6B). When inhibitors were injected into the oocytes (figure 
3.3.6C), or pre-incubated with oocytes for 30min (figure 3.3.6D), a more obvious decrease of 
Na+-dependent isoleucine or leucine uptake was observed by both NSC63912 (benztropine) 
and NSC22789, the latter showing stronger inhibition. To study the action of selected inhibitors 
in an in vitro system that is closer to the in vivo situation, we used sections of inverted mouse 
small intestine. In this preparation, similar amounts of leucine were taken by sodium-dependent 
transport (B0AT1) as well as sodium-independent transport of unknown origin. The two 
inhibitors NSC63912 (benztropine) and NSC22789 blocked the sodium-dependent uptake 
significantly without interfering with the sodium-independent uptake (figure 3.3.6E). 
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Figure 3.3.6: Efficacy of B0AT1 inhibitors in different systems. A) Xenopus oocytes were injected 
with cRNA encoding hB0AT1, hcollectrin or combinations thereof. Four days post injection, 
[14C]isoleucine (100µM) uptake was measured over a period of 15min. Ten oocytes were selected from 
each group and un-injected oocytes were used as negative controls. *, p<0.05; ****, p<0.0001; n.s. no 
significance, as compared to un-injected oocytes. B) Four days after injection, [14C]isoleucine uptake 
was measured over a period of 15min in the presence of 300µM inhibitors. Data is presented as the 
uptake level in hB0AT1+hcollectrin cRNA injected oocytes minus the uptake level in uninjected oocytes. 
C) Three days after injection with cRNA encoding hB0AT1 and hcollectrin, Xenopus oocytes were 
injected with 40nL of 3mM compound NSC63912 and NSC22789 dissolved in 100mM KCl. Uptake 
of [14C]isoleucine (100µM) was measured over a period of 20min 47min post inhibitor injection. D) 
Four days after injection, the oocytes were pre-incubated in buffer containing 300µM inhibitors for 
30min before the measurement of [14C]isoleucine uptake over 30min in the presence of 300µM 
inhibitors. Data is shown as the uptake activity of hB0AT1+hcollectrin cRNA injected oocytes after 
subtracting the uptake activity of uninjected oocytes. This experiment was performed by Stephen 
Fairweather. *, p<0.05; **, p<0.01; ****, p<0.0001; n.s. no significance, as compared to control 
(hB0AT1 and hcollectrin co-injected oocytes with substrate incubated only). E) Inhibition by compound 
NSC63912 and NSC22789 (300µM) of Na+ -dependent leucine uptake in inverted sections of mouse 
small Intestine (n=4, e=5). *, p<0.05; as compared to control (inverted mouse small intestine with 
substrate incubated only). 
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3.3.7 Specificity of B0AT1 inhibitors 
The endogenous sodium-independent transport of the amino acid substrate in CHO-BC cells 
served as initial test of the selectivity of B0AT1 inhibitors. In addition, I tested the specificity 
of compound NSC63912 and NSC22789 by measuring their ability to inhibit amino acid 
transport via related transporters expressed in various cell lines. ASCT2 is an amino acid 
exchanger for neutral amino acids with partially overlapping substrate specificity. The activity 
of ASCT2 was measured as Na+-dependent L-glutamine (100µM) uptake level in 143B cells, 
a cancer cell line highly expressing ASCT2 [58]. The Na+-independent L-glutamine uptake 
level was negligible in this cell line [58], therefore, I only measured L-glutamine uptake in 
sodium containing buffer to represent its Na+-dependent transport by ASCT2 without 
subtraction of the Na+-independent uptake activity (figure 3.3.7A). Even closer in substrate 
specificity to B0AT1 are the system L amino acid exchangers LAT1 and LAT2. RT-PCR (figure 
3.3.7B) showed gene expression of both LATs as well as the heavy chain of the transporter, 
4F2hc, in MCF-7 breast cancer cells. System ATB0,+ and ASCT2 were also detected in this cell 
line. The activity of these transporters in this cell line could be discriminated by a competition 
uptake assay (figure 3.3.7C). To this end, the uptake of 100µM leucine was challenged by 
10mM amino acids (arginine, threonine and leucine) or the amino acid analogue 2-
aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), an inhibitor of LAT1 and LAT2. The 
Na+-independent leucine uptake level in MCF-7 cells was more than two-fold higher than Na+-
dependent uptake of leucine, the latter most likely mediated by ASCT2 and ATB0,+. The Na+-
independent leucine uptake was completely blocked by leucine itself, as well as by BCH. It 
was largely inhibited by Thr (a substrate more preferred by LAT2), but not by Arg, which is 
not transported by system L. The Na+-dependent leucine uptake was also inhibited by leucine 
and BCH (substrates of ATB0,+), Thr (substrate of both ASCT2 and ATB0,+) and slightly 
inhibited by Arg (substrate of ATB0,+). To discriminate between LAT1 and LAT2, ⍺-methyl-L-
Tyrosine (specific inhibitor of LAT1 [257]) was employed. In figure 3.3.7D, the combined Na+-
independent L-leucine uptake by LAT1 and LAT2 was inhibited by BCH (inhibitor of both 
LAT1 and LAT2), whereas ⍺-methyl-L-Tyrosine was used to visualize the contribution by 
LAT1. Both NSC63912 and NSC22789 partially inhibited ASCT2 and system L in these two 
cell lines, but NSC22789 showed higher selectivity as demonstrated by lesser inhibition of 
system L and ASCT2 (figure 3.3.7A&D). The substrate analogue S-Benzyl-L-Cysteine, by 
contrast, showed poor selectivity, as demonstrated by strong inhibition of system L in MCF-7 
cells (figure 3.3.7D). 
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Figure 3.3.7: Specificity of B0AT1 Inhibitors. A) The uptake of [14C]glutamine (100µM) was 
measured in Na+-containing transport buffer over a period of 6min in the presence of 300µM inhibitors 
as an indicator of ASCT2 activity (n=3, e=5). B) Gene expression of amino acid transporters in MCF-
7 cells detected by RT-PCR. The expected bands are: LAT1 (407bp), LAT2 (432bp), 4F2hc (481bp), 
ATB0,+ (394bp), ASCT2 (351bp). Clathrin and Actin were used as house-keeping genes (n=1, e=1). C) 
MCF-7 cells were incubated in Hank’s +/-Na+ buffer containing 100µM [14C]leucine as well as 10mM 
competitors (arginine, threonine, BCH, leucine) for 6min before measuring the accumulation of 
radioactivity. The result is shown as average leucine uptake ± std, and the Na+ (net) uptake (red columns) 
was calculated by subtracting -Na+ uptake (green columns) from the total leucine uptake (n=3, e=1). D) 
The sodium-independent uptake of [14C]leucine (100µM) was measured over a period of 6min in the 
presence of 300µM B0AT1 inhibitors, 10mM BCH (LAT1 and LAT2 inhibitor), or 1mM ⍺-methyl-L-
Tyrosine (LAT1 specific inhibitor) in Na+ depleted Hank’s buffer. Data was normalized to the uptake 
level of control cells, which were only treated with leucine (n=3, e=5). *, p<0.05, as compared to control. 
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3.3.8 In-vivo test of benztropine in C57BL/6NCrl female mice 
The B0AT1 inhibitor benztropine is commercially available and was previously used in mice 
to study its influence on energy expenditure [254]. Hence, we tested this compound in 6-8-
month-old C57BL/6NCrl female mice to see whether inhibition of B0AT1 in vivo contributed 
to the effect on energy expenditure. We have previously described that mice lacking Slc6a19 
have improved glucose tolerance [42] and therefore decided to measure the effect of 
benztropine on blood glucose levels. Five pairs of littermates and two pairs of mice matched 
by date of birth (DOB) were separately and randomly distributed to treated- and untreated- 
groups in this pharmacological study, and the drug was given to the mice orally by mixing with 
chow. Inhibition of B0AT1 is readily detectable by increases of the amino acid levels in 24hr 
urine and faecal samples (Kiran Javed personal communication). Hence, urine and faecal 
samples were collected before (d0) and after (d7 and d14) the administration of the drug and 
processed for metabolomic analysis by GC-MS to observe whether benztropine inhibited 
B0AT1 in vivo. In addition, we performed intraperitoneal glucose tolerance tests (IPGTT) on 
d0 and d14 to measure the effect of benztropine on glucose homeostasis. Overall, benztropine-
treated mice had improved glucose tolerance on d14 compared to d0 (p<0.005), but the 
untreated group did not (figure 3.3.8A&B). When comparing the IPGTT data on d14 between 
these two groups, the benztropine-treated mice had a significantly better glucose tolerance than 
the untreated mice (figure 3.3.8C). The average body weight was slightly decreased 14 days 
after drug administration in the treated group, without reaching statistical significance, while 
there was no change in body weight in the untreated group throughout the whole experiment 
(figure 3.3.8D). 
With regard to amino acid levels in urine (figure 3.3.9) and faecal (figure 3.3.10) samples, we 
did not observe increases of any amino acids in samples from the drug-treated group compared 
to untreated mice, nor in post-treated samples compared to pre-treated samples. However, we 
did see increases of some amino acid related metabolites in urine samples from the benztropine-
treated group, which are not substrates of B0AT1. These included N-Acetyl Glycine, Adipic 
acid, 2-Hydroxyadipic acid, and N-Acetyl Glutamic acid (figure 3.3.11). 
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Figure 3.3.8: Glucose tolerance and body weight of benztropine-treated mice compared to 
untreated mice. A) IPGTT before treatment (d0) and 14 days after oral administration of benztropine 
(1.25mg per 5g chow per day) (d14) in the treated group. B) IPGTT on d0 and 14 days after eating 
normal chow soaked with the same amount of water in untreated group. Area Under Curve (AUC) was 
compared for statistical significance between d0 and d14 in A) and B). C) Average AUC at d14 was 
compared between benztropine-treated group and untreated group. *, p<0.05. D) Average body weight 
(g) of mice in the two groups on d0 (green) and d14 (red). n=7 
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Figure 3.3.9: Comparison of amino acid levels between 24hr urine samples of benztropine-treated 
mice and untreated control mice. The samples were collected on day 0 (baseline) and day 14 after 
treatment and analyzed by GC-MS. The d14 data of each group was normalized to the d0 data of the 
same group, and the latter one was regarded as 100., T-test was used for analysis of differences between 
groups (n=7). 
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Figure 3.3.10: Comparison of amino acid levels between 24hr faecal samples of benztropine-
treated mice and untreated control mice. The samples were collected on day 0 (baseline) and day 14 
after treatment and analyzed by GC-MS. The d14 data of each group was normalized to the d0 data of 
the same group, and the latter one was regarded as 100%. T-test was used to analyze differences between 
groups (n=7). 
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Figure 3.3.11: Comparison of amino acid related metabolites between 24hr urine samples of 
benztropine-treated mice and untreated control mice. A) N-Acetyl glycine; B) Adipic acid; C) 2-
Hydroxyadipic acid; D) N-Acetyl glutamic acid. The samples were collected on day 0 (baseline) and 
day 14 after treatment and analyzed by GC-MS. The d14 data of each group was normalized to the d0 
data of the same group, and the latter one was regarded as 100%. T-test was used to analyze differences 
between groups (n=7). *, p<0.05; **, p<0.01; ***, p<0.001. 
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3.3.9 Structure-activity relationships of NSC63912 and NSC22789 related compounds 
As shown above, NSC63912 (benztropine) and NSC22789 were identified as the two best 
B0AT1 inhibitors. However, their IC50 values of 70-80µM suggested that they were not potent 
enough as drug candidates, which was confirmed in the in vivo experiments. The 
pharmacophore of B0AT1 inhibitors was comprised of two aromatic rings and the presence of 
a nitrogen-containing ring at a distance from the aromatic rings. In order to improve these tool 
compounds, our collaborators Praveen Kumar Tiwari and Indrapal Singh Aidhen (Indian 
Institute of Technology Madras) generated a series of systematically modified compounds to 
explore structure-activity relationships of inhibitors related to NSC63912 and NSC22789. It 
was concluded that converting the piperidine ring to a morpholine ring (labelled 3 in figure 
3.3.12) improved IC50 (a1<a2, b1<b2, c1<c2, d1<d2, e1<e2), whereas attaching a methyl-, 
methoxy- group or fluorine on the benzene ring (labelled 2 in figure 3.3.12) did not (by 
comparing a, b, c series). Next, I investigated whether these modified compounds were B0AT1 
substrates as measured using the membrane potential assay (figure 3.3.13). Generally, the 
morpholine-based compounds (a1, b1, c1, d1, e1) were substrates of B0AT1 while the 
piperidine-based compounds (a2, b2, c2, d2, e2) were not, and compounds without side chain 
or with smaller side chains were more likely binding to B0AT1 compared to those with larger 
side chains (the likelihood was decreased from top to bottom in figure 3.3.12). Overall, the 
change of compound activity was relatively minor. 
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Figure 3.3.12: Structure-activity relationships of B0AT1 inhibitors. IC50 values were measured by 
both FLIPR assay and [14C]isoleucine uptake assay. Encircled structural elements improve the IC50 
while structures highlighted by a square reduced affinity. Structure-activity relationships are discussed 
in the main text. 
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Figure 3.3.13: Testing inhibitors of B0AT1 as putative substrates. CHO-BC cells were pre-loaded 
with the blue dye in Hank‘s +Na+ buffer at room temperature for 30min. After baseline reading, 50µL 
of different B0AT1 inhibitors (labelled as shown in figure 3.3.12) were manually injected into each well 
at a final concentration of 300µM, with leucine (300µM) serving as a positive control (red line), while 
50µL of Hank‘s +Na+ buffer was injected as a negative control (green line) (n=3, e=1). 
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3.3.10 High-throughput screening at the Australian Drug Discovery Centre 
The high-throughput screening was conducted in the Australian Drug Discovery Centre using 
a liquid handling robot (Hamilton). The membrane potential assay was adapted to a 384-well 
format and used to screen a subset of the WECC diversity library, which is composed of 
160,000 selected small molecules from a number of different chemical compound vendors. 
Staff of the Australian Cancer Research Foundation (ACRF) Drug Discovery Centre randomly 
selected 20,000 compounds from this library in a way to ensure there was the largest spread of 
different sub libraries to maximally enlarge the structural variety. Each compound was tested 
in duplicate at a final concentration of 10µM. Based on the strongest inhibition of leucine-
induced depolarization, six compounds were selected for further characterization. Two novel 
inhibitors (WECC-0020422 and -0105368) were identified and showed higher potency 
compared to benztropine and NSC22789, with IC50 values of 1±0.4µM and 6±2µM, 
respectively. The IC50 curves were determined by radioactive uptake assay (chemical structures 
withheld for IP reasons) and are shown in figure 3.3.14. 
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Figure 3.3.14: Chemical compounds selected from high-throughput screening. The IC50 values 
were determined by [14C]leucine uptake assay. The radioactivity was measured from lysates of cells 
treated for 6min with Hank’s +/-Na+ buffer containing 100µM substrate and different concentrations 
(0.3, 1, 3, 10, 30, 100µM) of compounds. The +Na+ (net) uptake (solid circle) was calculated by 
subtracting -Na+ uptake (hollow circle) from the total uptake, and the results were normalized to controls 
and shown as average of triplicates ± std (n=3, e=1). 
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3.4 Discussion 
The high capacity and simple procedure of the FLIPR membrane potential assay renders it 
suitable for measurement in a 96-well format and was later adapted to 384-well format. As a 
result, it was used for the primary experimental screening for B0AT1 inhibitors using CHO-BC 
cells. Voltage sensitive dyes have been widely employed in the screening of ion channel 
inhibitors [151, 258, 259] and transporter inhibitors [235, 260]. Amino acid analogues are 
frequently used as inhibitors of amino acid transporters. For example, the non-metabolized 
analogue of L-leucine, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH), is used as an 
inhibitor of system L transporters (LAT), but has to be applied at a concentration of 10mM to 
inhibit this transport activity completely [261]. At this concentration, BCH was also found to 
suppress B0AT1 [73]. The non-metabolized neutral amino acid analogue and system A substrate, 
N-Methylaminoisobutyric acid (MeAIB), has been used for many years as a competitive 
inhibitor of system A transporters [262]. The amino acid analogues can not only be 
transportable substrates and competitive inhibitors for amino acid transporters, but also be non-
transportable noncompetitive blockers, e.g. α-methyltryptophan was identified as a blocker for 
SLC6A14 (ATB0,+) [263]. Due to the structural similarity to the original amino acids, these 
analogues are often substrates of the transporters as well. Accordingly, they often exert 
inhibitory effects by competitively and reversibly binding to the target transporters. Moreover, 
they are usually unsuitable for clinical development of drug candidates due to limited 
specificity with regard to the transporter target and low affinity. To systematically identify 
novel B0AT1 inhibitors, we selected 24 commercially available substrate analogues (analogues 
of L-cysteine, L-methionine and L-serine) and tested them in two screening systems (FLIPR 
and radioactive uptake assays). Among them, S-benzyl-L-cysteine was identified as the most 
potent B0AT1 inhibitor with an IC50 of 398±29µM based on the radioactive uptake assay (figure 
3.3.1C). As a substrate analogue, S-benzyl-L-cysteine was also accepted as a substrate of the 
transporter (compound No.4 in figure 3.3.1B). Accordingly, it acted as a competitive inhibitor 
of the transport (figure 3.3.5A). However, S-Benzyl-L-Cysteine was a more potent inhibitor of 
the endogenous system L transporter, inhibiting this transporter with an IC50 value of 33±3µM 
in CHO-BC cells and also strongly inhibiting system L in MCF-7 cells. Thus, using amino acid 
analogues did not seem to be a promising strategy to identify specific B0AT1 inhibitors, which 
was also reported in the inhibitor screening of other transport systems [264]. We also noticed 
an obvious discrepancy of IC50 values determined by our two assays. The IC50 values were 
overall lower in the FLIPR membrane potential assay compared to the radioactive substrate 
uptake assay, which was also demonstrated in previous studies [265]. Because cells cannot be 
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washed after incubation with the dye and the amount of available inhibitor is usually small, the 
inhibitors have to be incubated with the FLIPR blue dye for 30min on the cells before the assay, 
whereas the cells were only exposed to the inhibitors for 6min during the radioactive uptake 
assay and in the immediate presence of substrate. The prolonged exposure time in the FLIPR 
assay could cause some non-specific effects on the fluorescent signals, for example, by 
activating or inhibiting endogenous ion channels, which would change the membrane potential. 
The compounds could also quench the dye inside the membrane. The longer exposure may also 
facilitate diffusion of the inhibitors across the phospholipid bilayer, allowing them to bind to 
the transporter on the cytosolic face. Together these effects may explain the lower IC50 values 
generated in this assay. Such bias once again emphasizes the importance of using assays other 
than the FLIPR assay for compound screening studies especially when determining the 
characteristics of the inhibitors. 
Since substrate analogues were not suitable as drug candidates, we performed virtual screening 
of compound libraries including a variety of compounds inhibiting other SLC6 family members 
and their analogues. Moreover, we also analyzed nimesulide, a previously published B0AT1 
inhibitor [249]. Virtual screening uses computational techniques to screen small-molecule 
compound libraries to identify structures that are most likely to bind to a drug target. With the 
development of computational techniques and the elucidation of high-resolution structures of 
protein receptors, it is increasingly used in the early stage of drug discovery studies [266, 267]. 
Based on the data of the docking study, we eventually selected the 40 highest-scoring chemical 
compounds from a 14,434 compound subset of the ZINC database for the first round of 
screening. While more economical than experimental screening, computational screening has 
a number of shortcomings, such as exclusion of protein flexibility, incomplete accounting of 
water molecules in binding and incomplete accounting of specialized interactions [266]. To 
overcome these obstacles, molecular dynamics (MD) simulation technique was developed to 
observe the dynamic processes of molecules with high resolution in space and time, improving 
the molecular docking in which proteins are considered rigid and the accuracy of predicted 
docking poses was low [268]. However, MD is computationally demanding and can only be 
used for selected compounds. To exclude false positives derived from computational screening, 
it is frequently used in a combination with a high-throughput in vitro cell-based assay. When 
testing the 40 compounds selected from virtual screening at a concentration of 300µM by 
FLIPR membrane potential assay, only 11 of them inhibited the leucine stimulated signal 
(figure 3.3.2A). The second round of virtual screening was based on a similarity search starting 
with two selected inhibitors from batch 1, namely NSC63912 and NSC186059. This process 
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yielded another 40 compounds, which were selected from 158 structurally-similar compounds 
and subsequently tested in vitro. This time, the fraction of molecules that were active inhibitors 
was obviously higher compared to that of the 1st batch (21 out of 40 compounds significantly 
inhibited leucine-induced depolarization) (figure 3.3.3A). Our best two compounds so far, 
NSC63912 (benztropine) and NSC22789 (2-benzyl-1-(3-phenylpropyl)piperidine), were 
characterized as competitive and non-competitive inhibitors, respectively (figure 3.3.5 B&D), 
with IC50 values of 44-90µM (FLIPR assay) and 71-78µM (uptake assay) (figure 3.3.2B and 
3.3.3B), which is significantly above the recommended range for drug candidates (IC50 within 
lower micromolar to nanomolar range [269, 270]). Competitive inhibitors are competing with 
the substrates for the binding site, so the inhibitory effect will fade away when more substrates 
are present, for instance after food intake. On the contrary, non-competitive inhibitors block 
the transport of the substrate without binding to the active binding site, hence, the inhibitory 
effect will not be influenced by increased concentration of extracellular substrate. For drug 
development, non-competitive inhibitors are preferred, because the competition by end 
products of protein digestion will not occur. 
We also noticed that in the presence of some substrate analogues or NCI compounds, 
hyperpolarization signals were seen instead of depolarization peaks after the addition of 
transport substrate leucine (figure 3.3.1A, 3.3.2A, 3.3.3A). The cause of this hyperpolarization 
is unknown at this stage, but is typically caused by activation of K+ efflux or Cl- influx, however, 
there is no endogenous voltage gated potassium channels expressed in CHO cells [271]. 
To improve the potency of initial lead structures, similarity searches [272], and modifications 
of their chemical structures [273] are commonly performed. The modifications can include the 
removal, addition or replacement of the side chains or rings to increase the hydrophobicity or 
hydrophilicity of the compound [274]. Pharmacophore modelling could be used to increase the 
number of compounds that can be screened by molecular docking. This technique uses the 
geometric and chemical characteristics of ligands or receptors to identify common functional 
groups and geometric arrangements. Large number of compounds can be quickly screened 
computationally for the presence and geometrical arrangements of the identified molecular 
features. This method was previously used to identify novel inhibitors for neurotransmitter 
transporters from SLC6 family [275]. Pharmacophore screening can be performed by ligand-
based or structure-based methods [276]. The ligand-based method uses common structural 
features of a series of known ligands to identify the essential parts for the interaction between 
ligands and the targeted receptor. It allows certain modifications to the pharmacophore to study 
structure-activity relationships of a series of related inhibitors (figure 3.3.10). Structure-based 
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methods, by contrast, involve a comprehensive analysis of the 3D structure of a targeted 
receptor, or a ligand-receptor complex, to set up a pharmacophore based on the analyzed 
features of the active binding site and its spatial relationships [276]. 
Xenopus laevis oocytes are commonly used as an ex-vivo system to study the activity and 
function of the transporters [73, 277]. Surprisingly, the inhibitory effect of the two selected 
compounds (NSC63912 and NSC22789) was much weaker when the transporter was expressed 
in this system. At 300µM NSC63912 and NSC22789 only caused a 10-30% reduction of 
leucine uptake either after injecting compounds directly into the oocyte (figure 3.3.6C) or after 
pre-incubating the oocytes with compounds for 30min (figure 3.3.6D). Without these 
manipulations, no inhibition of leucine uptake was observed (figure 3.3.6B). Weaker inhibition 
in the oocyte expression system compared to mammalian cell models was seen in other studies, 
such as targeting amino acid transporter LAT3 for anti-prostate cancer therapies. In this case, 
the IC50 value determined in mammalian cell lines was almost 20-fold lower than that measured 
in oocytes [278]. Moreover, compounds inhibiting a renal organic cation transporter were 
found to have a much lower Ki value in stably expressed MDCK cells compared to the 
transporter transiently expressed in oocytes [279]. A potential explanation for this could be that 
the vitellin layer surrounding oocytes forms a natural barrier for hydrophobic compounds [280], 
or that inhibitors block the transporters from the inside of the oocytes, where the inhibitors are 
captured by the abundant egg-yolk [281]. 
Apart from affinity, the selectivity of novel inhibitors is another important factor when 
choosing a suitable lead compound. High potency but poor selectivity may cause toxicity and 
side effects in the clinic, hence, the selectivity of compounds is usually monitored in the very 
early stages of drug development [282]. In this study, we used two cell lines to test the 
selectivity of B0AT1 inhibitors: 143B cells, a cell line highly expressing ASCT2, and MCF7 
cells, which highly express LAT1 and LAT2 together with their heavy chain 4F2hc, as well as 
ATB0,+. ATB0,+ (SLC6A14) is upregulated in a variety of cancer tissues to provide all essential 
amino acids for cell growth [283, 284]. It is difficult to differentiate the uptake of leucine by 
LAT1 and LAT2, because the amino acid analogue BCH inhibits both isoforms, while the more 
recently developed inhibitor α-methyl-L-tyrosine proved to be more selective for LAT1 over 
LAT2 [257]. Hence, the difference between the inhibition caused by this compound and by 
BCH was regarded as the activity of LAT2 (figure 3.3.7D). B0AT1 inhibitors NSC63912 
(benztropine) and NSC22789 showed moderate inhibition of sodium-dependent glutamine 
uptake in 143B cells (figure 3.3.7A) and of sodium-independent leucine uptake in MCF-7 cells 
(figure 3.3.7D). However, benztropine was previously identified as a potent inhibitor of the 
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dopamine transporter (SLC6A3) with an IC50 of around 0.2µM, as well as the human proline 
transporter hPROT (SLC6A7) with an IC50 of 0.75µM [285]. Both transporters are in the same 
family as B0AT1. Thus, more potent and selective inhibitors of B0AT1 are required to be further 
developed as drug candidates. 
In humans, mutations inactivating B0AT1 cause a largely benign clinical condition named 
Hartnup disorder. It mainly manifests with aminoaciduria and occasionally a pellagra-like skin 
rash [77]. In rodents, the SLC6A19 knockout (KO) mice demonstrated significant 
improvement of glycaemic control and prevention of obesity and insulin resistance, without 
showing any congenital defects or severe conditions [42, 105]. The metabolic phenotype of 
these KO mice was generated by a series of physiological changes, such as increased glucose 
removal particularly by heart, decreased adipose tissue mass, browning of white adipose tissue, 
increased ketone bodies production, decreased hepatic glucose output and liver triglycerides 
levels. These physiological changes were most likely caused by elevated release of GLP-1, GIP 
and FGF21 [105]. Therefore, there are sufficient reasons for us to suggest that B0AT1 can be 
inhibited in adult humans without severe side-effects. It will be of great interest to analyse the 
metabolic phenotype of Hartnup disorder patients, to find out whether it is similar to that of 
Slc6a19 deficient mice, which would provide a much stronger link between B0AT1 inhibitors 
and their presumed antidiabetic effect. However, due to the limited number of diagnosed cases 
in Australia and around the world, it is problematic to collect sufficient patient samples for 
statistical analysis. One of the identified inhibitors, benztropine, was previously tested at the 
maximal daily dose of 250mg/kg diet in mice to observe its effect on energy expenditure, 
showing no long-term effect on energy balance or body composition in both obese and lean 
animals [254]. Moreover, benztropine was also used in the past as a drug to treat Parkinson’s 
disease [286] and proved to be effective in the treatment of secondary progressive multiple 
sclerosis as well [287]. When we treated wild-type C57BL6/NCrl mice with benztropine for 2 
weeks, an improved glucose tolerance was seen after intraperitoneal injection of glucose in 
treated mice compared to untreated mice (figure 3.3.8C, p<0.05), and the benztropine-treated 
group demonstrated a better glucose tolerance after 2 weeks’ treatment as compared to baseline 
(figure 3.3.8A, p<0.005), whereas the untreated group did not (figure 3.3.8B). However, the 
amino acid levels in urine and faecal samples were not increased (figure 3.3.9&3.3.10), and 
only the levels of amino acid related metabolites were elevated in benztropine-treated urine 
samples (figure 3.3.11), whereas loss of neutral amino acid in urine was observed in the 
SLC6A19 KO mice [105], suggesting that the influence of benztropine on glucose metabolism 
was through mechanisms other than inhibition of B0AT1. For example, urinary excretion of 
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acetylglycine was increased post BCAA dietary restriction in Zucher-fatty rats due to the 
restoration of skeleton muscle glycine levels, which reduce the acyl CoA burden from insulin 
resistance by conjugation with the acyl groups to gain membrane permeability [288]. Adipic 
aciduria was previously reported as a secondary outcome to food, specifically gelatins [289]. 
More importantly, to evaluate the efficacy of B0AT1 inhibitors in vivo, reliable biomarkers in 
varied samples (urine, faecal or plasma) are required to detect successful inhibition of the 
transporter [290]. 
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Conclusion 
Docking studies using homology models were used as a preliminary screening method to 
identify potential inhibitors from a set of approximately 15,000 compounds. The computational 
screening performed in combination with suitable validated transport function assays 
eventually allowed us to identify novel inhibitors for B0AT1. Affinity and selectivity was 
evaluated in various in vitro, in vivo and ex vivo systems. However, compounds with improved 
potency (IC50 within lower micromolar to nanomolar range) and improved selectivity for 
B0AT1 are required for future lead development and for testing in rodents or even humans. The 
leading compounds identified in this study can be the base of future compounds with higher 
affinities for this transporter by using the structure-activity approach. Pharmacological 
inhibition of B0AT1 by small molecules should be capable of replicating the advantageous 
metabolic phenotype of Slc6a19 deficient mice, including better glycaemic control and 
improved lipid profile [105]. As compared to dietary protein restriction, the inhibition of amino 
acid absorption in small intestine and reabsorption in kidney by the application of B0AT1 
blockers should be more well-tolerated by diabetic patients. This study has provided useful 
tools for drug discovery studies, from the generation of cell models, the validation of screening 
assays, to the characterization and modification of inhibitors. 
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Appendix: sequence of primers used in this study 
Primer 
Name 
sense primer (5’-3’) antisense primer (5’-3’) 
hB0AT1 TACGGTGTGGACAGGTTCAA GTACTTCAGGTCCCCGTTCA 
hcollectri
n 
CGAATTCCACCATGTTGTGGCTG
CTCT 
AGAATTCAACAGCCCTTCAGAG
AGG 
hLAT1 CTTTGCCTATGGAGGATGGA AGAGCAGCGTCATCACACAC 
hLAT2 GCCTCAATGCATCCATCTTT GGGACTCTGGCAGGTAAACA 
4F2hc GAGCCGAGAAGAATGGTCTG AGCCGATTGCAAGAGACTGT 
hATB0,+ AGAGGCTCTAGCCCAACTCC AGCTCTCCACCATAGCCAGA 
hASCT2 TCCTGGATCTTGCGAGAAAT GGGCAAAGAGTAAACCCACA 
Actin GCTCACCATGGATGATGATATCGC GGAGGAGCAATGATCTTGATCT
TC 
Clathrin GACAGTGCCATCATGAATCC TTTGTGCTTCTGGAGGAAAGAA 
 
 
